0000862668-24-000017.txt : 20240514 0000862668-24-000017.hdr.sgml : 20240514 20240514160231 ACCESSION NUMBER: 0000862668-24-000017 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ESCALON MEDICAL CORP CENTRAL INDEX KEY: 0000862668 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 330272839 STATE OF INCORPORATION: PA FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-20127 FILM NUMBER: 24944123 BUSINESS ADDRESS: STREET 1: 435 DEVON PARK ROAD STREET 2: SUITE 824 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 6106886830 MAIL ADDRESS: STREET 1: 435 DEVON PARK ROAD STREET 2: SUITE 824 CITY: WAYNE STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: INTELLIGENT SURGICAL LASERS INC DATE OF NAME CHANGE: 19930328 10-Q 1 esmc-20240331.htm 10-Q esmc-20240331
00008626686/30TRUE2024Q3FALSEfalse7,415,329FALSE000-201270.0010.00135,000,00035,000,0007,415,3297,415,3297,415,3297,415,3290.0010.0012,000,0002,000,0002,000,0002,000,000xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesesmc:votexbrli:pure00008626682023-07-012024-03-3100008626682024-05-1300008626682024-03-3100008626682023-06-300000862668us-gaap:SecuredDebtMember2024-03-310000862668us-gaap:SecuredDebtMember2023-06-300000862668us-gaap:ProductMember2024-01-012024-03-310000862668us-gaap:ProductMember2023-01-012023-03-310000862668us-gaap:ProductMember2023-07-012024-03-310000862668us-gaap:ProductMember2022-07-012023-03-310000862668us-gaap:ServiceMember2024-01-012024-03-310000862668us-gaap:ServiceMember2023-01-012023-03-310000862668us-gaap:ServiceMember2023-07-012024-03-310000862668us-gaap:ServiceMember2022-07-012023-03-3100008626682024-01-012024-03-3100008626682023-01-012023-03-3100008626682022-07-012023-03-310000862668us-gaap:PreferredStockMember2023-06-300000862668us-gaap:CommonStockMember2023-06-300000862668us-gaap:AdditionalPaidInCapitalMember2023-06-300000862668us-gaap:RetainedEarningsMember2023-06-300000862668us-gaap:PreferredStockMember2023-07-012023-09-300000862668us-gaap:CommonStockMember2023-07-012023-09-300000862668us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000862668us-gaap:RetainedEarningsMember2023-07-012023-09-3000008626682023-07-012023-09-300000862668us-gaap:PreferredStockMember2023-09-300000862668us-gaap:CommonStockMember2023-09-300000862668us-gaap:AdditionalPaidInCapitalMember2023-09-300000862668us-gaap:RetainedEarningsMember2023-09-3000008626682023-09-300000862668us-gaap:PreferredStockMember2023-10-012023-12-310000862668us-gaap:CommonStockMember2023-10-012023-12-310000862668us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310000862668us-gaap:RetainedEarningsMember2023-10-012023-12-3100008626682023-10-012023-12-310000862668us-gaap:PreferredStockMember2023-12-310000862668us-gaap:CommonStockMember2023-12-310000862668us-gaap:AdditionalPaidInCapitalMember2023-12-310000862668us-gaap:RetainedEarningsMember2023-12-3100008626682023-12-310000862668us-gaap:PreferredStockMember2024-01-012024-03-310000862668us-gaap:CommonStockMember2024-01-012024-03-310000862668us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000862668us-gaap:RetainedEarningsMember2024-01-012024-03-310000862668us-gaap:PreferredStockMember2024-03-310000862668us-gaap:CommonStockMember2024-03-310000862668us-gaap:AdditionalPaidInCapitalMember2024-03-310000862668us-gaap:RetainedEarningsMember2024-03-310000862668us-gaap:PreferredStockMember2022-06-300000862668us-gaap:CommonStockMember2022-06-300000862668us-gaap:AdditionalPaidInCapitalMember2022-06-300000862668us-gaap:RetainedEarningsMember2022-06-3000008626682022-06-300000862668us-gaap:PreferredStockMember2022-07-012022-09-300000862668us-gaap:CommonStockMember2022-07-012022-09-300000862668us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000862668us-gaap:RetainedEarningsMember2022-07-012022-09-3000008626682022-07-012022-09-300000862668us-gaap:PreferredStockMember2022-09-300000862668us-gaap:CommonStockMember2022-09-300000862668us-gaap:AdditionalPaidInCapitalMember2022-09-300000862668us-gaap:RetainedEarningsMember2022-09-3000008626682022-09-300000862668us-gaap:PreferredStockMember2022-10-012022-12-310000862668us-gaap:CommonStockMember2022-10-012022-12-310000862668us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-310000862668us-gaap:RetainedEarningsMember2022-10-012022-12-3100008626682022-10-012022-12-310000862668us-gaap:PreferredStockMember2022-12-310000862668us-gaap:CommonStockMember2022-12-310000862668us-gaap:AdditionalPaidInCapitalMember2022-12-310000862668us-gaap:RetainedEarningsMember2022-12-3100008626682022-12-310000862668us-gaap:PreferredStockMember2023-01-012023-03-310000862668us-gaap:CommonStockMember2023-01-012023-03-310000862668us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000862668us-gaap:RetainedEarningsMember2023-01-012023-03-310000862668us-gaap:PreferredStockMember2023-03-310000862668us-gaap:CommonStockMember2023-03-310000862668us-gaap:AdditionalPaidInCapitalMember2023-03-310000862668us-gaap:RetainedEarningsMember2023-03-3100008626682023-03-310000862668us-gaap:ConvertiblePreferredStockMember2024-01-012024-03-310000862668us-gaap:ConvertiblePreferredStockMember2023-01-012023-03-310000862668us-gaap:ConvertiblePreferredStockMember2023-07-012024-03-310000862668us-gaap:ConvertiblePreferredStockMember2022-07-012023-03-310000862668us-gaap:StockOptionMember2024-01-012024-03-310000862668us-gaap:StockOptionMember2023-01-012023-03-310000862668us-gaap:StockOptionMember2023-07-012024-03-310000862668us-gaap:StockOptionMember2022-07-012023-03-3100008626682018-02-142018-02-1400008626682018-02-1400008626682022-07-012023-06-300000862668us-gaap:NotesPayableToBanksMember2018-06-290000862668us-gaap:NotesPayableToBanksMember2023-07-012024-03-310000862668esmc:TDBankMemberus-gaap:NotesPayableToBanksMember2023-03-290000862668esmc:TDBankMemberus-gaap:NotesPayableToBanksMember2023-03-292023-03-290000862668esmc:TDBankMemberus-gaap:NotesPayableToBanksMember2023-04-292023-04-290000862668esmc:TDBankMemberus-gaap:NotesPayableToBanksMember2024-03-310000862668us-gaap:SecuredDebtMember2024-03-310000862668us-gaap:SecuredDebtMember2023-03-312023-03-310000862668us-gaap:SecuredDebtMember2023-07-012024-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2023-07-012024-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012024-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668us-gaap:CustomerConcentrationRiskMemberesmc:CustomerTwoMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668esmc:AccountsReceivableBenchmarkMember2023-07-012024-03-310000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-07-012024-03-310000862668us-gaap:CustomerConcentrationRiskMemberesmc:CustomerTwoMemberus-gaap:AccountsReceivableMember2023-07-012024-03-310000862668us-gaap:AccountsReceivableMember2023-07-012023-09-300000862668esmc:CustomerOneMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-07-012023-09-300000862668us-gaap:AccountsReceivableMember2024-01-012024-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000862668esmc:SupplierTwoMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000862668us-gaap:AccountsReceivableMember2023-07-012024-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMemberus-gaap:SalesRevenueNetMember2023-07-012024-03-310000862668us-gaap:AccountsReceivableMember2023-01-012023-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668esmc:SupplierTwoMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668us-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMemberus-gaap:SalesRevenueNetMember2022-07-012023-03-310000862668esmc:SupplierTwoMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-07-012023-03-310000862668esmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMember2023-07-012024-03-310000862668esmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMember2023-07-012024-03-310000862668esmc:AccountsPayableBenchmarkMemberesmc:SupplierTwoMemberus-gaap:SupplierConcentrationRiskMember2023-07-012024-03-310000862668esmc:AccountsPayableBenchmarkMemberesmc:SupplierThreeMemberus-gaap:SupplierConcentrationRiskMember2023-07-012024-03-310000862668esmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMember2023-07-012023-09-300000862668esmc:AccountsPayableBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberesmc:SupplieroneMember2023-07-012023-12-310000862668esmc:AccountsPayableBenchmarkMemberesmc:SupplierTwoMemberus-gaap:SupplierConcentrationRiskMember2023-07-012023-12-310000862668us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2024-01-012024-03-310000862668us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2023-07-012024-03-310000862668us-gaap:GeographicConcentrationRiskMembercountry:USus-gaap:SalesRevenueNetMember2022-07-012023-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMemberus-gaap:SalesRevenueNetMember2023-07-012024-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMemberus-gaap:SalesRevenueNetMember2022-07-012023-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012024-03-310000862668us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-07-012023-03-310000862668us-gaap:GeographicConcentrationRiskMember2022-07-012023-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


 FORM 10-Q
QUARTERLY PERIOD PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934


For the Quarterly Period ended March 31, 2024
Commission File Number 0-20127


Escalon Medical Corp.
(Exact name of registrant as specified in its charter)

Pennsylvania 33-0272839
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
435 Devon Park Drive, Suite 824, Wayne, PA 19087
(Address of principal executive offices, including zip code)
(610) 688-6830
(Registrant’s telephone number, including area code)


N/A
Former name, former address and former fiscal year, if changed since last report
Securities registered pursuant to Section 12(b) of the Act: NONE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company. or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 


Large accelerated fileroAccelerated filero
Non-accelerated filer
x
Smaller reporting companyx
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). o  Yes  x  No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 7,415,329 shares of common stock, $0.001 par value, outstanding as of May 13, 2024.




TABLE OF CONTENTS
  Page
PART I Financial Information
Item I.
Item 2.
Item 3.
Item 4.
PART II Other Information
Item 6.



1

PART I. FINANCIAL INFORMATION


Item I. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


2

ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

March 31,
2024		June 30,
2023
(Unaudited)
ASSETS
Current assets:
Cash $564,707 $889,674 
Restricted cash256,390 256,293 
Accounts receivable 1,491,827 1,807,599 
    Less: allowance for credit losses(132,624)(153,878)
Accounts receivable, net1,359,203 1,653,721 
Inventories, net1,804,929 1,587,989 
Other current assets166,600 249,790 
Total current assets4,151,829 4,637,467 
Property and equipment, net53,971 34,064 
Right-of-use assets276,089 503,647 
License and patent, net54,355 69,986 
Other long term assets62,787 62,787 
Total assets$4,599,031 $5,307,951 
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current portion of note payable $33,262 $37,087 
Current portion of EIDL loan3,172 3,105 
Accounts payable1,118,057 1,205,510 
Accrued expenses589,877 651,978 
Related party accrued interest 112,389 112,389 
Current portion of operating lease liabilities
282,950 329,638 
Deferred revenue403,069 426,227 
Other short-term liabilities86,333 87,125 
Total current liabilities2,629,109 2,853,059 
Note payable, net of current portion135,483 159,511 
EIDL loan, net of current portion 143,289 146,435 
Operating lease liabilities, net of current portion15,974 214,103 
Total long-term liabilities294,746 520,049 
Total liabilities2,923,855 3,373,108 
Contingencies (Note 10)
Shareholders' equity:
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized; 2,000,000 shares issued and outstanding (liquidation value of $961,173 and $922,331)645,000 645,000 
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding 7,415 7,415 
Additional paid-in capital69,702,043 69,702,043 
Accumulated deficit(68,679,282)(68,419,615)
Total shareholders’ equity1,675,176 1,934,843 
Total liabilities and shareholders’ equity$4,599,031 $5,307,951 
See notes to unaudited condensed consolidated financial statements.
3


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Net revenues:
Products$2,567,387 $3,285,396 $8,101,834 $8,582,183 
Service plans128,114 148,918 407,904 462,436 
Revenues, net2,695,501 3,434,314 8,509,738 9,044,619 
Costs and expenses:
Cost of goods sold1,578,727 1,720,853 4,835,402 5,021,470 
Marketing, general and administrative1,117,534 938,161 3,401,902 3,108,177 
Research and development155,848 185,750 515,213 641,316 
Total costs and expenses
2,852,109 2,844,764 8,752,517 8,770,963 
(Loss) income from operations(156,608)589,550 (242,779)273,656 
Other expense
Interest expense(5,541)(4,315)(16,888)(15,188)
Income tax expense— — — — 
Net (loss) income(162,149)585,235 (259,667)258,468 
Undeclared dividends on preferred stocks12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Net (loss) income per share
Basic (loss) income per share$(0.02)$0.08 $(0.04)$0.03 
Diluted (loss) income per share$(0.02)$0.04 $(0.04)$0.02 
Weighted average shares—basic7,415,329 7,415,3297,415,329 7,415,329
Weighted average shares—diluted7,415,32913,478,9367,415,32913,478,936
See notes to unaudited condensed consolidated financial statements.
4


ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2024 AND 2023
(UNAUDITED)


 Series A Convertible Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Shareholders’
Equity
 Shares AmountSharesAmount  
Balance at June 30, 20232,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,419,615)$1,934,843 
Net loss— — — — — (21,197)(21,197)
Balance at September 30, 20232,000,000 645,000 7,415,329 7,415 69,702,043 (68,440,812)1,913,646 
Net loss— — — — — (76,321)(76,321)
Balance at December 31, 20232,000,000 645,000 7,415,329 7,415 69,702,043 (68,517,133)1,837,325 
  Net loss— — — — — (162,149)(162,149)
Balance at March 31, 20242,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,679,282)$1,675,176 

 Series A Convertible Preferred StockCommon StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Shareholders’
Equity
 Shares AmountSharesAmount  
Balance at June 30, 20222,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,876,441)$1,478,017 
Net loss— — — — — (320,724)(320,724)
Balance at September 30, 20222,000,000 645,000 7,415,329 7,415 69,702,043 (69,197,165)1,157,293 
Net loss— — — — — (6,043)(6,043)
Balance at December 31, 20222,000,000 645,000 7,415,329 7,415 69,702,043 (69,203,208)1,151,250 
Net income— — — — — 585,235 585,235 
Balance at March 31, 20232,000,000 $645,000 7,415,329 $7,415 $69,702,043 $(68,617,973)$1,736,485 


See notes to unaudited condensed consolidated financial statements.
5

ESCALON MEDICAL CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
For the Nine Months Ended March 31,
20242023
Cash Flows from Operating Activities:
Net (loss) income$(259,667)$258,468 
Adjustments to reconcile net loss to net cash used in operating activities:
Change in allowance of doubtful accounts20,354 (93,400)
Depreciation and amortization
26,763 34,424 
Non cash lease expense
227,558 215,772 
Change in operating assets and liabilities:
Accounts receivable274,164 (107,573)
Inventories(216,940)(61,238)
Other current and non-current assets83,189 27,798 
Accounts payable (87,453)35,375 
   Accrued expenses
(62,101)(33,063)
Change in operating lease liability
(244,817)(226,404)
Deferred revenue(23,158)(36,985)
  Other short term and long term liabilities(792)(42,955)
Net cash used in operating activities(262,900)(29,781)
Cash Flows from Investing Activities:
  Purchase of equipment (31,038)(6,687)
 Purchase of patents— (7,155)
Net cash used in investing activities
(31,038)(13,842)
Cash Flows from Financing Activities:
Repayment of note payable(27,853)(3,165)
Repayment of EIDL loan(3,079)(2,686)
Net cash used in financing activities(30,932)(5,851)
Net decrease in cash, cash equivalents and restricted cash(324,870)(49,474)
Cash and restricted cash, beginning of period1,145,967 850,034 
Cash and restricted cash, end of period$821,097 $800,560 
Cash, cash equivalents and restricted cash consist of the following:
End of period
Cash $564,707 $544,320 
Restricted cash 256,390 256,240 
$821,097 $800,560 
6

Beginning of period
Cash $889,674 $593,869 
Restricted cash 256,293 256,165 
$1,145,967 $850,034 

Supplemental Schedule of Cash Flow Information:
Interest paid$16,985 $15,697 
See notes to unaudited condensed consolidated financial statements
7

Escalon Medical Corp. and Subsidiaries
Notes to Unaudited Condensed Consolidated Financial Statements

1. Organization and Basis of Presentation

          Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc.

    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.
The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of March 31, 2024, and the results of operations and cash flows for the interim periods ended March 31, 2024 and 2023, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on October 13, 2023. Operating results for the three months and nine months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2024.

    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”

2. Going Concern

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies, the price of, and demand for, the Company’s products and its ability to raise capital to support its operations.

To date, the Company’s operations have not generated sufficient revenues to enable consistent profitability. Through March 31, 2024, the Company had incurred historical recurring losses from operations and incurred negative cash flows from operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the next 12 months following the issuance of these unaudited condensed consolidated financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, and implementing cost-cutting measures. The Company may not be successful in any of these efforts.

3. Summary of Accounting Policies

Recently Issued Accounting Standards
8




In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (“ASC 326”), authoritative guidance amending how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The guidance requires the application of a current expected credit loss model, which is a new impairment model based on expected losses. The new guidance is effective for interim and annual reporting periods beginning after December 15, 2022. The adoption of the new guidance will not have a material impact on the Company's unaudited consolidated financial statements. The Company adopted the current expected credit loss model prospectively from fiscal year 2024, and assessed the allowance for expected credit losses to reflect the risk of loss, even when that risk is remote. The Company continues to use the aging matrix in conjunction with the historical information, current conditions, and reasonable and supportable forecasts. The Company groups most of the trade receivable by pools after adoption of the new standards while it analyzed the credit loss of the trade receivables one by one before adoption. The major difference is the estimate of the current expected credit loss for the receivable that are current on their payment. For the nine-month period ended March 31, 2024, the adoption of the new guidance did not have a material impact on the Company's unaudited consolidated financial statements. The Company will continue to assess the current expected credit loss. It may need to recognize a credit loss in the income statement earlier than under the legacy guidance at certain times when the expected credit loss is increased.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable and Allowance for Credit Losses

Accounts receivables are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company adopted the current expected credit loss model prospectively from fiscal year 2024, and assessed the allowance for expected credit losses to reflect the risk of loss, even when that risk is remote. The Company continues to use the aging matrix in conjunction with the historical information, current conditions and reasonable and supportable forecasts. The Company groups most of the trade receivable by pools after adoption of the new standards while it analyzed the credit loss of the trade receivables one by one before adoption. The major difference is the estimate of the current expected credit loss for the receivables that are current on their payment. With adoption of the new standards, the small credit loss rate applied to current receivables will be mostly offset by the lower expected credit rate applied to over 120 days past due when less than 100% of expected credit loss is applied. The historical credit loss rate is adjusted for current conditions and management's assessment for factors such as international relations, economic conditions, and special-term contracts etc. For the nine-month period ended March 31, 2024, the adoption of the new guidance did not have a material impact on the Company's unaudited consolidated financial statements. The Company will continue to assess the current expected credit loss. It may need to recognize a credit loss in the income statement earlier than under the legacy guidance at certain time when the expected credit loss is increased. The Company recorded an allowance for credit losses of approximately $132,624 and $153,878 as of March 31, 2024, and June 30, 2023, respectively.

The activity for the allowance for credit losses during the three-month and nine-month periods ended March 31, 2024, and the fiscal year ended June 30, 2023, is as follows:

9




 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 2024202320242023
Balance, at the beginning of the period$133,524 $241,349 $153,878 $236,349 
Provision (Reversal)— (98,400)(20,354)(93,400)
Write-offs(900)— (900)— 
Balance, at the end of the period$132,624 $142,949 $132,624 $142,949 

Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely have impact on the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.


Deferred Revenues

    The Company records deferred revenues when cash payments are received or due in advance of its performance. The Company’s deferred revenues relate to payments received for the customer care plans for a 12-month period. The consideration received is recognized monthly over the service period. Revenue recorded that was included within prior period deferred revenue was $165,000 and $43,000, respectively for the three-month periods ended March 31, 2024 and 2023. Revenue recorded that was included within prior period deferred revenue was $440,000 and $300,000, respectively for nine month periods ended March 31, 2024, and 2023.

(in thousands)For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Beginning of Period$316 $259 $426 $332 
Additions284 185 560 425 
Revenue Recognized197 149 583 462 
End of Period$403 $295 $403 $295 

(Loss) earnings Per Share    
The Company utilizes the two-class method to compute net (loss) income per common share. These participating securities included the Company’s convertible preferred stock which accrues dividends payable. The two-class method requires (loss) earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.

Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had
10




all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.

Diluted net income per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options. The Company analyzed the potential dilutive effect of any outstanding dilutive securities under the “if-converted” method and treasury-stock method when calculating diluted earnings per share, in which it is assumed that the outstanding participating securities convert into common stock at the beginning of the period or date of issuance, if later. The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. As of March 31, 2024 and 2023, the average market prices for the years then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive.
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Numerator:
  Numerator for basic loss per share:
 Net (loss) income$(162,149)$585,235 $(259,667)$258,468 
Undeclared dividends on preferred stock12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Numerator for diluted loss per share:
Diluted (loss) income$(162,149)$585,235 $(259,667)$258,468 
Undeclared dividends on preferred stock12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Denominator for basic (loss) earning per share
Denominator for basic (loss) earning per share - weighted average shares outstanding
7,415,329 7,415,329 7,415,329 7,415,329 
Weighted average preferred stock converted to common stock— 6,063,607 — 6,063,607 
 Denominator for diluted (loss) income assumed conversion7,415,329 13,478,936 7,415,329 13,478,936 
Net (loss) income per share:
Basic net (loss) income per share$(0.02)$0.08 $(0.04)$0.03 
Diluted net (loss) income per share$(0.02)$0.04 $(0.04)$0.02 
11





The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.

For the Three Months Ended March 31,For the Nine Months Ended March 31,
2024202320242023
Stock options157,000 157,000 157,000 157,000 
Convertible preferred stock6,407,820 — 6,407,820 — 
Total potential dilutive securities not included in loss per share6,564,820 157,000 6,564,820 157,000 

Income Taxes

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of March 31, 2024 and June 30, 2023, the Company has recorded a full valuation allowance against its deferred tax assets.

    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. As of March 31, 2024, and June 30, 2023, no accrued interest or penalties were required to be included on the related tax liability line in the consolidated balance sheets.

4. Inventories

March 31,
June 30,
(in thousands)20242023
Inventories:
        Raw Material$1,027 $882 
        Work-In-Process388 86 
        Finished Goods650 881 
Total inventories$2,065 $1,849 
Allowance for obsolete inventory(260)(260)
Inventories, net$1,805 $1,588 

12




5. Related Party Transactions and Preferred Stock

    As of March 31, 2024, and 2023, the related party interest accrual of $112,389 related to the debt prior to the exchange, remained as an on demanded payable.
On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”).  Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).
    
    Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders.  As a result of this voting power, the Holders as of March 31, 2024 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders.

    Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”).  The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion.

    Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of March 31, 2024, and June 30, 2023, the cumulative dividends payable are $316,173 ($0.1581 per share) and $277,331 ($0.1387 per share), respectively.

    Mr. DePiano Sr. passed away on October 3, 2019, and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as Chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.

6. TD Note Payable

    On June 29, 2018, the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.0% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.74 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.74% per annum based on a year of 360 days. The Company was required to put $250,000 in the TD bank savings account as collateral. The Loan is guaranteed by Mr. DePiano Jr.

TD bank elected to exercise the term note conversion option to convert the loan balance of $201,575 to a five-year term note effective March 29, 2023 the "Conversion Date"). The scheduled monthly principal and interest payments in the amount of $4,247 began on April 29, 2023. Commencing on the Conversion Date, the aggregate principal balance outstanding bears interest at a fixed per annum rate of 9.49% pursuant to the loan's terms and conditions.

The future note payable payments as of March 31, 2024 are as follows:

Year ending June 30,
TD Note Payment
13




2024 (remainder of FY 2024)
8,530 
2025
37,434 
2026
41,145 
202745,224 
202836,412 
Total
$168,745 

7. Long-term debt


Economic Injury Disaster Loan ("EIDL")

    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received a $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.

    The future annual principal amounts to be paid as of March 31, 2024 are as follows:
Year ending June 30,EIDL Payment
2024 (remainder of FY 2024)$782 
20253,202 
20263,324 
20273,451 
20283,582 
Thereafter132,120 
Total$146,461 

8. Concentration of Credit Risk

Credit Risk

Financial instruments, which potentially subject the Company to the concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely addresses the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral.

Major Customer

    One customers accounted for 13% of net revenue during the three-month period ended March 31, 2024. One customer accounted for 11% of net revenue during the nine-month period ended March 31, 2024. No customer accounted for more than 10% during the three-month and nine-month periods ended March 31, 2023.

    As of March 31, 2024, the Company had two customers that represented 16% and 11% of the total accounts receivable balance. As of June 30, 2023, the Company had one customer that represented 24% of the total accounts receivable balance.

Major Supplier
14





    The Company's two largest suppliers accounted for 36% and 11% of total purchases for the three-month period ended March 31, 2024. The Company's one largest supplier accounted for 40% of total purchases for the nine-month period ended March 31, 2024. The Company's two largest suppliers accounted for 44% and 11% of total purchases for the three-month period ended March 31, 2023. The Company's two largest suppliers accounted for 44% and 10% of total purchases for the nine-month period ended March 31, 2023.

    As of March 31, 2024, the Company had three suppliers that represented 29%, 12%, and 11% of the total accounts payable balance. As of June 30, 2023, the Company had two suppliers that represented approximately 36% and 11% of the total accounts payable balance.

Disaggregated Revenue

    Domestic and international sales from operations are as follows:
(in thousands)For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Domestic$1,339 50 %$1,903 55 %$4,394 52 %$5,258 58 %
Foreign1,357 50 %1,531 45 %4,116 48 %3,787 42 %
Total$2,696 100 %$3,434 100 %$8,510 100 %$9,045 100 %

9. Leases

    The Company leases certain facilities and equipment under operating leases. Total lease expense, under ASC 842, was included in cost of goods sold and marketing, general and administrative costs in our unaudited condensed consolidated statements of operations for the three and nine months ended March 31, 2024, and 2023 as follows:

For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Operating lease costs:
Fixed$84,970 $85,324 $254,992 $256,084 
Total:$84,970 $85,324 $254,992 $256,084 

    Supplemental cash flow information was as follows:
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$88,224 $86,350 $262,387 $256,883 
Total$88,224 $86,350 $262,387 $256,883 


    The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate)
under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of March 31, 2024:
15




Operating
2024 (reminder of FY 2024)$88,514 
2025212,415 
20263,928 
20271,200 
20281,200 
Thereafter600 
Total lease payments307,857 
Less interest 8,933 
Present value of lease liabilities$298,924 

    Average lease terms and discount rates were as follows:
March 31,June 30,
20242023
Weighted-average remaining lease terms (years)
Operating leases
0.971.67
Weighted-average discount rate
Operating leases
5.72 %5.69 %

10. Contingencies
The Company, from time to time is involved in various legal proceedings and disputes that arise in the normal course of business. These matters have included intellectual property disputes, contract disputes, employment disputes and other matters. The Company does not believe that the resolution of any of these matters has had or is likely to have a material adverse impact on the Company’s business, financial condition or results of operations.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

    Certain statements contained in, or incorporated by reference in, this report are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which provide current expectations or forecasts of future events. Such statements can be identified by the use of terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “possible,” “project,” “should,” “will,” and similar words or expressions. The Company's forward-looking statements include certain information relating to general business strategy, growth strategies, financial results, liquidity, the Company's ability to continue as a going concern, discontinued operations, research and development, product development, the introduction of new products, the potential markets and uses for the Company's products, the Company's ability to increase its sales campaign effectively, the Company's regulatory filings with the FDA, acquisitions, dispositions, the development of joint venture opportunities, intellectual property and patent protection and infringement, the loss of revenue due to the expiration or termination of certain agreements, the effect of competition on the structure of the markets in which the Company competes, increased legal, accounting and Sarbanes-Oxley compliance costs, information security, cybersecurity and data privacy risks, defending the Company in litigation matters and the Company's cost saving initiatives. The reader must carefully consider forward-looking statements and understand that such statements involve a variety of risks and uncertainties, known and unknown, and may be affected by assumptions that fail to materialize as anticipated, including risks related to the COVID-19 pandemic, inflation, the ability to continue as a going concern including the ability to raise capital, manage operations and pursue business partnerships and cost-cutting measures, and the other risks described in the Company's Form 10-K for the fiscal year ended June 30, 2023. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. It is not possible to foresee or identify all factors affecting the Company's forward-looking statements, and the reader therefore should not consider the list of such factors contained in its periodic report on Form 10-K for the year ended June 30, 2023 and this Form 10-Q quarterly report to be an exhaustive statement of all risks, uncertainties or potentially inaccurate assumptions.
16





Executive Overview—nine-month periods ended March 31, 2024, and 2023
The following highlights are discussed in further detail within this Form 10-Q. The reader is encouraged to read this Form 10-Q in its entirety to gain a more complete understanding of factors impacting Company performance and financial condition.

•Consolidated net revenue decreased approximately $535,000 or 5.9%, to $8,510,000 during the nine months ended March 31, 2024, as compared to the same period of last fiscal year. The decrease in net revenue is mainly attributed to a decrease in sales of Sonomed's ultrasound products of $467,000 during the nine months ended March 31, 2024.

•Consolidated cost of goods sold totaled approximately $4,836,000, or 56.8%, of total revenue for the nine months ended March 31, 2024, as compared to $5,021,000, or 55.5%, of total revenue of the same period of last fiscal year. The increase of 1.3% in cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences during the nine months ended March 31, 2024.

•Consolidated marketing, general and administrative expenses increased $294,000, or 9.5%, to $3,402,000 for the nine months ended March 31, 2024, as compared to the same period of last fiscal year. The increase in marketing, general and administrative expenses is mainly due to the recovery of bad debts of $113,000 during the prior year, tax expenses, and increase travel expense during the three months ended March 31, 2024.

•Consolidated research and development expenses decreased $126,000, or 19.7%, to $515,000 for the nine months ended March 31, 2024, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expenses is mainly due to decreased image management consulting expense during the nine months ended March 31, 2024.
Company Overview

    The following discussion should be read in conjunction with the interim unaudited condensed consolidated financial statements and the notes thereto, which are set forth in Item 1 of this report.

    The Company operates in the healthcare market specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the FDA. The FDA requires extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing. The Company's Internet address is www.escalonmed.com. Under the trade name of Sonomed-Escalon the Company develops, manufactures and markets ultrasound systems used for diagnosis or biometric applications in ophthalmology, develops, manufactures and distributes ophthalmic surgical products under the Trek Medical Products name, and manufactures and markets image management systems.
Critical Accounting Estimates
The preparation of unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact amounts reported therein. On a regular basis, we evaluate these estimates. These estimates are based on management’s historical industry experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

For a description of the accounting policies that, in management’s opinion, involve the most significant application of judgment or involve complex estimation and which could, if different judgment or estimates were made, materially affect our reported financial position, results of operations, or cash flows, see the notes to consolidated financial statements included in the Form 10-K for the year ended June 30, 2023.

During the nine months ended March 31, 2024, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses, however there were no significant impact and no changes in our significant accounting estimates to our unaudited condensed consolidated financial statements.
17





Results of Operations
Three Months and Nine Months Ended March 31, 2024, and 2023
The following table shows consolidated net revenue, as well as identifying trends in revenues for the three months and nine months ended March 31, 2024, and 2023. Table amounts are in thousands:
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 20242023% Change20242023% Change
Net Revenue:
Products$2,568 $3,285 (21.8)%$8,102 $8,582 (5.6)%
Service plans128 149 (14.1)%408 463 (11.9)%
Total$2,696 $3,434 (21.5)%$8,510 $9,045 (5.9)%
    
Consolidated net revenue decreased approximately $738,000 or 21.5%, to $2,696,000 during the three months ended March 31, 2024, as compared to the same period of last fiscal year. The decrease in net revenue is mainly attributed to a decrease in sales of Sonomed's ultrasound products of $701,000 during the three months ended March 31, 2024.

Consolidated net revenue decreased approximately $535,000 or 5.9%, to $8,510,000 during the nine months ended March 31, 2024, as compared to the same period of last fiscal year. The decrease in net revenue is mainly attributed to a decrease in sales of Sonomed's ultrasound products of $467,000 during the nine months ended March 31, 2024.

The following table presents the domestic and foreign sales for the three months and nine months ended March 31, 2024, and 2022. The table amounts are in thousands:
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Domestic$1,339 49.7 %$1,903 55.4 %$4,394 51.6 %$5,258 58.1 %
Foreign1,357 50.3 %1,531 44.6 %4,116 48.4 %3,787 41.9 %
Total$2,696 100.0 %$3,434 100.0 %$8,510 100.0 %$9,045 100.0 %

The following table presents consolidated cost of goods sold and as a percentage of revenues for the three months and nine months ended March 31, 2024, and 2022. Table amounts are in thousands:

 
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 2024%2023%2024%2023%
Cost of Goods Sold:
$1,579 58.6 %$1,721 50.1 %4,836 56.8 %5,021 55.5 %
Total$1,579 58.6 %$1,721 50.1 %4,836 56.8 %5,021 55.5 %


Consolidated cost of goods sold totaled approximately $1,579,000, or 58.6%, of total revenue for the three months ended March 31, 2024, as compared to $1,721,000, or 50.1%, of total revenue of the same period of last fiscal year. The increase of 8.5% in the cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences during the three months ended March 31, 2024.

Consolidated cost of goods sold totaled approximately $4,836,000, or 56.8%, of total revenue for the nine months ended March 31, 2024, as compared to $5,021,000, or 55.5%, of total revenue of the same period of last fiscal year. The increase of 1.3% in the cost of goods sold as a percentage of total revenue is mainly due to changes in product sales mix and geographic differences during the nine months ended March 31, 2024.

18




    The following table presents consolidated marketing, general and administrative expenses for three months and nine months ended March 31, 2024, and 2023. Table amounts are in thousands:
 
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 20242023% Change 20242023% Change 
Marketing, General and Administrative:
$1,118 $938 19.2 %$3,402 $3,108 9.5 %
Total$1,118 $938 19.2 %$3,402 $3,108 9.5 %

Consolidated marketing, general and administrative expenses increased $180,000, or 19.2%, to $1,118,000 for the three months ended March 31, 2024, as compared to the same period of last fiscal year. The increase in marketing, general and administrative expenses is mainly due to the recovery of bad debts of $113,000 during the prior year, tax expenses, and increase travel expense during the three months ended March 31, 2024.

Consolidated marketing, general and administrative expenses increased $294,000, or 9.5%, to $3,402,000 for the nine months ended March 31, 2024, as compared to the same period of last fiscal year. The increase in marketing, general and administrative expenses is mainly due to he recovery of bad debts of $113,000 during the prior year, temporary hiring costs, increased network expenses and travel expenses during the nine months ended March 31, 2024.

The following table presents consolidated research and development expenses for the three months and nine months ended March 31, 2024, and 2023.
Table amounts are in thousands:
For the Three Months Ended March 31, For the Nine Months Ended March 31,
 20242023% Change  20242023% Change
Research and Development:
$156 $186 (16.1)%515 $641 (19.7)%
Total$156 $186 (16.1)%$515 $641 (19.7)%

Consolidated research and development expenses decreased $30,000, or 16.1%, to $156,000 for the three months ended March 31, 2024, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expenses is mainly due to decreased image management consulting expenses offset by the increased current year's new consulting services designing the housing and mechanical inner parts of probes during the three months ended March 31, 2024.
Consolidated research and development expenses decreased $126,000, or 19.7%, to $515,000 for the nine months ended March 31, 2024, as compared to the same period of last fiscal year. Research and development expenses were primarily expenses associated with the introduction of new or enhanced products. The decrease in research and development expenses is mainly due to decreased image management consulting expense during the nine months ended March 31, 2024.

Russia-Ukraine War

In February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed by many countries against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption.

Israel-Hamas war

19




In October 2023, Hamas terrorists attacked Israel, and then Israel declared war and decimated the Gaza Strip. The Israel-Hamas war and conflicts could affect economic activity via lower trade with the Middle East, disruption of supply chain and collection of trade receivables in the region.

The Company has operations or activities in countries and regions outside the United States. As a result, its global operations are affected by economic, political, and other conditions in the foreign countries in which it does business as well as U.S. laws regulating international trade, although the Company has not yet assessed that these wars have had a material effect on its financial position or results of operations.    

Liquidity and Capital Resources

Our total cash on hand as of March 31, 2024 was approximately $565,000 of cash on hand and restricted cash of approximately $256,000 compared to approximately $890,000 of cash on hand and restricted cash of $256,000 as of June 30, 2023.

Because the Company's operations have not historically generated sufficient revenues to enable profitability, we will continue to monitor costs and expenses closely and may need to raise additional capital or take other actions to fund operations.

The Company expects to continue to fund operations from cash on hand and through capital raising sources if possible and available, which may be dilutive to existing stockholders, through revenues from the licensing of the Company's products, or through strategic alliances. Additionally, we may seek to sell additional equity or debt securities through one or more discrete transactions, or enter a strategic alliance arrangement, but can provide no assurances that any such financing or strategic alliance arrangement will be available on acceptable terms, or at all. Moreover, the incurrence of indebtedness in connection with a debt financing would result in increased fixed obligations and could contain covenants that would restrict our operations.

As of March 31, 2024, we had an accumulated deficit of approximately $68.7 million, historically incurred recurring losses from operations and negative cash flows from operating activities. These factors raise substantial doubt regarding our ability to continue as a going concern, and our ability to generate cash to meet our cash requirements for the following twelve months as of the date of this form 10-Q.
    
The following table presents overall liquidity and capital resources as of March 31, 2024, and June 30, 2023. Table amounts are in thousands:
 
March 31,June 30,
 20242023
Current Ratio:
Current assets$4,152$4,637
Less: Current liabilities2,6292,853
Working capital$1,523$1,784
Current ratio1.58 to 11.63 to 1
Debt to Total Capital Ratio:
Note payable, lease liabilities, and EIDL loan$614$890
Total debt 614890
Total equity 1,6751,935
Total capital $2,290$2,825
Total debt to total capital 26.8%31.5%
20




Working Capital Position
Working capital decreased approximately $261,000 as of March 31, 2024, and the current ratio decreased to 1.58 to 1 from 1.63 to 1 when compared to June 30, 2023.
Debt to total capital ratio was 26.8% and 31.5%  as of March 31, 2024, and June 30, 2023, respectively. The decrease of debt to total capital ratio is mainly due to lease payments.
Cash Flow Used in Operating Activities
During the nine months ended March 31, 2024, the Company used approximately $263,000 of cash in operating activities as compared to cash of approximately $30,000 used in operating activities during the nine months ended March 31, 2024.
    For the nine months ended March 31, 2024, its cash used in operations is due to an increase in inventory of $217,000, a decrease in accounts payable of $87,000, a decrease in lease liability of $245,000, and a decrease in deferred revenue of $23,000, offset by a decrease in accounts receivable of $274,000 and a decrease in current assets of $83,000. The remaining offsetting items for cash provided by operations is comprised of less significant items.
     For the nine months ended March 31, 2023, its cash used in operations is due to operating income of $258,000, an increase in accounts payable of $35,000, and a decrease in other current and non-current assets of $28,000, offset by an increase in accounts receivable of approximately $108,000, an increase of inventory of $61,000, a repayment of employer tax deferral of $43,000, and a decrease of other deferred revenue of $37,000 and a decrease in accrued expense of $33,000. The remaining offsetting items for cash provided by operations is comprised of less significant items
Cash Flows used in Investing Activities
Cash flows used in investing activities for the nine months ended March 31, 2024 was due to purchase of fixed assets of $31,000. Cash flows used in investing activities for the nine-month period ended March 31, 2023 was due to the addition to the patent of $7,000 and addition to the fixed assets of $7,000.
Cash Flows Used in Financing Activities
For the nine months ended March 31, 2024 the cash used in financing activities was due to loan payments of $28,000 and repayment of EIDL loan of $3,000. For the nine months ended March 31, 2023 the cash used in financing activities was due to an auto loan payment of $3,000 and repayment of EIDL loan of $3,000.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk

None.

Item 4. Controls and Procedures

(A)    Evaluation of Disclosure Controls and Procedures

The Company's management, with the participation of the Company's Chief Executive Officer and Principal Financial and Accounting Officer, have established disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the officers who certify the Company's financial reports and to other members of senior management and the Board of Directors.

Based on their evaluation of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2024, the Chief Executive Officer and Principal Financial and Accounting Officer of the Company have concluded that such disclosure controls and procedures are not effective to ensure that the information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its Chief Executive Officer and Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosure. We identified a material weakness in internal control related to the proper design and implementation of controls over our estimates relating to the valuation of inventory and allowance for doubtful accounts, specifically over the precision of management’s review during the year end June 30, 2023.


21




(B)    Internal Control over Financial Reporting

There have not been any changes in the Company's internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act), during the third quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Part II. OTHER INFORMATION
Item 5. Other Information

None.
Item 6.    Exhibits


Signatures
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Escalon Medical Corp.
(Registrant)
Date: May 14, 2024By:/s/ Richard J. DePiano, Jr.
Richard J. DePiano, Jr.
Chief Executive Officer
Date: May 14, 2024By:/s/ Mark Wallace
Mark Wallace
Chief Operating Officer and Principal Accounting & Financial Officer

22
 EX-31.1 2 esmc_2024331-10qex311.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
I, Richard J. DePiano, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Escalon Medical Corp.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/    Richard J. DePiano Jr.
Richard J. DePiano Jr.
Chief Executive Officer
Date: May 14, 2024


 EX-31.2 3 esmc_2024331-10qex312.htm EX-31.2 Document

Exhibit 31.2


Certification of Principal Financial Officer
I, Mark Wallace, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Escalon Medical Corp.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
/s/    Mark Wallace
Mark Wallace
Date: May 14, 2024


 EX-32.1 4 esmc_2024331-10qex321.htm EX-32.1 Document

Exhibit 32.1

Certification pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
I, Richard J. DePiano Jr., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Quarterly Report of Escalon Medical Corp. on Form 10Q for the quarterly period ended March 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 14, 2024
 
/s/    Richard J. DePiano Jr.
Richard J. DePiano Jr.
Chief Executive Officer



 EX-32.2 5 esmc_2024331-10qex322.htm EX-32.2 Document

Exhibit 32.2

Certification pursuant to 18 U.S.C. Section 1350,
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Mark Wallace, Chief Operating Officer and Principal Accounting & Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Quarterly Report of Escalon Medical Corp. on Form 10-Q for the quarterly period ended March 31, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 14, 2024
 
/s/    Mark Wallace
Mark Wallace
Chief Operating Officer and Principal Accounting & Financial Officer



 EX-101.SCH 6 esmc-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements Of Operations link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements Of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Going concern (Notes) link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Inventory (Notes) link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Line of Credit link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Long term debt (Notes) link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Concentration of credit risk (Notes) link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Leases (Notes) link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Going concern (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Line of Credit (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Long term debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Concentration of credit risk (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Commitment and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Going concern (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Significant Accounting Policies (Inventory) (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Significant Accounting Policies (Accounts Receivable) (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Significant Accounting Policies (Net Income (loss) Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Significant Accounting Policies Earning per share details (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Significant Accounting Policies Income tax (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Significant Accounting Policies deferred revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Significant Accounting Policies New accounting pronouncements recently adopted (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Line of Credit (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Line of Credit - Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Long term debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Concentration of credit risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Commitment and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 esmc-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 esmc-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 esmc-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Increase (Decrease) in Other Deferred Liability Increase (Decrease) in Other Deferred Liability Variable Rate [Domain] Variable Rate [Domain] Accrued expenses Accrued Liabilities, Current Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Total current assets Assets, Current Inventory Valuation Reserves Inventory Valuation Reserves Preferred Stock [Member] Preferred Stock [Member] Research and development Research and Development Expense Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Convertible Preferred Stock, Shares Issued upon Conversion Convertible Preferred Stock, Shares Issued upon Conversion Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Restricted Cash Restricted Cash Accounts Receivable, after Allowance for Credit Loss Accounts Receivable, after Allowance for Credit Loss Supplemental Schedule of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Dividends Payable, Date to be Paid Preferred Stock, Amount of Preferred Dividends in Arrears Line of Credit Debt Disclosure [Text Block] Other Notes Payable, Current Other Notes Payable, Current Other Nonoperating Income (Expense) Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Secured Long-term Debt, Noncurrent Secured Long-Term Debt, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Net Income (loss) Per Share Earnings Per Share, Policy [Policy Text Block] Accounts payable Accounts Payable, Current Supplier one [Member] Supplier one [Member] Supplier one [Member] Concentration Risk, Percentage Concentration Risk, Percentage Total other (expense) income Nonoperating Income (Expense) Preferred stock, shares authorized Preferred Stock, Shares Authorized Restricted Cash, Current Restricted Cash, Current Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Supplier [Axis] Supplier [Axis] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Accounts Receivable Accounts Receivable [Policy Text Block] Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Operating Activities Geographical [Axis] Geographical [Axis] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Organization and Description of Business and Business Conditions Nature of Operations [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Concentration Risk [Line Items] Concentration Risk [Line Items] Other Notes Payable, Noncurrent Other Notes Payable, Noncurrent Revenue Recognition Revenue [Policy Text Block] Customer [Axis] Customer [Axis] Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Current liabilities: Liabilities, Current [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Going concern [Abstract] Going concern [Abstract] Going concern [Abstract] Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Total shareholders' equity Balance Balance Equity, Attributable to Parent Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized;2,000,000 issued and outstanding Preferred Stock, Value, Issued Preferred Stock, Value, Issued Deferred Revenue, Revenue Recognized Deferred Revenue, Revenue Recognized Debt Security Category [Axis] Debt Security Category [Axis] Earnings (Loss) Per Share, Diluted Earnings (Loss) Per Share, Diluted Earnings Per Share, Diluted Increase (Decrease) in Deferred Revenue Increase (Decrease) in Deferred Revenue Convertible Preferred Dividends, Net of Tax Convertible Preferred Dividends, Net of Tax Concentration Risk Type [Axis] Concentration Risk Type [Axis] Payments to Acquire Intangible Assets Payments to Acquire Intangible Assets Earning per share [Abstract] Earning per share [Abstract] Earning per share [Abstract] Preferred Stock, Shares Issued Preferred Stock, Shares Issued Net (loss) income Net Income (Loss) Total current liabilities Liabilities, Current Entity Emerging Growth Company Entity Emerging Growth Company Lease Lessee, Operating Leases [Text Block] Interest Payable, Current Interest Payable, Current Inventory, Finished Goods, Gross Inventory, Finished Goods, Gross LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] Customer two Customer two [Member] Customer two Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Shareholders equity: Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Document Fiscal Period Focus Document Fiscal Period Focus Inventory, Gross Inventory, Gross 2024 (reminder of FY 2024) Lessee, Operating Lease, Liability, to be Paid, Year One Dividends Payable, Amount Per Share Dividends Payable, Amount Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of Goods and Services Sold Cost of Goods and Services Sold Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion Related Party Transaction, Amounts of Transaction Related Party Transaction, Amounts of Transaction Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Deferred Revenue, Additions Deferred Revenue, Additions Deposits Assets, Noncurrent Deposits Assets, Noncurrent Significant Accounting Policies Significant Accounting Policies [Text Block] Common Stock [Member] Common Stock [Member] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Recognized revenue that was included within prior period deferred revenue Recognized revenue that was included within prior period deferred revenue Recognized revenue that was included within prior period deferred revenue Product and Service [Axis] Product and Service [Axis] Statement, Equity Components [Axis] Equity Components [Axis] Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Accrued Liabilities Short-term Lease Payments Short-Term Lease Payments Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] 2026 Long-Term Debt, Maturity, Year Two Entity Small Business Entity Small Business Interest portion in the future lease payments Interest portion in the future lease payments Interest portion in the future lease payments Supplier [Domain] Supplier [Domain] Local Phone Number Local Phone Number Increaser(Decrease) in Accounts Receivable Increase (Decrease) in Accounts Receivable Property and equipment, net Property, Plant and Equipment, Net Accounts Receivable Accounts Receivable [Member] 2024 (remainder of FY 2024) Long-Term Debt, Maturity, Remainder of Fiscal Year Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Common Stock, Voting Rights Common Stock, Voting Rights Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Debt instrument, term Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Contractual Obligation, Fiscal Year Maturity Contractual Obligation, Fiscal Year Maturity [Table Text Block] Net Cash Provided by (Used in) Financing Activities Net Cash Provided by (Used in) Financing Activities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Line of Credit Facility [Table] Line of Credit Facility [Table] Accumulated Deficit [Member] Retained Earnings [Member] Concentration Risk, Customer Concentration Risk, Customer Total liabilities and shareholders' equity Liabilities and Equity Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Earnings (Loss) Per Share, Basic Earnings Per Share, Basic Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Option [Member] Equity Option [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Liquidity Disclosure [Policy Text Block] Substantial Doubt about Going Concern [Text Block] Revenues Revenues Revenues Net Income (Loss) Available to Common Stockholders, Diluted Net Income (Loss) Available to Common Stockholders, Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service [Domain] Product and Service [Domain] New accounting pronouncements recently adopted [Abstract] New accounting pronouncements recently adopted [Abstract] New accounting pronouncements recently adopted [Abstract] Lease, Cost [Table Text Block] Lease, Cost [Table Text Block] Increase (Decrease) in Inventories Increase (Decrease) in Inventories Entity Address, City or Town Entity Address, City or Town Cash Flows from Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Principles of Consolidation Consolidation, Policy [Policy Text Block] Document Quarterly Report Document Quarterly Report Total long-term liabilities Liabilities, Noncurrent Interest expense Interest Expense Document Transition Report Document Transition Report Secured Debt, Current Secured Debt, Current Related Party Transactions Related Party Transactions Disclosure [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable Common stock, shares authorized Common Stock, Shares Authorized Inventory, Raw Materials, Gross Inventory, Raw Materials, Gross Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Supplier Three Supplier Three [Member] Supplier Three Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Operating Lease, Liability, Current Operating Lease, Liability, Current 2027 Long-Term Debt, Maturity, Year Three Convertible Preferred Stock [Member] Convertible Preferred Stock [Member] Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Net Supplier Concentration Risk [Member] Supplier Concentration Risk [Member] Increase (Decrease) in Other Operating Liabilities Increase (Decrease) in Other Operating Liabilities Monthly principal and interest payments Debt Instrument, Periodic Payment, Principal Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning of Period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, End of Period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Accounts Receivable Accounts Receivable, before Allowance for Credit Loss Operating Lease, Cost Operating Lease, Cost Accounts Receivable, Credit Loss Expense (Reversal) Accounts Receivable, Credit Loss Expense (Reversal) Accounts Receivable, Credit Loss Expense (Reversal) Additional paid-in capital Additional Paid in Capital Common stock, shares issued Common Stock, Shares, Issued Total Long-term Debt Long-Term Debt Marketing, general and administrative Selling, General and Administrative Expense 2028 Long-Term Debt, Maturity, Year Four Income Taxes Income Tax, Policy [Policy Text Block] Inventory, Work in Process, Gross Inventory, Work in Process, Gross Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Total costs and expenses Costs and Expenses Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss Document Type Document Type Deferred Revenue Deferred Revenue Deferred Revenue Deferred Revenue 2025 Long-Term Debt, Maturity, Year One Note Payable Notes Payable to Banks [Member] Geographic Concentration Risk [Member] Geographic Concentration Risk [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Inventory Inventory, Policy [Policy Text Block] Long-term Debt, Weighted Average Interest Rate, at Point in Time Long-Term Debt, Weighted Average Interest Rate, at Point in Time Increase (Decrease) in Other Operating Assets Increase (Decrease) in Other Operating Assets Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Document Period End Date Document Period End Date Accounts Receivable, Allowance for Credit Loss Accounts Receivable, Allowance for Credit Loss [Table Text Block] Entity Central Index Key Entity Central Index Key Concentration Risk Disclosure [Text Block] Concentration Risk Disclosure [Text Block] Customer Concentration Risk [Member] Customer Concentration Risk [Member] Other short-term liabilities Other Liabilities, Current Variable Rate [Axis] Variable Rate [Axis] International [Member] Non-US [Member] Income Statement [Abstract] Income Statement [Abstract] Debt Instrument, Periodic Payment Debt Instrument, Periodic Payment Accounts Receivable, Allowance for Credit Loss, Writeoff Accounts Receivable, Allowance for Credit Loss, Writeoff Costs and expenses: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Revenue Benchmark [Member] Revenue Benchmark [Member] Lender Name [Axis] Lender Name [Axis] Inventory Disclosure [Text Block] Inventory Disclosure [Text Block] Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Other current assets Other Assets, Current Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax Concentration Risk, Supplier Concentration Risk, Supplier Preferred Stock Dividends, Income Statement Impact Preferred Stock Dividends, Income Statement Impact Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Entity Tax Identification Number Entity Tax Identification Number Concentration of credit risks [Abstract] Concentration of credit risks [Abstract] Concentration of credit risks [Abstract] Inventory, net Inventory, Net Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Repayments of Notes Payable Repayments of Notes Payable Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Interest Paid, Excluding Capitalized Interest, Operating Activities Interest Paid, Excluding Capitalized Interest, Operating Activities Statistical Measurement [Axis] Statistical Measurement [Axis] Entity Interactive Data Current Entity Interactive Data Current Long-term Debt [Text Block] Long-Term Debt [Text Block] Debt Instrument, Basis Spread on Variable Rate Debt Instrument, Basis Spread on Variable Rate Product [Member] Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Weighted Average Number of Shares Outstanding, Diluted Weighted average shares - diluted Weighted Average Number of Shares Outstanding, Diluted Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Lessee Disclosure [Abstract] Supplier two [Member] Supplier two [Member] Supplier two Revenue Recognition and Deferred Revenue [Abstract] Revenue Recognition and Deferred Revenue [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment Note payable, face amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Current assets: Assets, Current [Abstract] Total assets Assets Entity Address, State or Province Entity Address, State or Province Cover [Abstract] Cover [Abstract] Cash Flows from Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] 2028 Long-Term Debt, Maturity, Year Five Domestic [Member] UNITED STATES Common stock, shares outstanding Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Debt Instrument, Interest Rate During Period Debt Instrument, Interest Rate During Period Notes Payable to Bank Notes Payable to Bank Total lease payments Lessee, Operating Lease, Liability, to be Paid Other (expense) income: Other Income and Expenses [Abstract] schedule of inventory [Abstract] schedule of inventory [Abstract] schedule of inventory [Abstract] Other Operating Activities, Cash Flow Statement Other Operating Activities, Cash Flow Statement Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Preferred stock, number of votes per share Preferred Stock, Number of Votes per Share Preferred Stock, Number of Votes per Share Net Cash provided by (used in) Financing Activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Accounts Payable Benchmark [Member] Accounts Payable Benchmark [Member] Accounts Payable Benchmark [Member] Common stock, par value Common Stock, Par or Stated Value Per Share Secured Debt [Member] Secured Debt [Member] Total Shareholders' Equity [Domain] Equity Component [Domain] Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Schedule of Inventory, Current [Table Text Block] Schedule of Inventory, Current [Table Text Block] Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) Available to Common Stockholders, Basic TD Bank TD Bank [Member] TD Bank Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted average shares - basic Basic Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Basic Common Stock, Conversion Basis Common Stock, Conversion Basis Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] (Loss) income from operations Operating Income (Loss) Customer One [Member] Customer One [Member] Customer One [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Maturities of Line of Credit Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Service [Member] Service [Member] Net present value of new lease future payments Net present value of new lease future payments Net present value of new lease future payments Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Repayment of EIDL loan Repayment of EIDL loan Repayment of EIDL loan Accounts Receivable Benchmark [Member] Accounts Receivable Benchmark [Member] Accounts Receivable Benchmark [Member] Statement [Line Items] Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Net income (loss) per share Earnings Per Share [Abstract] Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] EX-101.PRE 10 esmc-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover - shares
 9 Months Ended
Mar. 31, 2024
May 13, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Entity Registrant Name Escalon Medical Corp.  
Entity Incorporation, State or Country Code PA  
Entity Tax Identification Number 33-0272839  
Entity Address, Address Line One 435 Devon Park Drive  
Entity Address, City or Town Wayne  
Document Transition Report false  
Entity File Number 000-20127  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19087  
City Area Code (610)  
Local Phone Number 688-6830  
Entity Emerging Growth Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   7,415,329
Title of 12(b) Security common stock, $0.001 par value  
Entity Central Index Key 0000862668  
Current Fiscal Year End Date --06-30  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Jun. 30, 2023
Current assets:    
Cash and cash equivalents $ 564,707 $ 889,674
Restricted Cash, Current 256,390 256,293
Accounts Receivable 1,491,827 1,807,599
Accounts Receivable, Allowance for Credit Loss (132,624) (153,878)
Accounts Receivable, after Allowance for Credit Loss 1,359,203 1,653,721
Inventory, net 1,804,929 1,587,989
Other current assets 166,600 249,790
Total current assets 4,151,829 4,637,467
Property and equipment, net 53,971 34,064
Operating Lease, Right-of-Use Asset 276,089 503,647
Finite-Lived Intangible Assets, Net 54,355 69,986
Deposits Assets, Noncurrent 62,787 62,787
Total assets 4,599,031 5,307,951
Current liabilities:    
Other Notes Payable, Current 33,262 37,087
Secured Debt, Current 3,172 3,105
Accounts payable 1,118,057 1,205,510
Accrued expenses 589,877 651,978
Interest Payable, Current 112,389 112,389
Operating Lease, Liability, Current 282,950 329,638
Deferred Revenue 403,069 426,227
Other short-term liabilities 86,333 87,125
Total current liabilities 2,629,109 2,853,059
Other Notes Payable, Noncurrent 135,483 159,511
Operating Lease, Liability, Noncurrent 15,974 214,103
Total long-term liabilities 294,746 520,049
Total liabilities 2,923,855 3,373,108
Shareholders equity:    
Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized;2,000,000 issued and outstanding 645,000 645,000
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding 7,415 7,415
Additional paid-in capital 69,702,043 69,702,043
Accumulated deficit (68,679,282) (68,419,615)
Total shareholders' equity 1,675,176 1,934,843
Total liabilities and shareholders' equity 4,599,031 5,307,951
Secured Debt [Member]    
Current liabilities:    
Secured Long-term Debt, Noncurrent $ 143,289 $ 146,435
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2024
Jun. 30, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred Stock, Shares Issued 2,000,000 2,000,000
Common stock, par value   $ 0.001
Common stock, shares authorized 35,000,000 35,000,000
Common stock, shares issued 7,415,329 7,415,329
Common stock, shares outstanding 7,415,329 7,415,329
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements Of Operations - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Revenue from External Customer [Line Items]        
Revenues $ 2,695,501 $ 3,434,314 $ 8,509,738 $ 9,044,619
Costs and expenses:        
Cost of Goods and Services Sold 1,578,727 1,720,853 4,835,402 5,021,470
Marketing, general and administrative 1,117,534 938,161 3,401,902 3,108,177
Research and development 155,848 185,750 515,213 641,316
Total costs and expenses 2,852,109 2,844,764 8,752,517 8,770,963
(Loss) income from operations (156,608) 589,550 (242,779) 273,656
Other (expense) income:        
Other Nonoperating Income (Expense) 0 0 0 0
Interest expense (5,541) (4,315) (16,888) (15,188)
Net (loss) income (162,149) 585,235 (259,667) 258,468
Preferred Stock Dividends, Income Statement Impact 12,830 13,006 38,842 38,735
Net Income (Loss) Available to Common Stockholders, Basic $ (174,979) $ 572,229 $ (298,509) $ 219,733
Net income (loss) per share        
Earnings (Loss) Per Share, Basic $ (0.02) $ 0.08 $ (0.04) $ 0.03
Earnings (Loss) Per Share, Diluted $ (0.02) $ 0.04 $ (0.04) $ 0.02
Weighted average shares - basic 7,415,329 7,415,329 7,415,329 7,415,329
Weighted Average Number of Shares Outstanding, Diluted 7,415,329 13,478,936 7,415,329 13,478,936
Product [Member]        
Revenue from External Customer [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax $ 2,567,387 $ 3,285,396 $ 8,101,834 $ 8,582,183
Service [Member]        
Revenue from External Customer [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax $ 128,114 $ 148,918 $ 407,904 $ 462,436
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements Of Shareholders' Equity - USD ($)
Total
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Balance at Jun. 30, 2022 $ 1,478,017     $ 69,702,043 $ (68,876,441)
Net (loss) income (320,724) $ 0 $ 0 0 (320,724)
Balance at Sep. 30, 2022 1,157,293     69,702,043 (69,197,165)
Balance at Jun. 30, 2022 1,478,017     69,702,043 (68,876,441)
Net (loss) income 258,468        
Balance at Mar. 31, 2023 1,736,485     69,702,043 (68,617,973)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Balance at Sep. 30, 2022 1,157,293     69,702,043 (69,197,165)
Net (loss) income (6,043) $ 0 $ 0 0 (6,043)
Balance at Dec. 31, 2022 1,151,250     69,702,043 (69,203,208)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Net (loss) income 585,235 $ 0 $ 0 0 585,235
Balance at Mar. 31, 2023 1,736,485     69,702,043 (68,617,973)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued 645,000   $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding $ 7,415 $ 7,415      
Common Stock, Shares, Outstanding 7,415,329 7,415,329      
Balance at Jun. 30, 2023 $ 1,934,843     69,702,043 (68,419,615)
Net (loss) income (21,197) $ 0 $ 0 0 (21,197)
Balance at Sep. 30, 2023 1,913,646     69,702,043 (68,440,812)
Balance at Jun. 30, 2023 1,934,843     69,702,043 (68,419,615)
Net (loss) income (259,667)        
Balance at Mar. 31, 2024 1,675,176     69,702,043 (68,679,282)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Balance at Sep. 30, 2023 1,913,646     69,702,043 (68,440,812)
Net (loss) income (76,321) $ 0 $ 0 0 (76,321)
Balance at Dec. 31, 2023 1,837,325     69,702,043 (68,517,133)
Preferred Stock, Shares Outstanding     2,000,000    
Preferred Stock, Value, Issued     $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding   $ 7,415      
Common Stock, Shares, Outstanding   7,415,329      
Net (loss) income (162,149) $ 0 $ 0 0 (162,149)
Balance at Mar. 31, 2024 $ 1,675,176     $ 69,702,043 $ (68,679,282)
Preferred Stock, Shares Outstanding     2,000,000    
Convertible Preferred Stock, Shares Issued upon Conversion 2.15        
Preferred Stock, Value, Issued $ 645,000   $ 645,000    
Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding $ 7,415 $ 7,415      
Common Stock, Shares, Outstanding 7,415,329 7,415,329      
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements Of Cash Flows - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Cash Flows from Operating Activities:        
Net (loss) income $ (162,149) $ 585,235 $ (259,667) $ 258,468
Accounts Receivable, Credit Loss Expense (Reversal) 0 (98,400) 20,354 (93,400)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization     26,763 34,424
Change in operating assets and liabilities:        
Increaser(Decrease) in Accounts Receivable     274,164 (107,573)
Increase (Decrease) in Inventories     (216,940) (61,238)
Increase (Decrease) in Other Operating Assets     83,189 27,798
Increase (Decrease) in Deferred Revenue     (23,158) (36,985)
Increase (Decrease) in Accounts Payable     (87,453) 35,375
Increase (Decrease) in Accrued Liabilities     (62,101) (33,063)
Increase (Decrease) in Other Operating Liabilities     (244,817) (226,404)
Other Operating Activities, Cash Flow Statement     227,558 215,772
Increase (Decrease) in Other Deferred Liability     (792) (42,955)
Net Cash Provided by (Used in) Operating Activities     (262,900) (29,781)
Payments to Acquire Property, Plant, and Equipment     (31,038) (6,687)
Cash Flows from Investing Activities:        
Payments to Acquire Intangible Assets     0 (7,155)
Net Cash Provided by (Used in) Investing Activities     (31,038) (13,842)
Net Cash provided by (used in) Financing Activities:        
Repayments of Notes Payable     (27,853) (3,165)
Repayment of EIDL loan     (3,079) (2,686)
Net Cash Provided by (Used in) Financing Activities     (30,932) (5,851)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect     (324,870) (49,474)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning of Period     1,145,967 850,034
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, End of Period 821,097 800,560 821,097 800,560
Cash and cash equivalents 564,707 544,320 564,707 544,320
Restricted Cash 256,390 256,240 256,390 256,240
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 821,097 $ 800,560 821,097 800,560
Supplemental Schedule of Cash Flow Information:        
Interest Paid, Excluding Capitalized Interest, Operating Activities     $ 16,985 $ 15,697
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Organization and Description of Business
 9 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business and Business Conditions Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc.
    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.
The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of March 31, 2024, and the results of operations and cash flows for the interim periods ended March 31, 2024 and 2023, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on October 13, 2023. Operating results for the three months and nine months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2024.

    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Going concern (Notes)
 9 Months Ended
Mar. 31, 2024
Going concern [Abstract]  
Liquidity Disclosure [Policy Text Block] . Going Concern
The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies, the price of, and demand for, the Company’s products and its ability to raise capital to support its operations.

To date, the Company’s operations have not generated sufficient revenues to enable consistent profitability. Through March 31, 2024, the Company had incurred historical recurring losses from operations and incurred negative cash flows from operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the next 12 months following the issuance of these unaudited condensed consolidated financial statements.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, and implementing cost-cutting measures. The Company may not be successful in any of these efforts.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Inventory (Notes)
 9 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Inventory Disclosure [Text Block] Inventories
March 31,
June 30,
(in thousands)20242023
Inventories:
        Raw Material$1,027 $882 
        Work-In-Process388 86 
        Finished Goods650 881 
Total inventories$2,065 $1,849 
Allowance for obsolete inventory(260)(260)
Inventories, net$1,805 $1,588 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related Party Transactions
 9 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions and Preferred Stock
    As of March 31, 2024, and 2023, the related party interest accrual of $112,389 related to the debt prior to the exchange, remained as an on demanded payable.
On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”).  Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).
    
    Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders.  As a result of this voting power, the Holders as of March 31, 2024 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders.

    Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”).  The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion.

    Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of March 31, 2024, and June 30, 2023, the cumulative dividends payable are $316,173 ($0.1581 per share) and $277,331 ($0.1387 per share), respectively.

    Mr. DePiano Sr. passed away on October 3, 2019, and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as Chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Line of Credit
 9 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Line of Credit On June 29, 2018, the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.0% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.74 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.74% per annum based on a year of 360 days. The Company was required to put $250,000 in the TD bank savings account as collateral. The Loan is guaranteed by Mr. DePiano Jr.
TD bank elected to exercise the term note conversion option to convert the loan balance of $201,575 to a five-year term note effective March 29, 2023 the "Conversion Date"). The scheduled monthly principal and interest payments in the amount of $4,247 began on April 29, 2023. Commencing on the Conversion Date, the aggregate principal balance outstanding bears interest at a fixed per annum rate of 9.49% pursuant to the loan's terms and conditions.

The future note payable payments as of March 31, 2024 are as follows:

Year ending June 30,
TD Note Payment
2024 (remainder of FY 2024)
8,530 
2025
37,434 
2026
41,145 
202745,224 
202836,412 
Total
$168,745 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Long term debt (Notes)
 9 Months Ended
Mar. 31, 2024
Debt Instrument [Line Items]  
Long-term Debt [Text Block]
Economic Injury Disaster Loan ("EIDL")

    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received a $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company.

    The future annual principal amounts to be paid as of March 31, 2024 are as follows:
Year ending June 30,EIDL Payment
2024 (remainder of FY 2024)$782 
20253,202 
20263,324 
20273,451 
20283,582 
Thereafter132,120 
Total$146,461 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Concentration of credit risk (Notes)
 3 Months Ended
Sep. 30, 2023
Concentration Risk [Line Items]  
Concentration Risk Disclosure [Text Block]
Credit Risk

Financial instruments, which potentially subject the Company to the concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely addresses the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral.

Major Customer

    One customers accounted for 13% of net revenue during the three-month period ended March 31, 2024. One customer accounted for 11% of net revenue during the nine-month period ended March 31, 2024. No customer accounted for more than 10% during the three-month and nine-month periods ended March 31, 2023.

    As of March 31, 2024, the Company had two customers that represented 16% and 11% of the total accounts receivable balance. As of June 30, 2023, the Company had one customer that represented 24% of the total accounts receivable balance.

Major Supplier
    The Company's two largest suppliers accounted for 36% and 11% of total purchases for the three-month period ended March 31, 2024. The Company's one largest supplier accounted for 40% of total purchases for the nine-month period ended March 31, 2024. The Company's two largest suppliers accounted for 44% and 11% of total purchases for the three-month period ended March 31, 2023. The Company's two largest suppliers accounted for 44% and 10% of total purchases for the nine-month period ended March 31, 2023.

    As of March 31, 2024, the Company had three suppliers that represented 29%, 12%, and 11% of the total accounts payable balance. As of June 30, 2023, the Company had two suppliers that represented approximately 36% and 11% of the total accounts payable balance.

Disaggregated Revenue

    Domestic and international sales from operations are as follows:
(in thousands)For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Domestic$1,339 50 %$1,903 55 %$4,394 52 %$5,258 58 %
Foreign1,357 50 %1,531 45 %4,116 48 %3,787 42 %
Total$2,696 100 %$3,434 100 %$8,510 100 %$9,045 100 %
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases (Notes)
 9 Months Ended
Mar. 31, 2024
Lessee Disclosure [Abstract]  
Lease Leases
    The Company leases certain facilities and equipment under operating leases. Total lease expense, under ASC 842, was included in cost of goods sold and marketing, general and administrative costs in our unaudited condensed consolidated statements of operations for the three and nine months ended March 31, 2024, and 2023 as follows:

For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Operating lease costs:
Fixed$84,970 $85,324 $254,992 $256,084 
Total:$84,970 $85,324 $254,992 $256,084 

    Supplemental cash flow information was as follows:
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$88,224 $86,350 $262,387 $256,883 
Total$88,224 $86,350 $262,387 $256,883 


    The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate)
under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of March 31, 2024:
Operating
2024 (reminder of FY 2024)$88,514 
2025212,415 
20263,928 
20271,200 
20281,200 
Thereafter600 
Total lease payments307,857 
Less interest 8,933 
Present value of lease liabilities$298,924 

    Average lease terms and discount rates were as follows:
March 31,June 30,
20242023
Weighted-average remaining lease terms (years)
Operating leases
0.971.67
Weighted-average discount rate
Operating leases
5.72 %5.69 %
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Commitment and Contingencies
 9 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Contingencies
The Company, from time to time is involved in various legal proceedings and disputes that arise in the normal course of business. These matters have included intellectual property disputes, contract disputes, employment disputes and other matters. The Company does not believe that the resolution of any of these matters has had or is likely to have a material adverse impact on the Company’s business, financial condition or results of operations.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Significant Accounting Policies (Policies)
 9 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
New Accounting Pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (“ASC 326”), authoritative guidance amending how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The guidance requires the application of a current expected credit loss model, which is a new impairment model based on expected losses. The new guidance is effective for interim and annual reporting periods beginning after December 15, 2022. The adoption of the new guidance will not have a material impact on the Company's unaudited consolidated financial statements. The Company adopted the current expected credit loss model prospectively from fiscal year 2024, and assessed the allowance for expected credit losses to reflect the risk of loss, even when that risk is remote. The Company continues to use the aging matrix in conjunction with the historical information, current conditions, and reasonable and supportable forecasts. The Company groups most of the trade receivable by pools after adoption of the new standards while it analyzed the credit loss of the trade receivables one by one before adoption. The major difference is the estimate of the current expected credit loss for the receivable that are current on their payment. For the nine-month period ended March 31, 2024, the adoption of the new guidance did not have a material impact on the Company's unaudited consolidated financial statements. The Company will continue to assess the current expected credit loss. It may need to recognize a credit loss in the income statement earlier than under the legacy guidance at certain times when the expected credit loss is increased.
Principles of Consolidation
The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable
Accounts receivables are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company adopted the current expected credit loss model prospectively from fiscal year 2024, and assessed the allowance for expected credit losses to reflect the risk of loss, even when that risk is remote. The Company continues to use the aging matrix in conjunction with the historical information, current conditions and reasonable and supportable forecasts. The Company groups most of the trade receivable by pools after adoption of the new standards while it analyzed the credit loss of the trade receivables one by one before adoption. The major difference is the estimate of the current expected credit loss for the receivables that are current on their payment. With adoption of the new standards, the small credit loss rate applied to current receivables will be mostly offset by the lower expected credit rate applied to over 120 days past due when less than 100% of expected credit loss is applied. The historical credit loss rate is adjusted for current conditions and management's assessment for factors such as international relations, economic conditions, and special-term contracts etc. For the nine-month period ended March 31, 2024, the adoption of the new guidance did not have a material impact on the Company's unaudited consolidated financial statements. The Company will continue to assess the current expected credit loss. It may need to recognize a credit loss in the income statement earlier than under the legacy guidance at certain time when the expected credit loss is increased. The Company recorded an allowance for credit losses of approximately $132,624 and $153,878 as of March 31, 2024, and June 30, 2023, respectively.

The activity for the allowance for credit losses during the three-month and nine-month periods ended March 31, 2024, and the fiscal year ended June 30, 2023, is as follows:
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 2024202320242023
Balance, at the beginning of the period$133,524 $241,349 $153,878 $236,349 
Provision (Reversal)— (98,400)(20,354)(93,400)
Write-offs(900)— (900)— 
Balance, at the end of the period$132,624 $142,949 $132,624 $142,949 
Inventory Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely have impact on the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year.
Net Income (loss) Per Share The Company utilizes the two-class method to compute net (loss) income per common share. These participating securities included the Company’s convertible preferred stock which accrues dividends payable. The two-class method requires (loss) earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.
Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had
all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.

Diluted net income per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options. The Company analyzed the potential dilutive effect of any outstanding dilutive securities under the “if-converted” method and treasury-stock method when calculating diluted earnings per share, in which it is assumed that the outstanding participating securities convert into common stock at the beginning of the period or date of issuance, if later. The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. As of March 31, 2024 and 2023, the average market prices for the years then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive.
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Numerator:
  Numerator for basic loss per share:
 Net (loss) income$(162,149)$585,235 $(259,667)$258,468 
Undeclared dividends on preferred stock12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Numerator for diluted loss per share:
Diluted (loss) income$(162,149)$585,235 $(259,667)$258,468 
Undeclared dividends on preferred stock12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Denominator for basic (loss) earning per share
Denominator for basic (loss) earning per share - weighted average shares outstanding
7,415,329 7,415,329 7,415,329 7,415,329 
Weighted average preferred stock converted to common stock— 6,063,607 — 6,063,607 
 Denominator for diluted (loss) income assumed conversion7,415,329 13,478,936 7,415,329 13,478,936 
Net (loss) income per share:
Basic net (loss) income per share$(0.02)$0.08 $(0.04)$0.03 
Diluted net (loss) income per share$(0.02)$0.04 $(0.04)$0.02 
The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.

For the Three Months Ended March 31,For the Nine Months Ended March 31,
2024202320242023
Stock options157,000 157,000 157,000 157,000 
Convertible preferred stock6,407,820 — 6,407,820 — 
Total potential dilutive securities not included in loss per share6,564,820 157,000 6,564,820 157,000 
Income Taxes
Income Taxes

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of March 31, 2024 and June 30, 2023, the Company has recorded a full valuation allowance against its deferred tax assets.

    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. As of March 31, 2024, and June 30, 2023, no accrued interest or penalties were required to be included on the related tax liability line in the consolidated balance sheets.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Significant Accounting Policies (Tables)
 9 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]
(in thousands)For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Beginning of Period$316 $259 $426 $332 
Additions284 185 560 425 
Revenue Recognized197 149 583 462 
End of Period$403 $295 $403 $295 
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Numerator:
  Numerator for basic loss per share:
 Net (loss) income$(162,149)$585,235 $(259,667)$258,468 
Undeclared dividends on preferred stock12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Numerator for diluted loss per share:
Diluted (loss) income$(162,149)$585,235 $(259,667)$258,468 
Undeclared dividends on preferred stock12,830 13,006 38,842 38,735 
Net (loss) income applicable to common shareholders$(174,979)$572,229 $(298,509)$219,733 
Denominator for basic (loss) earning per share
Denominator for basic (loss) earning per share - weighted average shares outstanding
7,415,329 7,415,329 7,415,329 7,415,329 
Weighted average preferred stock converted to common stock— 6,063,607 — 6,063,607 
 Denominator for diluted (loss) income assumed conversion7,415,329 13,478,936 7,415,329 13,478,936 
Net (loss) income per share:
Basic net (loss) income per share$(0.02)$0.08 $(0.04)$0.03 
Diluted net (loss) income per share$(0.02)$0.04 $(0.04)$0.02 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.

For the Three Months Ended March 31,For the Nine Months Ended March 31,
2024202320242023
Stock options157,000 157,000 157,000 157,000 
Convertible preferred stock6,407,820 — 6,407,820 — 
Total potential dilutive securities not included in loss per share6,564,820 157,000 6,564,820 157,000 
Accounts Receivable, Allowance for Credit Loss
 For the Three Months Ended March 31, For the Nine Months Ended March 31,
 2024202320242023
Balance, at the beginning of the period$133,524 $241,349 $153,878 $236,349 
Provision (Reversal)— (98,400)(20,354)(93,400)
Write-offs(900)— (900)— 
Balance, at the end of the period$132,624 $142,949 $132,624 $142,949 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Inventory (Tables)
 9 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current [Table Text Block]
March 31,
June 30,
(in thousands)20242023
Inventories:
        Raw Material$1,027 $882 
        Work-In-Process388 86 
        Finished Goods650 881 
Total inventories$2,065 $1,849 
Allowance for obsolete inventory(260)(260)
Inventories, net$1,805 $1,588 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Line of Credit (Tables)
 9 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Maturities of Line of Credit
Year ending June 30,
TD Note Payment
2024 (remainder of FY 2024)
8,530 
2025
37,434 
2026
41,145 
202745,224 
202836,412 
Total
$168,745 
Year ending June 30,EIDL Payment
2024 (remainder of FY 2024)$782 
20253,202 
20263,324 
20273,451 
20283,582 
Thereafter132,120 
Total$146,461 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Long term debt (Tables)
 9 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Maturities of Long-term Debt
Year ending June 30,
TD Note Payment
2024 (remainder of FY 2024)
8,530 
2025
37,434 
2026
41,145 
202745,224 
202836,412 
Total
$168,745 
Year ending June 30,EIDL Payment
2024 (remainder of FY 2024)$782 
20253,202 
20263,324 
20273,451 
20283,582 
Thereafter132,120 
Total$146,461 
Contractual Obligation, Fiscal Year Maturity The future annual principal amounts to be paid as of March 31, 2024 are as follows:
Year ending June 30,EIDL Payment
2024 (remainder of FY 2024)$782 
20253,202 
20263,324 
20273,451 
20283,582 
Thereafter132,120 
Total$146,461 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Concentration of credit risk (Tables)
 9 Months Ended
Mar. 31, 2024
Concentration of credit risks [Abstract]  
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Domestic and international sales from operations are as follows:
(in thousands)For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Domestic$1,339 50 %$1,903 55 %$4,394 52 %$5,258 58 %
Foreign1,357 50 %1,531 45 %4,116 48 %3,787 42 %
Total$2,696 100 %$3,434 100 %$8,510 100 %$9,045 100 %
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases (Tables) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Lessee Disclosure [Abstract]        
Lease, Cost [Table Text Block]    
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Operating lease costs:
Fixed$84,970 $85,324 $254,992 $256,084 
Total:$84,970 $85,324 $254,992 $256,084 
For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows for operating leases$88,224 $86,350 $262,387 $256,883 
Total$88,224 $86,350 $262,387 $256,883 
March 31,June 30,
20242023
Weighted-average remaining lease terms (years)
Operating leases
0.971.67
Weighted-average discount rate
Operating leases
5.72 %5.69 %
  
Short-term Lease Payments $ 88,224 $ 86,350 $ 262,387 $ 256,883
Lessee, Operating Lease, Liability, Maturity    
Operating
2024 (reminder of FY 2024)$88,514 
2025212,415 
20263,928 
20271,200 
20281,200 
Thereafter600 
Total lease payments307,857 
Less interest 8,933 
Present value of lease liabilities$298,924 
  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Going concern (Details) - USD ($)
Mar. 31, 2024
Jun. 30, 2023
Going concern [Abstract]    
Retained Earnings (Accumulated Deficit) $ (68,679,282) $ (68,419,615)
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Significant Accounting Policies (Inventory) (Details) - USD ($)
Mar. 31, 2024
Jun. 30, 2023
schedule of inventory [Abstract]    
Inventory, net $ 1,804,929 $ 1,587,989
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Significant Accounting Policies (Accounts Receivable) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Sep. 30, 2023
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2022
Jun. 30, 2022
Accounting Policies [Abstract]                  
Accounts Receivable, Allowance for Credit Loss $ 132,624   $ 142,949 $ 132,624 $ 142,949 $ 133,524 $ 153,878 $ 241,349 $ 236,349
Accounts Receivable, Credit Loss Expense (Reversal) 0 $ 93,400 98,400 (20,354) $ 93,400        
Accounts Receivable, Allowance for Credit Loss, Writeoff $ (900) $ 0 $ 0 $ (900)          
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Significant Accounting Policies (Net Income (loss) Per Share) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                
Net (loss) income $ (162,149) $ (76,321) $ (21,197) $ 585,235 $ (6,043) $ (320,724) $ (259,667) $ 258,468
Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic $ (174,979)     $ 572,229     $ (298,509) $ 219,733
Basic Weighted average shares outstanding 7,415,329     7,415,329     7,415,329 7,415,329
Weighted Average Number of Shares Outstanding, Diluted 7,415,329     13,478,936     7,415,329 13,478,936
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Significant Accounting Policies Earning per share details (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Sep. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                
Net (loss) income $ (162,149) $ (76,321) $ (21,197) $ 585,235 $ (6,043) $ (320,724) $ (259,667) $ 258,468
Net Income (Loss) Available to Common Stockholders, Diluted $ (174,979)     $ 572,229     $ (298,509) $ 219,733
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6,564,820     157,000     6,564,820 157,000
Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic $ (174,979)     $ 572,229     $ (298,509) $ 219,733
Convertible Preferred Dividends, Net of Tax             $ 38,842 $ 38,735
Weighted average shares - basic 7,415,329     7,415,329     7,415,329 7,415,329
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock             0 6,063,607
Weighted average shares - diluted 7,415,329     13,478,936     7,415,329 13,478,936
Earnings (Loss) Per Share, Basic $ (0.02)     $ 0.08     $ (0.04) $ 0.03
Earnings (Loss) Per Share, Diluted $ (0.02)     $ 0.04     $ (0.04) $ 0.02
Preferred Stock Dividends, Income Statement Impact $ 12,830     $ 13,006     $ 38,842 $ 38,735
Net Income (Loss) Available to Common Stockholders, Basic $ (174,979)     $ 572,229     $ (298,509) $ 219,733
Convertible Preferred Stock [Member]                
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 157,000     157,000     157,000 157,000
Equity Option [Member]                
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6,407,820     0     6,407,820 0
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Significant Accounting Policies deferred revenue (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Revenue Recognition and Deferred Revenue [Abstract]        
Deferred Revenue $ 316,000 $ 259,000 $ 426,227 $ 332,000
Deferred Revenue, Additions 284,000 185,000 560,000 425,000
Deferred Revenue, Revenue Recognized 197,000 149,000 583,000 462,000
Deferred Revenue 403,069 295,000 403,069 295,000
Recognized revenue that was included within prior period deferred revenue $ 165,000 $ 43,000 $ 440,000 $ 300,000
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Significant Accounting Policies New accounting pronouncements recently adopted (Details) - USD ($)
Mar. 31, 2024
Jun. 30, 2023
New accounting pronouncements recently adopted [Abstract]    
Operating Lease, Right-of-Use Asset $ 276,089 $ 503,647
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Inventory (Details) - USD ($)
Mar. 31, 2024
Jun. 30, 2023
Inventory Disclosure [Abstract]    
Inventory, net $ 1,804,929 $ 1,587,989
Inventory, Raw Materials, Gross 1,027,000 882,000
Inventory, Work in Process, Gross 388,000 86,000
Inventory, Finished Goods, Gross 650,000 881,000
Inventory Valuation Reserves (260,000) (260,000)
Inventory, Gross $ 2,065,000 $ 1,849,000
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related Party Transactions (Details)
 9 Months Ended 12 Months Ended
Feb. 14, 2018
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
vote
$ / shares
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Related Party Transactions [Abstract]      
Related Party Transaction, Amounts of Transaction | $ $ 645,000    
Preferred Stock, Shares Issued | shares 2,000,000 2,000,000 2,000,000
Preferred stock, number of votes per share | vote   13  
Common Stock, Voting Rights   77.81  
Convertible Preferred Stock, Shares Issued upon Conversion | shares   2.15  
Common Stock, Conversion Basis   4,300,000  
Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion   36.70%  
Dividends Payable, Amount Per Share | $ / shares $ (0.0258) $ (0.1581) $ (0.1387)
Dividends Payable, Date to be Paid | $   $ 316,173 $ 277,331
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Line of Credit (Details) - Note Payable - USD ($)
 9 Months Ended
Apr. 29, 2023
Mar. 29, 2023
Mar. 31, 2024
Jun. 29, 2018
Line of Credit Facility [Line Items]        
Notes Payable to Bank       $ 250,000
Debt Instrument, Interest Rate, Stated Percentage       5.00%
Debt Instrument, Basis Spread on Variable Rate     74.00%  
Debt Instrument, Interest Rate During Period     5.74%  
TD Bank        
Line of Credit Facility [Line Items]        
Debt Instrument, Interest Rate, Stated Percentage   9.49%    
Note payable, face amount   $ 201,575    
Debt instrument, term   5 years    
Monthly principal and interest payments $ 4,247      
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Line of Credit - Maturity Schedule (Details) - TD Bank - Note Payable
Mar. 31, 2024
USD ($)
Line of Credit Facility [Line Items]  
2025 $ 8,530
2026 37,434
2027 41,145
2028 45,224
2028 36,412
Total $ 168,745
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Long term debt (Details) - USD ($)
 9 Months Ended
Mar. 31, 2023
Mar. 29, 2023
Mar. 31, 2024
Secured Debt [Member]      
Debt Instrument [Line Items]      
Debt instrument, term 30 years    
Debt Instrument, Periodic Payment     $ 731
Long-term Debt     $ 150,000
Secured Debt [Member]      
Debt Instrument [Line Items]      
Long-term Debt, Weighted Average Interest Rate, at Point in Time     3.75%
2024 (remainder of FY 2024)     $ 782
2025     3,202
2026     3,324
2027     3,451
2028     3,582
Thereafter     132,120
Long-term Debt     146,461
Note Payable | TD Bank      
Debt Instrument [Line Items]      
Debt instrument, term   5 years  
2025     8,530
2026     37,434
2027     41,145
2028     45,224
Long-term Debt     $ 168,745
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Concentration of credit risk (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended
Mar. 31, 2024
Sep. 30, 2023
Mar. 31, 2023
Dec. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Concentration Risk [Line Items]            
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]         Domestic and international sales from operations are as follows:
(in thousands)For the Three Months Ended March 31, For the Nine Months Ended March 31,
2024202320242023
Domestic$1,339 50 %$1,903 55 %$4,394 52 %$5,258 58 %
Foreign1,357 50 %1,531 45 %4,116 48 %3,787 42 %
Total$2,696 100 %$3,434 100 %$8,510 100 %$9,045 100 %
  
Revenues $ 2,695,501   $ 3,434,314   $ 8,509,738 $ 9,044,619
Customer Concentration Risk [Member] | Customer One [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Customer One   No   One  
Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Revenues           $ 9,045,000
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 13.00%   10.00%   11.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer two            
Concentration Risk [Line Items]            
Concentration Risk, Percentage          
Revenue Benchmark [Member] | Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 100.00%   100.00%   100.00% 100.00%
Revenues $ 2,696,000   $ 3,434,000   $ 8,510,000 $ 9,045,000
Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Supplier   two     three  
Accounts Receivable Benchmark [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Customer         two  
Accounts Receivable            
Concentration Risk [Line Items]            
Concentration Risk, Customer two one two   one  
Accounts Receivable | Customer Concentration Risk [Member] | Customer One [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage   24.00%     16.00%  
Accounts Receivable | Customer Concentration Risk [Member] | Customer two            
Concentration Risk [Line Items]            
Concentration Risk, Percentage         11.00%  
Domestic [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 50.00%   55.00%   52.00% 58.00%
Revenues $ 1,339,000   $ 1,903,000   $ 4,394,000 $ 5,258,000
International [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 50.00%   45.00%   48.00% 42.00%
Revenues $ 1,357,000   $ 1,531,000   $ 4,116,000 $ 3,787,000
Supplier one [Member] | Revenue Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 36.00%   44.00%   40.00% 44.00%
Supplier one [Member] | Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage       36.00% 29.00%  
Supplier two [Member] | Revenue Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage 11.00%   11.00%     10.00%
Supplier two [Member] | Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage       11.00% 12.00%  
Supplier Three | Accounts Payable Benchmark [Member] | Supplier Concentration Risk [Member]            
Concentration Risk [Line Items]            
Concentration Risk, Percentage         11.00%  
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Jun. 30, 2023
Lessee Disclosure [Abstract]          
Operating Lease, Cost $ 84,970 $ 85,324 $ 254,992 $ 256,084  
Short-term Lease Payments 88,224 $ 86,350 262,387 $ 256,883  
2024 (reminder of FY 2024) 88,514   88,514    
2025 212,415   212,415    
2026 3,928   3,928    
2027 1,200   1,200    
2028 1,200   1,200    
Thereafter 600   600    
Total lease payments 307,857   307,857    
Interest portion in the future lease payments 8,933   8,933    
Net present value of new lease future payments $ 298,924   $ 298,924    
Operating Lease, Weighted Average Remaining Lease Term 11 months 19 days   11 months 19 days   1 year 8 months 1 day
Operating Lease, Weighted Average Discount Rate, Percent 5.72%   5.72%   5.69%
XML 48 R9999.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Label Element Value
Restricted Cash us-gaap_RestrictedCash $ 256,293
Restricted Cash us-gaap_RestrictedCash $ 256,165
EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $R KE@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !,@*Y8L&ULS9+! M3L,P#(9?!>7>.LW&#E&7"X@32$A, G&+$F^+:)HH,6KW]K1AZX3@ 3C&_O/Y ML^361&E"PN<4(B9RF&]&W_59FKAE1Z(H ;(YHM>YGA+]U-R'Y#5-SW2 J,V' M/B (SC?@D;35I&$&5G$A,M5:(TU"32&=\=8L^/B9N@*S!K!#CSUE:.H&F)HG MQM/8M7 %S##"Y/-W >U"+-4_L:4#[)P'MZ?"GK5J[/ MI'N#TZ_L))TB;MEE\NOJ[G[WP)3@8EWQVZI9[P277$B^>9]=?_A=A7VP;N_^ ML?%%4+7PZR[4%U!+ P04 " !,@*Y8F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M $R KEAF.%BB@ 4 = 8 >&PO=V]R:W-H965T&UL MM9EM;]LV%(7_"N$-0PO4L4@YCM,E!ARGV8(UK5MG*[IA'QB)MH5(HD;2=OSO M=RG94AI0UZI0?XGU=D[XD")Y1%YLI'K42R$,>4KB5%]VEL9D;WL]'2Q%PO6) MS$0*=^92)=S J5KT=*8$#W-1$O>8YPUZ"8_2SN@BOS95HPNY,G&4BJDB>I4D M7&VO1"PWEQW:V5_X'"V6QE[HC2XROA S8?[,I@K.>J5+&"4BU9%,B1+SR\Z8 MOIWXGA7D3_P5B8U^=DPLRH.4C_;D-KSL>+9$(A:!L18"7Q:(V [ 7LAH'Z-P-\)_!RT*%F. M=] MTPMV^JM"SVKTY^1.IF:IR;LT%.&W^AZ4I2P0VQ?HBJ&&=UR=$)^^(;F74RE4I$U35$F]0X@V:X4V%BF1H.R&! M8<#9>+A3V>UJ^QVJ;\EY5G*>H:5[EYK(V*9;1+8C O 'GC@I#_CH@,

=R) M,((C,I$J.W'!HC8M88T-F!MJ52 5E7J5&;>$W=-8 M;CX=NW!134O<\Q+WO GN/7\BMR&\R]$A7(RXH^]W/7;&AOZY MBQ75MF2E7C7=>DUHQV$([OK-_H"\A^?(Q]39H@YW691]F9$_ 808A628CB M6>;ERUJ.OE,EUU$:N/LI[ND>>G%16] J'U$\U;P$G4IM8&+\.\IJ)Y@#CO3< M&[J;]!A)B591B>())Q]OQO"I6P^&&[P:4.^U$^P8T8A6V8CBH>:]M%%FNI0I MVAEQD\%PV!T,?<_)=XPT1*LX1!OEH7>)4(LH79#?P,$LH163C*=;)RMN6#^J M'B,'T2H(T49)R(ZJ$/-@P%E(Y>;#?3[(M,N#0( -F(2%H9/W&%F(55F(-89[,EY'(QY6!:20-H;LZB7]0>MG50^%VFKO99R=>!XE M&5=DS>.:E_<8 8A5 8@U"D 32+(*9I?;-!1/Y _A9L>M(.=YPP$;#(9.SF/D M'U;E'X:GE(/:[A4])ST M!BZZ1US7L8 &!:0 M,7>/KBW3#ZYK"U:E']8H_>P[9/'-;/.>_?:J:3_<\:MS0V."JUIR^E7J\1NE MGMO4"%5L8MG!AN_!G3L,N&,-)Z[Z7L[>LSTFF\3SK3=- KL:66PWE5?+[;UQ MOJG5JQXO]@;ON WRFL1B#E+OY Q&1E5LMQ4G1F;YCM6#-$8F^>%2\% H^P#< MGTMI]B?V'Y2;GJ/_ 5!+ P04 " !,@*Y84QV#1!L' !7'P & 'AL M+W=O[%8B\8B8Z%RJ(KTDZS3[\C6;%LD6)L(!=M?!B._AF1\\U89X^J M^J;G4AKT8U&4^GPT-V;Y=C+1Z5PNA#Y52UG"-S-5+82!M]7#1"\K*;)FT:*8 M4(S#R4+DY6AZUGQV4TW/U,H4>2EO*J17BX6HGM[+0CV>C\CH^8/;_&%NZ@\F MT[.E>)!WTGQ=WE3P;K+UDN4+6>I^MTM+UFO7#W];/W#TWP$,R] MT/)2%7_GF9F?C^(1RN1,K ISJQY_EVU O/:7JD(W_Z/'UA:/4+K21BW:Q:!@ MD9>;O^)'FXB=!2086$#;!?30!:Q=P)I -\J:L*Z$$=.S2CVBJK8&;_6+)C?- M:H@F+^O;>&#->U&(,I7HKG:LT0GZ>G>% M?GWSV]G$P$7KI9.TO<#[S07HP 4^B>H4,3)&%-/ L?S2O_R/50G+<;.<[2^? M0*C;>.DV7MKX8T/QKJI*E@8)K2&PMZYX-@X"MX/Z6+W52Y'*\Q&<&RVKM1Q- M?_Z)A/B=*[I7IY="SY$H,Y36+^3W5;X6!02O75%O7(6-J_KL MKZ<\#"(+'J/V-KF$;CSQ M'064ARS!/:%.,YHPMU"^%5](ET9N79P$"8EI/YL. MNQA'/$G<*L.MRO!8E6-T44#);@XU%']T6=N""UA)X31D :] %QV MG,51[ X@V@80'1^ F!E9'1=&9.>7\81BU@O#81=R%E'B#B/>AA%[P_A8KF$3 MJ^IIC$KIW,RQ:P,$"4UZ AUV/(Z2>&"C)%N!B5?@%S.'E*9[-=$E,W'D)PQQ M_\S99C1(HIVCN2>2X(Y1V"OS3V5$<8#,ULVN@(!P.'?]=+H,0Q8%830@=0>G MQ"OUIH(.JS)/3=VM2^X2>AXS>/];;[M".$LBTM=KF[$ AP-5EW0P)%[^3+^ M5F'R\@%=2^B%QJAIXT[4[.2KENBB3K13-;5O=!3BV$JS;<S]02,\[YLVRQ,DC@<4-U!CO@I M=R672N=0U;8R59D.@X[8" MI%/<9\J+9OMJ.=,2/NLVA\QPV&UX!D LS:_/: MAISA*.$#U95TF"/A0)'X3;AF.YR:A3H(."!'#-K1/I,*28"0"K]MB\N37[4 @]!F\WQ(Y[!A-0C:4Y0Z!U(_ *SF357VP;B4T MF2OGCJ4VR +,<&@EUV$'%8(.''[:$8_ZB;>I57JN*G,"FV*Q6ZF=@FV6Q2%C M_7;=9181.E %:(<\>@CR4ILJ3JTVUB!G"<%6=AV&,1"0#^W=CG_4/^!O M*J@]L<%(%,16BAUV') ]P&S:X8N^@"_/>7M!NF-*XTG4'TD=9I0$! ],_K0C M&?63;+,["E4^'+:7;5+1)( 9HZ_7MN,4PQ XH+=C&O4SK=7[@DK'S)9 7;6: M8H\;#RVBWLM;_M!=Y!D M?DC>R0KN"+I J2K7,# VXPM=L/NNLLF+^S>+[5 MU]M>:#/=^_NWUNGNLR,2,&J->DZ[,&#]FC#9>>I9/W+^)*J'O-2HD#-8B$\C MV.35YBGNYHU1R^9!Z+TR1BV:EW,IX&C5!O#]3$$GW;ZIGZUNGZ5/_P=02P,$ M% @ 3("N6"B+-QW8 @ 9PD !@ !X;"]W;W)K<"SWU,F.*:]_7208YU1U9 M@, G*ZER:K"KUKXN%-#4)>7<#X-@X.>4"2^>N'MS%4]D:3@3,%=$EWE.U9]; MX'([];K>TXU[MLZ,O>''DX*N80'F6S%7V/-KE93E(#23@BA83;V;[O5L;.-= MP'<&6[W7)M;)4LH'V[E+IUY@@8!#8JP"Q_H94DUS"3_P5*33;V11U)8T9*;>[G]##L_?:N72*[=/]E6L8.A1Y)2&YGO MDI$@9Z*ZTL?=/.PE='L'$L)=0GAN0K1+B)S1BLS9^D@-C2=*;HFRT:AF&VYN M7#:Z8<*^Q851^)1AGHEG4J3X3B EV-*2LY0:[-Q23D4"9&&%-7D[IPJ$R<"P MA/)WY#UY37RB,[RK)[Y!#JOF)[LQ;ZLQPP-C?J6J0Z+N%0F#L->2/CN>_J44 MF!ZX]*B9[J/[>@K">@I"IQ<=T%L8M(R%:8A^W:=@U>ZX(F,/5PD6E0&_#B-Z^Z@^!#F_'_)-:8AJB>ANB8>CS' M]0-*XKDA!%=E07D*;[4IKZ+3LEV(3!YT@Z$[\S;Z?4U$-T%X-VKL, MM*I#0DN32<7^0MH&7&GV]U#P0V=_SY!/QS6@^S5T_TSH106]J*#OM"[;@?MG M I^.:P /:N#!4>"9S',L_G-JX:C0I4M@<$G)#&LSPPO,G%4OPQ?3&O5;Y_^, MP ;SJ&8>7<[,#I;+Z 7&L-?M1^'X&>[IN ;MN*8=7TZ+IP9MJ$B96+=8PLW,ZXE ;W6=?,\"0$R@;@ M\Y64YJEC-]OZ;!7_ U!+ P04 " !,@*Y8E,+WW (' !N(P & 'AL M+W=O##F,19L MRM.OR5RNKD;^",W9(MZF\A-__H-5!E'%-^.I*/Y'SR76M49HMA62KZO!\ 3K M)"O_QB^5(PX& (]Y *D&$'V /2]L)Q82SC MR67.GU&NT,"F/A3>+T:#OY),)9GC[<-IGS_V:/ M_O/L+6?8=2+8!9]]A.\3V[%LR] BYVL4O4B69W&*ID4&LAQ]>P]X= M)(?XR MA;XD=\SDJMI=B$T\8U"Y3LVFOSR$W:M7TU^'Y(L')(L&HBL%2&GCI#3 MQ[Z/D#"YOQSI%B-5;]A-B!M0:N'+\>[0LUV<[< _[+1Q81?G4ROP;+^-B[JX MP'(<%P=[Q--RT8#SB.53 M6\O%+L[Q;>I81,O%+HY:!#N>9Q16UMKTRXNL'WL:DLW[,)LQ\)!QPT&'+9\['EF-_BU M&_Q7JH]@<3Y;%<;/H12E?*,$@LERWY !U'>TXC$UP'SJ44LSO NCF!*LI4G4 MA;D.MK%K-CNHS0YZS?[,)01\UJE')K.#SA,0'Q[4"C2[33C'\5R]"'=QOD<) MQ=I"BDPXSPI"_$&)=D,-$"I#'@M!8T"T.H\RCM,7=?2 M0V\ 4E\U+,T%)D+B$,_3?!H9@,2S77HD_/A '^/>5G0G5R!_SJJX[YUA;$<5 MTT#]:%"V<%"V:"BV=DQ($Q/2FY=E3#[RK,K&;(ENRQP]BZHX&>-#.CEBZ7GY M*B1\'1+U0MHV-_(<]VK+R6T&DIQ!,ZXRT6B@W5TME#JZ"#3!0 -2W5 ##+N^ MKVM (X[B US;Y$;OXG[!^Y%)=)8>E""CS8[I*:'OZU77 *10GNV.V09"0@/7 MU;\_1[1K6 MF;$)5Y.TVBOQ[4[&&V"V9;FZ5[HPV_<=77P88=Z!C]LN:50H[I>A*A7V2[QL M2M>[.$GCQY0AR=&4K]<\*]VU EG*[ M.]60;.&@;-%0;.VX-*(9]ZOF*,XS:$]BG[7W$)4'%96^]"PI_<-LLLYUG3\U MP #EZZEI)G/TQ#22'4O+1CSC?O7<8WZ8I%MI/ :\J4A?=4 7UK4L/$+6<8"1 MC)@=0!H%3?H5]-?BH!HJ>;P#I;)DY9)4QZB/Q\)/NDK6/4;*=(_YG_T(7%ZZQNV(IC_5>WJ0GG^ '61;T!YUA> MT!&U)IQ+G(Y:&1^\/P"F+8L7-P2:\6TFRU^0Z[OURR'7Q2L1VOT;?#'%AOLA MOHC*5S\:^O)-E ]QODPR@5*V@*FL2+XIWEYXY!+\7GQF\Z,T F=DR>2_*0 M]#W'-*]?B_)C]2YKK?OIM-J^WU_F]WY>UUL:OS;,/O2J_:K==I^<<'GA>O M-Q,T^?2'G[*GY[KYP_3V>IL^\7M>_[R]*\6SZ1%EE:WYILJ*C5?RQYO)M^@= M"\*FPK[$+QE_K4X>>TU7'HKB8_/D^]7-Q&]:Q'.^K!N(5/QZX0N>YPV2:,=O M+>CD&+.I>/KX$SK;=UYTYB&M^*+(_Y.MZN>;R6SBK?ACNLOKGXK7[WC;H:#! M6Q9YM?_?>VW+^A-ON:OJ8MU6%BU89YO#[_3W=B!.*B#24P&W%7"G L8]%4A; M@70K!#T5:%N!=BJ0L*="T%8(NA'F/17"ML*>S.EAL/8C':=U>GM=%J]>V906 M:,V#/5W[VF* LTTSL^[K4KR:B7KU[:+8K,0\X2M//*J*/%NEM7AR7XM?8@+5 ME?>O1^_^.2WY%G]PTM^VV7U']ZE]_-]['W]U3?7TUHTI(&;+MN@'PY! M<4_0?Q=UFANJ+>S5%L5Z+2;C?5TL/WK__9&O'WCYJP$FML/LCS;V[-%M=9AMOD6XST3D;*!L 72YWZUV^IR'FC]DRJWO0IH+K M(^'X2#C>P]-QO;\XD"MHWM55G6Y6V>;)1*@5M-G^WE7;=,EO)F)_JWCYPB>W M?_\;"OWW)IHAP>(#6+ ':_;1EUNQJS;_KJ*WF08/$!+#PA+Z2!SAUD3 8$IG!'C]Q1*W?M%E8=B/O* MO_)]Y&W3TGMI.'SOD>!"]+[Y\:K#NDQW]7-19G_RU7LONJ HN"!X_NG%;$^Y M)Y:M5]C7K[59KE. :JQ%HF$J9S%DQ 02C &!*1,@.$Z 8,P$4/;>BZ'-UPKI M2EZ@[9<->6)2=?B##)I @C$@,(6_\,A?:.7O0YJGFR7WTMK[8;>Y\HA_X6$? M8Q-MH;9,$(UF/HK4D5Y8([KNJ)!@B=Z#],P\O>!E M.$?S"(6!>;SGQ_&>@ZWTN3[>QI5NC>@ZWI!@B=Z#GO'6"PZL=.1+*>K__VN] MQ5#R_6!&PUEGJ.VQ7,<:%"T!16-0:"IK)P8"&KM.?DQ+L4[0?IT0(WE(7R@1 M">DLZ+)GC>G,'B1:8NA$SUHQE!2+)431/"(]BT7*>/0F.MZ.ZII+@J+%:*R4 M!PW+H-!4(J6:1]!RW@[HS"&HH$- MF8"B,2@T=1Y(;8_>0-S;,9TY'"OO0<,FH&@,"DVE44I\-%KC#RJM%FI8:MEC M.F^SH#+?T(F^C$8O.2"WD%3Z"$#J(X.Z#K5V+M"PU!\NDAB"=<7^8'O4P9!B M'XU6^S%?'K-J\QPTRGV$ [\[*J!Z'Q0M,72B;PX:)3_V"?9G/<,N-3^RB_YS MLVI(+;X 18N1KMA[LFK(L P*3?V04WH)V.XEN&?5=D#GCSA![8<6;3"K!HW* MH-!4"J6Q@.W&PF?+JNWM&3=F."!QF50:&I M%$K!C^V"__,E>-9V.<\$W4@P)7B0,1-0- :%ILX#Z75@N]=Q7H('Z3XLL.XI M]"1XH*8'*!J#0E-IE-X)?A/OQ([J3"2H=X+'>B>@81D4FGJ\6'HG!-H[(?JA M#-/;U\(>V/GP\$A7!#0J@T)3R9&N"/E"71$RQL=8C"H5V_OHNHN"HC$H-)5? MZ7:0-W [R$A_8C&V8&QOI3-#H$8&%)K*T,G7+^Q&1L_!0*-R)[H)@>:$SK0/ MK.PQG7=&2+2$Z!Y(CW(WE!3*G:)YB'H,$R(-$V(W3$;Y1\1@'6"$YMV#F$0_ MZM#UCX:+)(9H7?]HN$'J<$@C@]B-C)X/J=_SHH!%"TQ=*)OM9A.,Z*@2IR,5>*@81D4 MFOIE4:G$*;02MP,Z?]$35*_3D7H=-"J#0E,IE'J=?J%ZW=XNYYDP2M>#QDQ MT1@4FCH/I*ZG;Z#K[9C.'(X5_Z!A$U T!H6FTBC%/QTM_@=E%]75L%EVV6,Z M;[.@XM_0B9Z,QE!R0';1DVL3 ,0_-6CM*"08=8=[6/P/%TD,T;KB?[A!ZG!( M\4]'B__3T\'F66@0_S,2$=RU;NTQG6U^S!GH3D,WPQLNDAC" M=3.\$2U2!T3Z!L%9URH8K=- %^=FZ]0>T_5]!Q0M,72B)\4SE!RP3@,ITX,W MN5;!CNJZH8"BQ<'8:Q5 PS(H-)5(*=0#NU!?%)L77M;90\Z]/E(/Z9ZWVXHW MD$/YYL)<([^'8//3,;S2#K_8F^3,&ZB.!T5C4&@JN=(.".QV@'O^'NB"WGA" MS1[8F<)Q41/0J P*327GY(;#4;<@_/69>=NN@1-JHTK%]CXZ+S[8^P_?XIL7 M@71! KL+J')W6QW=_X_5#4=;'>/WSFZ8J730'Q^F-1U)^>-)>('^^Q MO_T?4$L#!!0 ( $R KEBN2A?R# @ #4Q 8 >&PO=V]R:W-H965T M&ULM5MM;Z,Z%OXK5G:UZDCI!-N\=MM(;6!T*\W@G.!I-/[Z]<&"@$.;C+K_=( .7X;&9Z]/WA,7C:E?+!87N_"%_;$RA^[ MAUS<+5J4.-FRK$AXAG*VOIG=XJN FK)!9?&OA+T61]=(#N69\S_DS7U\,S/D M+V(IBTH)$8J/ UNQ-)5(XG?\V8#.VCYEP^/K=_0OU>#%8)[#@JUX^N\D+C&8K8.]VGYR%]_8\V +(D7\;2H_J+7QM:8H6A?E'S;-!:_8)MD]6?XLR'B MJ(' @1N0I@$9-C G&M"F 3VU![-I8)[:@]4TJ(:^J,=>$>>'9;B\SODKRJ6U M0),7%?M5:\%7DLF)\E3FXMM$M"N7*Y[%PNTL1N*JX&D2AZ6X>2K%AY@/98&^ MK]$J+#;HBYA3!;I$/YY\=/'W3]>+4G0O0191T]5=W169Z(JB;SPK-P4*1)^^1 M0=N)0"L\.C41.A^O<[Y%WWT&W.?$.,ZP7R=8($FL)YOS-8WI@I]^;O8,"Y27A2?4))% M?,L@/]00=@4AMX?#\A+;!)O>]>)P3/'8SG(M0JV^F0_ $1O_ M1^P#=3 NN=B=(YY%2RUB>9(BWZS=4KU];Y_K5">;K M! LT@?4\Z+0>=)2SV6<"-$K".C7*8A1N>5XF?U4/()\HX<[UB4XPWQDO!-NQ MZ6 AC*VH:1(37@=NRZ*KWJ$V8?;"!G.[*)A8%I+3- F?DW1ZGKLZ.=4)YNL$ M"S2!]3SDM1[RE//\/HN$6!&H%SZKK^2&A8!@#CE(B7VN@W2"^=YXTCLFMH?A M?VQVB0W'C&2;RB/J_WV4%L"CP7,Q[,QI6@YQ*J%%+>DXY;\"K<^6[-4.:07L MJ.VYU@2OG43#2I4QQ6L;7Q_"MZG@JD8^FU>M.JU!Z_'E.J8US"H .VI19XK6 M3EUAM;R:IC7?B]GZM4LL0&:5X&PH->RIG:N3<5BM MXTZ,LA]1K.SD;(IUHOD8$'W$-%T\%,J@(;%-8R(MQIT^Q$KQLASM6:W@FW=' M=]V1'LBP5A6H%<'Y)8,/G\ABY^U,<8 MG\!I#3*L5=]I1?,;M/[2MXDW/&8*0$//J>A ?+>;C!):)9I6-!\#ZHMB@XZB!&!GVZX#,TPZC4:, ML\[/I3@K3CD_)UIEFE8T7RM:H NM[Z%.\1&UXH/6P'U6AME+(I)FA=)3XY[M M(:U*CXPEW#"H ":7#IX*W*13>42M\CX(W- " -G5JOBTHOD$4G) 4('L,'7- MB=2#=(J/J-_*M1SOCCG>OW/\)A3;7YY$LIRF M^E*FU\-GO08/+$]XC "Y.94NT"JTS.=B3,3TJE.HE:=VIQVQUZ2+)..$5&J]B#H#:WR5"N: M3\:J$V/3\D:U'H"A:QD&G?)&)T^)6IYJ\T8@#-1^&,L_EV##&PQU!=D9AF4/ M"T-.Q L^QNM7;76ZDZK?#;:\5-4?K",#K-4:OTVS;-,QAJ.'[$R3DN'H3\0+ M/L;KC[[3=%2MZ0:3 1PS\)++LJDWK 2"[UWN[0Z]0Y3]!1M6+P74I\? ME;2*G;4NMTYX!MA'K^%*)G!+H9>2>"[SG";C M686[1/@O^8O)Y*@VFI]\,*SN]6S_:958=%P]B7LOBAO' &:6[0W/+!='9>!; MEK]4]?<%JEX.UX7 [=.VQO^VJFP?/+_#5RL,//?Q55!7\'?P]3\4? MSD085 M*&5KT97QV1%+.:]K].N;DN^J(O1G7I9\6UUN6!BS7!J([]=<2.7F1G;0_J?$ M\K]02P,$% @ 3("N6!DM"YYM!@ U@X !@ !X;"]W;W)K8CRX.FN MF3:X[8[M9IC]^IRRW3VP(01%0DS[4N53IRXN'VZLN_8U41"WC3;^J*A#:-^. MQ[ZLJ9%^S[9DL+*RKI$!0[<>^]:1K*)0H\>SR>3EN)'*%,>'<>["'1_:+FAE MZ,()WS6-=-L3TG9S5$R+?N*36M>!)\;'AZU;!67543!@0:2H#:Y#XN:$%:']X3C@-)89 MEUGS2=(\^Q?-;\2Y-:'VXM145-V7'P/E '760SV9/:KP7+H]L3\=B=ED=O"( MOOW!]/VH;_\)IH_$PAIOM:IV3%PX\F2"[*GXH(PTI9):7&*2$)G!BS_F2Q\< M8NO/AQA* X>!L#Y]M:WLJ2CHN6SW T5Q\^^F;ZSV:3=QEK'$W? 9Z.Q>2& M@,K7 "<:DD9D^T9B4ZNR9KRZJ\@+A?BHU(V*!0Q;-% 5GQU=%Q$O+V]JRR;: MC<&:[Y9>54HZ1?ZMN+3&-E2-Q)DIP6*&E&C_G#Q7JU5X-BTNHO^^TKP M]/QL)\3'9TWB[$+\8'6ES+H7^0P&LND"U9_I]"(21:(FJ4-=2D>H0NZ:0)AO MB;-"?8&*?EM%(,FVB=%&FFZ%%.DL 7S16V_7V/OB>Y=;9JBOQP;#!\A6\*()%Q*P[O4L0 M9=B4.%QNXQF_(@A!4H=_=4I *3;P)?>#0D<&IF"E0;WVV!&ZQ12"09X MJ2DJKJ475YU3'O0E+G%$-,'+%87M2-!J!?K*1,H=C[#R7C$" R&)&Y)_\Z30 MN:#$*8LPSKU.;2\$_O@H=Y M0PXD#9B^G\\O!@PH.1 ,V-'6VK%55[8D$NH!V[ MAXWE5M8&8P-QUI7:>GC?"\-;=!3;;H/'^:>J1H))'(N@IQI.*L/ MZNH>??"A=JU)T3>SBC;J!#8CK/D)MLBSW)YD :=8JHJ7'YE=846*0=2 M)J-/F&@7C@+-+H9O6;H.]>-Y8JTB1F4(5<:C&V6?90/%2BJG4P'8$0&8*C$9 M78AF!%;VW4BJJ-'GY-$/^E28R&6?\VHI?2U6:()]Y((W]WQ@H[*5%\2=TE>J MHRP^]N]2U/LJ9J&G_YEZOK:=KJ!1<#O/7H7,56=2!8ENC85VI_H_%#)4#C#/ MZG6*Q6BB_5 >H3D@I_'\M@N0N8[B<0>^)CF MIQ\_[*\<^7UHJ9A;?*UQY]"G?W\.KJZ L-ZR%^B6KY^<*S'Z.L1X3QVCN\O= MP;V[;B ,!1GHX!5;7@M<3MR(V,3MQ\^+7TX8+DHX0J;J;XAML\2[H^\3+L\7 M>[GB\J9GQS [/-KFZ:VRVYY>?$"RQITK-*T@.ME[ M]:(0+KVBTB#8-KYT?L '#$_9X[\!4$L#!!0 ( M $R KEA_3&K_3@4 $H, 8 >&PO=V]R:W-H965T&UL MG5=9;QLW$/XKA JD+>!(LNP<]2$@3GH$: HC2=N'H _LKEZ+1EFZ]"*GKI-_=D''; MZ]GI;-QXK3=MY(W%^JJ7&WI#\<_^UF.UF%"4[L@&[:SPU%S/GIU>W)SS_7SA M+TW;L/*FN9TLVB S5D1$D?N[H.1G#0##CXX YFU2RX/[WB/Y+ M]AV^5#+08FP*S^@K,3^*5L[$- MXF>K2!W*+V#29-=JM.MF=2_@*^GGXNST1*R6J_-[\,XF/\\RWMG_\O/=LRI$ M#T;\<\S5@G1^'(FKY"+TLJ;K&/EY?WV'D^V7E^'_KZ=_TQ M::7C3KS0H38N)$_BW:TSNMZ)M_0IBAOCZ@]'[;X?>2Y*#)X/,7C;$KZ[7MK= M@^^>KDZ?7 :!6O>2JR4(";TA5>]1/2(Z(85-745>N$8T")SS0<161E%+E%;3 M\#4=)P3H06Q0&0"R2C3:2EMK:3@#\ X:YN)-JML)2]O:)$4GHDHQZ[8N"J,[ M'4E!_P64$0L#.KD4!-D6B(3V$-FD?)J\YV7OG4IU#">HSCMTG7Z\9-$CQL-+ M40-@0ZQ9*-=1B+HNMCJ/4N:.LTFF!.-2R$H;3@I0.FD36YUR@.J:0FB2,3L@ M(IH4LW>B\:Z;E.W+J*PD.*.$0T,A#M5@)\XJJ( O/F-)JPE>L&^]US5!^TF6 M5FC,Q=)R^F4:)[U\B[,RFH]$>JD#8B5['9$.;(34]\X?9 \NS\5;)Y2,=%S# M'E%:>5>RM2'+F_ BI*;1M>:P>[AF$\(,361E97(6@PYQ2%4#.XIU4-EZES:M M0/&#&F/U'U@ =8K)PKE6H@6.0VC@B2?>XVBB: (4Y@SL$]KN"5K:2'X.$(@ M$N)I.A0 3'XOD$SB6+0H](FK)80HCA E" GERJ6*?=U(KUCV6,CVA*7VV<@9$CM@XA,?T'ZL.:9&52N5BXPO!HEB_P3*N< MD\\E"*MC+ISB&!PM9-LQ^C?A% Y41!89I5YRA/G%_<(UO)X:?-ZV&MGE&%#7 MH\*8'# #(X71_^9DL5L221P8S**I2P7GB/$KS1TF^9 C4Z6 M'ABF_'V;;\IE=@\-2C 'I7J/E[D<>S*%+\CK$3=R8Y+>Y^#>29-HS[DAU;)S MR0Z^U@9G&M4CCWF:.V['@P:B#8IP\\$H)4+KDE$'=5)E?[G>[B?) M!49>"# UHF>%5O>00T^5&SYGVX8P\/)S#RG=5X.UF1M%>8@/ZQ3SHB/)[W4X MB"EP=YE!U?Y[P:3EPZF J4'EHR2/S1"+O?FN([_)4RS;"-J446_:G0;E9V4^ M_'R]3-EHK? Q"$,-1)?S)X]FPI?)M2RBZ_.T6+F(V3-_MACVR?,%G#<.(^*P M8 73OP_K_P!02P,$% @ 3("N6#>,8Y^8 @ L@4 !@ !X;"]W;W)K M%=0OA9+1F*WQ ^WT]US0+6TK.2Y2&*PD: ME^-@VAW.>B[>!_S@N#$[8W"9+)1Z=I/;?!Q$SA *S*PC,'J]X"4*X4!DXW?# M#-HCG7!WO*5?^]PIEP4S>*G$$\]M,0[2 ')[7Y@DT^?GLY%:^H+1*O\'Q-V71G(Q"2UBW&68-8E8CXG<0%W"G MI"T,?)8YYO_J0[+3>HJWGF;Q0> =TV>0=#L01W'O "]IZ0AF:-PP>1^PUOS^%H@*X\*_R=?ZTD0A)UX)A+L(6J#).Y.?'? MPCT2V-$-X9YM2&Q1'HK3^=:96@,)&D*Z0"NN>3T MO^9PHU1N8-"/*+H+C\H2@>]X.H*X$PWZGIKV+F JJ(,PF2%0+P*U,$J@Q59" M?W \B$Z:YX[)#DAJ;IX2U;0^.=GWH<*=.BI1KWRW,)"I2MJZI-K5MB%-ZSK\ M&UYW,[K0%9<&!"Y)&IV=]P/0=8>H)U:M?54NE*4:]\."FBIJ%T#[2T7EV$S< M 6V;GOP!4$L#!!0 ( $R KEB([/W,I@< # 3 9 >&PO=V]R:W-H M965T6;R- M6I1,Y50X90IA:74UN)F\^W#&Z\."_RK:N>,EQKMPG^QBVMG6)Q6SIN\W@P-D=! M0(M9A7W^^IZT])2).VG]7OQB9>%D M\)>[''G@\ZI16F-]B%C3%[#>BJ^F\!LG/A499?W](^C5*C=ME/LP?17PJ[1# M,9LD8CJ>GKV"-VN-G06\V=\V5OQ^LW3>XNU_S]D=8<^>A^6\>>=*F=+5 (GA MR&YI$Q(R098!4A2>XP"/;4EM)S?O?3";39+9XVR[U)NS,:.E% M:96QS0@]IAM9K"G!4BXH6"M9,X'TS3#"M(*@O5QJ&HIOA?B)EI!B]V)RQMI- M%E&G6Y.7LM@+"MIDK)414GQD@9]J&>)F;8E07KPXX3T__K"83L?OGTZ'BM.R<(DXL$.$W'R%42MAWCDM*?'OYW@ZDE6W&ZD0BDI@@\_ MWL'!SJ0*3G'B=?O MM8@VC@@?P'U-@XNS\V0\'G/(BU25&)6YJ2 ?DX$+1_P A7C:83PEM>6@BQ7H M:H)O2FO65N:]>)L=N9XB<+N8LM @V,&M%"Q\(*OP=(.=Q9:L5XQ]S/ZN\X[F M#D[\)!&9 ,RXQQ!PF_*ZIQ0_6F(O&S&9B:WAX)<8CR 2> MQ+ )KZF6SE%,6A=M :(+,NL -C[A!!(.'H.%81LG$R,UB0\]EI DOU,AEOON M7K9R,G_O(O F^G3(54$B)@[G7A0&(D+;$!1$P/:Y()^I(1!8T$J!^5ISU*!0 MB7@^*IRRA)'Y?+B8_*NQI(O]3Y1GO[;*/U3+/T#B/N?9C:DI,A5!GP8RFA1! M>)H=6P?==FC%BXXIL)$Q^I;; Q1/+Q0H;*O"-/:$*^)^5XI6I-BY( M7E:@#T7B\$3[GLF]6*E'J,1YAKH8V%BFQ0D^' MD_..-Z%WCO5/D_'VH/H]6WK(QE^"N?U9KI/N$'7G$6VNX"#<5KD0<%9?9G^@ M9@8+5%22MK4YDO=G*J[FB*>97&R$DOUW+0OU5[[=U]+6 (__UI)A*9W5! MIFYU/TMF3ZIL%SUA0_M9/KL8SL=MEN,/AE<^Q(?S_04BP%%5'N8Y/0XLKDOQ M$X27\C(T*,3\W*J,BLS!W3JMX@F45CD_P4;H6?M%%@4W-)93A(^SX7AZONA4 M[I.@4'VD=0A'2,A(_MRTH+!+0F6/7@S!R6+B%*54V2%."=JA>"A"C\)PL;3<*>(M M8[] >JBE<:]7.C:;==@.\I)8]Y8$UY)0>4Z9BL3,JG@.-_YKSV0<-4$71&]5 M:1WKS8% S?KZ;*G/G!=]<]@ O%0ZD--: M 1*12U'N.79+LZ7A*W>(+U5!8C9..I>)0]X]XU9.LC>SR44RF<_$R9LQ3HO% MY)" IP'TS70^3V:S25PP6\P["SAQ7!E;6(T*>MQ0ES*8+WP1R)_7*X=/*N]H;11\059&F T3,ZZ"68 M&J@D\:[5" VV2P/'Y+ MW6"@<[1^MJ M,![.SP>Q\VE>O"G#-Y&E\=[DX7%#$LG%"S"_,FB_ZQ<6T'XDN_X_4$L#!!0 M ( $R KE@8,Y_>P@0 /@) 9 >&PO=V]R:W-H965TRF@V;(LQTF6&,A+BS5H-Z/M5A3#/M 2;;.52)6D MXOC?[SG2LKTA#?;%)BG><\\]=SSR6TM-C4VMWE:R];R^&0U>N92/< MP+12X\O2V$9X3.UJZ%HK116,FGJ89]GIL!%*)[/+L#:WLTO3^5II.;?DNJ81 M=GLC:[.Y2D9)O_!.K=:>%X:SRU:LY'OI_VCG%K/A'J52C=1.&4U6+J^2Z]'% M3<'[PX8_E=RXHS%Q) MCOO#D=7659$Q(UK+TC"#P]R!O95TS$&A\W6$F>Y=L M>#SNT5^%V!'+0CAY:^J/JO+KJ^0LH4HN15?[=V;SJ]S%,V&\TM0N_-(F[LVG M"96=\Z;9&8-!HW3\%X\['8X,SK)O&.0[@SSPCHX"RSOAQ>S2F@U9W@TT'H10 M@S7(*>\MOBK8^=D;S,DLZ=;*2OG+H0 MZDI6_[8?@LN>4-X3NLF?!7PK[(#&HY3R+"^>P1OO QP'O/$W\.[DPM.=-;^:7:_:[KO@)N?LZ*CLY3\6M*M:5JAMR2UE_!&@A:= YQS5!N! ML[*R4N+H>52C7].'.U2^_H)#6$KUH/0*!O6.;1G8DGQ0E=0EL!9;?&VM:91S MQFY)&Q\VGN23+,VR;$ ?P$ %S\Z3R>]-9+6J:6_2/WA]OMP)'R(%W0F@^Q[:J6%1]TU WK=4P4?WMSI5J@*(2I=JA9N%J(6"+T'"P$#IQ1U MV=7P4A&+RZ+9G<]L,"W810F7:'W4&NCAR#S J^_9IB2JS^@ L%=+TM#>.?1- M0BU:I07W/1@>XQXP=/7H5SY"1^5D< C M)B:@-!IJAKO#M.$"X/(*BS'_H="/4G>"XY%.IA/>)VB)N^+G(, !4BZ7,EPB MA":%LHMG*A\'N.3VX!"=6"8O8EQ\C59=#:X--\IZ>U0XG+G]06C%EBO0]=J) M)DC%S(HT+Z:TD"LP!OPU$.J]]P%G!)8EYWA7HO_ADNZ*'%6^XK0_4;J==QYT M&&.!J-V!%XX+R_&(" Y5TE?/^: X1_5TUG5(&DO72_NC"\JY$"1T1Y/@@HRB M+#O/O3BHBKC%HI:'^%$<0(X2]Q$+C:5J,"QZ?4C%*1\6$QU,J)FF> MA_4SG(&T&.7TP7BH=D*CT[-TBGU/M?WAT6W<2+L*;PXN>*0S7LS[U?VSYCK> MYH?M\4T$$59*HRG+)4S1-28)V?C.B!-OVG"W+XS'2R$,UWB:2[8M*RQ4AO;"(^A7:2NM2RJ&-2HM,BRD[014B>S29R[M[.) MZ;R2FN\MN:YIA-U>V>V124S(UY#(/;:IID@1 K+GU $/BL^(J5"D"@ M\>\6,]EO&0*?VSOT#U$[M,R%XRNC_I*57TZ3LX0JKD6G_&>S_HVW>L8!KS3* MQ?^T[GV+\X3*SGG3;(/!H)&Z_XJG[3D\"SC+7@DHM@%%Y-UO%%E>"R]F$VO6 M9(,WT((1I<9HD),Z).6+MUB5B/.S.Z,7Y-DVD#+W=/B[\>R.)JD'=O!(RRW. M98]3O()S3I^,]DM'-[KBZO_Q*3CMB14[8I?%FX"?A#VF83Z@(BM&;^ -]T*' M$6_X"MYUD'>KG;<=:LK3]SLXT*WGQOW]DMP>;?0R6K@J%ZX5)4\3W 7'=L7) M[)>?\I/LUS>XCO9<1V^AQZ2\BTF)K+\_\).G2V7*QQ>IO@GV,M6;TFC3R!(G M\D]G-W0MG7#8D>Z,T'28W-Q>WR5'%#XD'6K#R87FBKRAUIJ5K)AX!V%92:[# MTKQSV-PY=N27PI.PC!JV%N>M-L1/+5O)NI0H.8&B:UICT0A(&>?(U !:L>Z8 M*OP!S2^9KHPU6JRD[1P=7OWQ]?;Z77Y^1*U E6'OXYXA*)7,E:,2Y.=,G>NI MEF8%22)<*089*S9AF] F H52M-(+1< B'6ZX(O0Z*WQ8#&0UA S0KLHE"6"C MOJ7N1&PF %^R4'X)%(BG@'K0/JO%32RQ >T&OY!$+Q@K5B$\K/'=-# ME-= R@91):,Y5>!ZD(^S099EO3*%=/2N0F-O15(C2^P\@2>'U R/3\<_]RY; M[/XZAZ6,-BRLBQS":3;ABB(3.T<_Y#<(]>=!]A.6VLEBJ,- M*6E,AT.*-15TR2ID CH"LC&KBW$ L-";10>%W=!WR"76%T0&=GA7!'M-P@$\P3V .$0+S%.9HG ?S#.88 MOM" E[ .%RN&[2*^2J'"(+IOW?O9 M_(:H1F*(2';OT3]P)LV=O^Y\7A+HHG*A?3@@/7: MH.-O!V&#_<^!V7]02P,$% @ 3("N6%)I $H8!0 $0X !D !X;"]W M;W)K&ULK5?;;MM&$/V5 1NW"9W:5E_WUGEI1,R;;BM 4,F4O.G'/FLK>3I3;7MD1T M<%M7RIX&I7/-\7AL\Q)K84>Z045?YMK4PM'0+,:V,2@*[U17XR2*]L>UD"J8 MGOAW'\WT1+>ND@H_&K!M70MS=X:57IX&<;!Z<2$7I>,7X^E)(Q9XB>Y3\]'0 M:+Q&*62-RDJMP.#\-'@='Y]E;.\-_I"XM(-GX$AF6E_SX%UQ&D0L""O,'2,( M^G>#YUA5#$0ROO28P9J2'8?/*_2W/G:*928LGNOJ3UFX\C0X#*# N6@K=Z&7 MOV ?SX3Q<$AZA\3K[HB\ MRC?"B>F)T4LP;$UH_.!#]=XD3BHNRJ4S]%62GYN>:Y6CPTO/VB']M7)V!$3VX_S'O6L0TV>0$WAO5:NM/"S*K#8]!^3PK7,9"7S+-D) M>(G-"-(HA"1*TAUXZ3KLU..ESPK[@H/]_!O9P#N'M?WKL8@[P.QQ0)X[Q[81 M.9X&-#DLFAL,IM]_%^]'/^V0FZWE9KO0'Y/[1MJ\TK8U")^O\-;!6:7SZT>5 M?P6[*[@'?2N54+D4%4AEG6EI]CD;PK*4>0D--8-R]+&ZHSD\^YOF%;@2X5S7 MC5!WX+0?YCLZ*N2O5EH'C9%$U'@PMA&V!*&*[@&_M/)&5!TY9=,9F3LL[JT( MO4#ZDB/9S2JT(]C9R$OI2@9JO&;]T!^DA04J-%Y000N%L7(NB;-H<159)<,D \4BV&"?G!]A,8NX6C4UZB-$1 4HSMEB6C+9/KA1$- M)1H$+:YV(T$L7RJ/_4E)SL2E$S0S/:)4#HWR88MJ!%>#BAA:A:G:A""*@L*W MY,(@\W69*;6H%I0<"D>Z@6!"#H%D"%\Q*@A2>D.8827QQL,(YSWND[B1<;QM MNN:DQ%:R9M&;V@I-*$J3.5>;#%?4EM--SHZ8JXK"-!S6>_&W-G"^DO>[&CJ( M/->MXKS0+@5QNL?A*&3L&U14P*(UJ^*XTB#^6//R!%0#J0NJ(RU2Q&"HR=/8 MKS'9:(-BFR'>Q: HY<\A^*"?PJ^U8:%"01SM/26>:_^ RC[&E8[@M67!FPK" MC=E;"FK.I1Z6@4MLT"]G7EJ\O^=9^_"](.VHBWKU&\TP$Q7U&*ZH?VTIG:L% M_"&S'B;[ 7&2?0MAURJ7;=-0KYIAT]&,Y!#]/*;^LKW)=@.E6W%ZRJ:EW F> M06SR39VTJ8!#W5:P)2"+=A(_M\&^/?(L^Q\C3^$_2?AZ#N!9$I[9^AS20-3# M'CS:"R%.Z&?W%&C$W;_H?\[,#G+1-$;?2CJ$\F*^W9_/$$&G!;%8&%P(AKOH M%ZTW--VLXRUG>Q\!*WA7G!M= UT NEW5\M;$F\*<%F:]M,?PTN]*NK4$8%_! MV[XX5SZ9PR/@(/\KHP]Z?UF)?0!RFZ1%,(MCS@Z,HATQ*YW/%GI.#SC,.)VD,&?ME81SO0\:&:7AP> 9 USY MG+Z )-P_VJ=^[.C2,$NS]>@PG,31>G041H3G1X\=^L:#8SJM'3 ]6L M.[&OWZ[O.Z^[8_Z]>7=9HE0MZ(@&%<[)-1H=3 +:=_T%I!LXW?A#_TP[6E3] M8TEW-C1L0-_GFDYS_8 )UK? Z3]02P,$% @ 3("N6 C;')B5! T H M !D !X;"]W;W)K&ULO5;;;N,V$/V5@;I;)(!J MRY(OLFL;2+(;M$5W&VS2+HJB#[1$2T0H44M2<=RO[PPI.W9NS5-?K"$]<^8^ MG/E&Z5M3JKA-?ZS5KIB%H^ZZ)M&CE7K96BYE<:3%M53&_/N52;13 (=A=?1%%:NN@OYPTK M^#6WOS=7&D_]/4HN*EX;H6K0?+T(S@:S\R'Q.X8_!-^8 QK(DY52MW3X.5\$ M$1G$)<\L(3#\W/$++B4!H1G?.LQ@KY($#^D=^J7S'7U9,<,OE/PJ>!I UAJKJDX8+:A$[;_LOHO#@4 :O2 0 M=P*QL]LK.+ADX^:PL M-Z?SOD5,^J>?=?+G7CY^07X*GU1M2P,?ZYSGQ_)]M&5O4+PSZ#Q^%? 3TSU( M!B'$43Q\!2_9.Y@XO.1%!XWA'#X(DTEE6LWAK[.5L1K+X>_GW/5HP^?1J$5F MIF$97P38 X;K.QXLO_]N,(Y^?,76X=[6X6OH/AG/&?4&,0,W)8<+536LWH+T M5QG7%AL3UBP34EB!5ZS.@7]K18.=9:'%K&G %M?,BKKHY'IPHRR3_@3\'B> MX6''?'9] >DP#F'##(@ZDRTF'@G(E+&@UE HE1LP2N9.&?;Z+2?P$ I>HR+I MKEF.U2PH$=263IC@0+4:%;$V%Q9A,X4Z4;FC$%+DC*Z-Q0\Y8$AA9SXR $XI ML!@'6VI,.NFI,5A0^1KE5*. %9:5^Q(+'1=2"3"2ESBFS PN.Z ;!W18XP?R M.Z;/I.,%'M+AX1^HWX[C[9U'G>(>1=]A=,/I)")B%"8H\P[B$5Y-8T>-PR@= M^@3-WLA\W3:-=/'"X&?,E+!&+S':?JC3=*1D_F_^7Y )#1.YRQ>K5%O;XUHB MU IC@_WJZA2S[$,E!5OM2ODAC'N?? 4\KF>*3AK&+CKI.$Q&%*]X'(=).NG" ME*9)5_1OY*4B8RO)844/&[Y/6*#89*B,;,=6P8%#?J$_Z];2W*%ZK]JJC&E9G7#KE3SS="%N"Y;IR MG5$I3;W L*TP0P[;*M\@SM='XD?1)8^*6OR#=JFZ<^H_VG+%))D&[CER]80V M')?"["!KKB!.,,/"3Z$U7/[I+D]]$D8#5R\CB =Q.!R,Z#"&))S&*9$3&(2X M>Q"9=B1F!3>3-?H/8SH>3+%]O)-H$J:C"=##@%%&7HYS*PVG20)7--.QW.Z8 M;/GS18,?C8TZ9VV4>T$W*""HX:JV'@/S28E:2Z+!)OKHU M@N<_L X=PX,3_"%%7L\)Y=*%./2&T^>(AW9]51RU)O$\!X_XRF\ M?^XQZQ]L&177A=NE\(TA3+]P[&_WZ]J9WU(>V/VNAR$H!(YKR=&PO=V]R:W-H965TPA/0U_K!\RGM4 I3@0L&G?*PF"2W@^O92/2CPC<#Z["W5Q+)'/%9 M#I^*2=(70F A)T'0O*S@#JP5(*;Q:XN9="[%<'^_0_\08^=8YCK '=KOIJ!R MDEPEJH"%;BP]XOHC;.,Y%[P<;8C_:MWJGF>)RIM 6&V-F4%E7+OJEVT>]@RN M^J\89%N#+/)N'466]YKT=.QQK;QH,YIL8JC1FLD9)T5Y(L^WANUH>H=598BS M3$J[0MVA(^.6X'(#89P2>Q"]--^BS5JT[!6T=^HS Y1!O7<%%'_;I\RLHY?M MZ,VRHX"?M>^IX>!,9?UL= 1OV(4[C'C#-\,-_\>K[DW(+8;&@_IQ.P_D^;7Y4T ,2)VX:2AK,JQ\2S$A9HW@7F%T!,&+.)V(_!!E7HE1KEM MBNB2N'VYGYO670V>-IV?,\9SL69[(JAJBYOXOCL^0@Z9AM^YZ>W'K0ID'8>D MYF -L/_(7VAS,=$V<9HP9]'EA?XA+#_&]Y(L:Y[!;B1],1 M:N -L]?%"B1V MPSZ9,+9YV5(X/;G*!I>@=>F7I MWHRHP"_C) Q2 D?MN.BDW;"];6?,'_5V4G-3+HV3LB_8M-^[/$^4;Z=?>R"L MX\29(_'\BMN2/QC@18'O%XBT.XB#[A,T_0U02P,$% @ 3("N6$:PC\F\ M$0 ?3D !D !X;"]W;W)K&UL[5M;<^.V%?XK M&&>;V#.TK;OEO;ATX?(!*2D*5(!B!M*[^^YP* ($5I-\VD M#YV\V!()'!R/I?EHMTK5XFF7%_;5V;:NJ^?7US;=JIVT5V6E"GBS M+LU.UO#5;*YM993,:-(NOYZ,1HOKG=3%V>N7].R]>?VR;.I<%^J]$;;9[:39 MOU%Y^?CJ;'SF'_R@-]L:'UR_?EG)C;I7]8?JO8%OUX%*IG>JL+HLA%'K5V=W MX^=OQB.<0"/^J=6CC3X+W,JJ+#_BEW?9J[,1E/HM4YE48N[-"V;HM;%1KPO MIHOV':DR.T;\5W95%OK?BFR%36G7\-? 9F)Y[9 M-Y.3!+^3YDI,QXF8C":S$_2F8?-3HC<]0F]HP_^Z6]G:@+'\>VC#3&\V3 \] MZ+FM9*I>G8&+6&4>U-GK+[\8+T8O3G ["]S.3E%__3V8>,RQ*0OXG"KPD=H. M,7N:W#M1B+\WA0)ACA>)J+=*?'MW_T9H:QN5B;O[#_3FZD$6J92[> M%2"=AI:\?&M4IFOQC]):M)0OOUA.)J,7=_=OQ72RH&_C%Q>)D$V]+8VN)?J? MV#0Z UI*2""2X4:V( :@IVL4_Z/.<[%3TC9&B907R'D!"$%B5]I:K ,W$E[4 M5L@B$ZDR-00A4<)&C- MF[ S60L)Y(JR]J0S <_64AOQ(/-&P1A3-INM*" . MZB(M=^I*_+B-N#7JET:#3DE.LJK 6B2%E7(M)#BJ,;"64$\51!N@'G$./&E?!\L@A#Z#8D@F@&(CPOID1G!*8 2)JO584T$@LNJB5 MT3L2A"R*!D1C5%4:,I0*7I69%2NUT46!3^0:AHNO%=C."CZ,Y^11$UY)9F7E M=U;W5R;UH!RW$I:6$(EP85@.MY/6R#[.>5O"UV+_E15-(1N0!(JD+"PX62;Q M2ZM""W;!)BQX?3>7^8"A2._3\A65*6W%(LGW8FW*'2QB4UAAKZ2AB)&P?%"H MUA&6.:0EVAF*<8@\JKS$_(-YA.88;3^B@'Z-V9:VZ M.P()@$(:IMA8Q1QL4",@1Z.?0(\XZ&?P:M+ HZZW-&BK(1$8C;O1!:=B>)\$ MN< DX!<>6=XCY&=;%G*5*_IJFPJ-@;[#;)5*6]LN;QNP_\JR?SG%0Q3,T/!3 MI1]HZFHOJA+RC;.?(4,!;1:9-&!M8.XP!80H"YGO?_6*C/1V9!EX4=!:]$\A MOV$IYGDG?P9E91I< ';/_H"4E*TU&J2G?-)J4-^DS79_(5#XB6S-$"0JN4<3 MO1+?NEG@1NIRA]G-N1=$,,AQ C(4.+E/41Q53SI4IK,_RI^Z"B;/]1:(!LA^ M\$E!78EW$*'D'MA&':(KI"5@AE^1W5B@FEGEZ-FR(<#[AM*+6>)H9R[R@J QC[62$0F,B;S$4&SO7!44)@!(_6-0JHS"'4E8^%0A=? M69UI:31FC+L\YYR0^CF>%DX&CRNLI!!CV?!6"F2M<@T $WD[)=!%$.CBI P^ M6/+#;YQ/#@*4TQ10B@"C*FE"ICTB,Q0L1D5=[SEFRA8F5:UB-ZI01J+,X+VB MY.*,]D-!FKI'HB3ONYW"<"O.SS[W;T_NV@AP Y"VH:-&_QA)S^VH(-+'YO$ MRV11'!R4&AG"$7X,)K6&/.V_0/(80/&=E)(L.0/5".LQ(F!HQ])F/TB% 1 MXD^N?Z7D03BR&W)!.&B5F- V)4K+!3"%8R6;!^J4JCQE+$+F\!:6US:&7J!V 'I-H;]<]7 :V5[R0++>0S% MM@5(G#$K #5@@4BB Y$">(T"E=N.C=%+#7DF Y""4 W+SK!Y+CL0/8W/%$@* AQGL15&:)0?0D8" M-WX'K7>'#7"J)(<'D6G0R8/.T-Z]Q/]$KK\?N?X)7/];X!J5N,>1ZT^4%T_M MG-&JA?C0\6YAD#,J>=EU_!HQ X0NP:=0#8A)UFM(3B@+@GKEHSHTT3[9\@%+ MT M^@SZQQ3IPS4@4 .1Z-_H+<'P.%CB#+.S*^@PWAV.QGB#X(Q4"D M1PRRC09?=>( 3EE#3B^-!2L%S"\M(ZZ"#)QR82Y=218"6;].HS H\TN,3.1D MV'B"XKY._RPU_F>EQF^I-#K[;-% T0O'W2B,"*^"*/]$3@[N\6P\G22+R8QL MX-EX/DV6-TNT(!C95RL.H3;==$2/I@FBK#9?N*8-?D7XZZ/#*7XB)%=OC?+6 MA2L=&)L]8FT>/L:9BD?VF$4_PZ"%_-CGP:I_Q(4[_>%H"3_H>^#FV!AD@Y:( M/KV1.6XY\2"X[7@Y?W .]$R,I]-D#M.>B31?T[+TI'S2= M/YS_ -G26)E?"$(%DQ?B_':9S$:C"W$^&273^0P^W$[YR4\ 3=0E!D%XA@_: M.?&W/KL@OP%&V5+@TVR2W#*C!\].H.EE0-/+T^W@ N A+/]$(;^O*G:H61R MR,SOBJ,_U2Z8HLT1X/P6WX*Q1# -82\8F+'UI0;(P)_*ID:LICD\^WIY;>CX M!<:%N 8A-I5LF,F(! (_H\>S2903DM]+J3EK-!EI'9-B^YC,SQ M8* 6@)(*#Y0X!DIC]E0/.-"B(V80JY@R:U(J+H,T7'@'X(^AC&HT*E88#Y0K MB,_*I@@J((H6<0',_>&P0-+I)>P@ ?8K6 /ATF0^0K1".!! Q/F>=QN C'8E M08*Q&BKX.O'Y!;)I;^*[-8:O)BYW6"&IIQ07(C,A.2+_K<"@[ !2?GI(/H$$93N987C >$S9=3"E MAG+"5\D@AA($G!GD?H^P)6S# M'Y! IFA2$!E:3\ZQR)DC$($E,U)8+&5T1=)/*4 ".<.AEBNV_MR9D!<:-0A6 MBEH-QK:=&!?X8.<0;%M;-O[XH4;2&5BM03_!M(-%O#@ M@ULG$'=S,"<\]NG.)R -/JH=-&SEFOG2FWLH42)U%$@0N7Y0H4IPTB.ED74: MJ@P2$C9"[7;- #^X/D5ATX[Q5 LB .;84WV3VQ#I;S]QCEB#6 DZG2,BN!#O M(4#?;X&%H=A_DMAP_R0.? V8$2 XCGSU8WF9YA)+7P6BYW("!C:UHACK^'' M#FP!WP(<$1:Y(Q>QK"6=ZDI2?+,*U,J]KZ#K(:^#X *FQL4^L HE&!X#0H&0 M?G1GI' M;+CZO1$+Z--'-\;-B:8*95T+ :%NA\3G2GTLR!#H@WOH54-)N$!7CI]X+J_$ MAX"0^UM+N-GC$"!Y77LRFE!$2:,G!YI"QW-ZS3"CD42]JT3S9,UL^?@12V0+ MY@^AP1>1CY3@<4>@14PB14.'EQ@I<$G7'HTD"DB!:EM<-_)4W[+\_K>QT=N1 M;594K%&&Q99-M"M:!1ND7(CYJ..K-V\E5+33V&-JYR@9=>CQE#P/M1$INVJ, M;22WHMDVO/EZR]@"[,% TX&6P2T".[1"9"@@H=*5ME0G^WYWF*"Q$P[8R\FV M8RV2Y,%])LF^[P7IV3BV:=IN44*"R_6&._^PZKHIV@/QKW7>>%CV.1;8'#5T M5&5CO6G\+AM+1)4W]J3G?(ZA)4'T-56+:Y*SM MS.DOF!)JCR1,>-'=E*BY=K3-CK;CG"5F^:@-.1ZQ(U/VPNSIRA#;Q_1HX^S;>^PUQ<$Z$A2S2]31&/GK=W!"L=E>4%M)$06PQ;.ICT0 MS.X&>@>D$:J+77/(&?5.FH] MC+:=_7Q+:(+VDSAZOB P$-]HYZ4234F8)Q* M-I3G!TKI&.FE>O7'M@Z^!RL#)%Z:Y^U'D@WG M.NH$!0T\I^31!2O/Q/EX,4G&L]L+^#Q?SI/)=(Y/)_/;9+&XP:>3^3*9+9:4 M>,$:$'^T6 /$T8SY/:&>;R9))/)+?%XNTSF(WHZ&=\"_6E/"MX>^W+PD?C_6Q9?*VS?%CV; MZ**^R#]_X_#+P[SCLTWD5C?);#Q/IL#CZ4\_]6GU!1EB3C\!A;[4(ADMILEB M=#/PI+^W;- ?-3FMC5F/QH3R +K#QG(\[07H\OP%''!W]__:$"!;);'23+">CR+[Z3WXL M:X M P FDAU6T'%YWPU.0'2^F!%1S]3ADQ/E]'C47J$>?:+_2>;SHWP:ON;R M&Z9WL9P_[N86'M<6-*K%9=3*Z%P"V8<:CG%4Y^:J.U'QI4GF%0-DCUTH\0 A M="?638V747W _!4[J&]<=N6+;&.J/_YZ>,D7YKJMB*-6TZA+6H_ M:PNN#\>-,(Y/IGK$K8@7J2 SC:*1!L6@_U^CECHL-^=L)%RG(UU6W%\@8E5 MZ(ZK<7IL+.:JDDB78/\5%L26Q5X-@Y=Y_HCME<) MC*+C])8K+[#SO]' J!4LP8;<1<.8O-! ]2$ A# R@>IB(X(;.BC%RAZ-G&,D& MA_E4'_:Y\8<4-[/10?22U,6PM:IPZZ2+$$;.QQ?'# "J\)I^&D%U];!/^2*[ MRYN_W&%!;]*?S!T$U%JEVX+N6N#=R?;:JJ=#8C\'3,4!D(YQ.LO0ZCO\)9HO MJ2^9P4MD\)(/)]KTA4?7%M%\5WM1 *+31VDV"I3$=DD\82!7A5IK'X"<-$@, M\Q'&/?(K+YU.H.$F+'@@GW.!HNNC)%T:(0ZQ 0RA M-:?8'(B48#)1E(ZX#WFM-7E_6U,@QO">BW9%R_*18Y1[H^N@O;.H(;\9O(M0 ME*YMGK4[H0:8W\BC,N'7,[X5'@!!61Q(K(4Q\1XZ;*_XW%S0K]Z&KY)>1[^( M W/G@% $$ &0 'AL+W=OZ ERB(BB1I)V>G^^ATI67$< M1<@>^C+ L,CC\;Y^Q^/Q:B_D@\H9T^BQ+"IU/3197EG8G%U>BT06OV)U$JBE+*G^L6"'V MUQ-W'8V1\60CQ(.9_)Y>3QQC$"M8HHT$"I\=NV%%802!&7]W,B>]2K/Q>'R0 M_JOU'7S94,5N1/&-ISJ_GL03E+*,-H7^(O:_LSB\)8-I-M K-VM(FOE+=5T<27%'DG##=+,P+IJ=X-QO#*@ MK+6$50[[]&+-MQ7/>$(KC99)(II*\VJ+[D3!$\X4FM[33<'4V=5,@S:S9Y9T MDE>M9/**Y#GZ)"J=*_2Q2EGZ?/\,K.Q-)0=35V14X"T7>D+O?EQNE):3*7T,.M_+\87GF^%RJFB;L>@+G0S&Y8Y/%^W=NZ'P8 ML=;OK?7'I"]N6<:D9"GZPG:L:AA&FQ]H*26MM@P.B<;HEJND$*J1#'VWJ*%[ M]JC1JA#)PZ [HPJ'W9GR"NE<-(I6J3I#<#!@"HIRR=@SO!&@E>06K@/39U#P M&H^!U/QY1Z,5V_*J,O"(#-TQR46*?@'N$/Y),(=_GYBQYQ&T3%-N3KE")/:1 M&P7!0ID\K:&/EX'K4V M1@03,K1M:?B*2K_ ME?T<[>U%#*[2'<1\R]H%"$.CE8:S9?@C[+L!]L#&\=&W4UFG@4Q$!2N&XR@R M=N7]NYBXY ,*L1-Z.'2B I8N?>Y>OK?FB;N]H-XB@\#BO?F]&0A!BWXEP3)RC M\W1*N1>:%J@6&OHB#J,^ D>QJX0VJ=JF!'0USXLQ" U"WPH]&/62,I*X49^X MT6CB=CVH,NT)XSN3"Q@M36[0*F&V*-R [URC/\"^H00CB-3:(@76MJ=%#MNJ][4]')2 MT>*L1WH*]XOO.&=PTSC8"Z"H3.=>2_D&0+-SD67PB)D;PM.>X]FIN:QM!D\, M)3BTAKH^P?/6T!>TH728';W,H 78VO>G.>, >OM(ZZG]$W?9ONR>V-OW,40= M JE0P3+8ZEQ$T/7)]LW93K2H[3MO(S2\&NTPAV-B'$RZPVG/ MV7N#7QS79F<,+I*Y4L]NH! .1#+^;)A!>Z1SW!UO MZ5<^=HIES@Q>*/'("UN.@S2 A>L%O9.K;_C)IZ^X^5*&-_"NK'M1P'DM;&J MVCB3@HK+IF>OFWO8<4@_45NDW.'I@!1:XKK=,-\PI@TC_H!Q#K=*VM+ -UE@ M\:]_2'I:4?%6U#0^"+QE^A22;@?B*.X=X"5MD(GG)?\-\I*;7"A3:X2GR=Q8 M3;_B][Z(&V!O/]!ERM"L6([C@%+!H'[!(/ORJ3N(OAZ0VVOE]@[1LWO*O*(6 M"&H!K?0.7-1:TQB>_$/! [Y:F J5/^\-X. 1^P.@:\]+?^\_:HF01!TXXA)L MJ6K#9&&._7NX)FEU<31#N&-KN&46-6<"/D.W$\5GU*=I#(^4DR%"6"/R=392X$PWZGIKVSF$BJ(PPF2-0 M00(U-TJ@Q=:%OG$\B(XW[8[(#DBJ<)X2-;0^*=GW6.%.,E6HE[YD&,A5+6V3 M5^UJ6Y4F33*^FS&ULC51M3]M #/XK5H8F)D7DO>U8&XE2 MT)A@JJ#;A*9]N"9N"OD@RH0-3Q5 M9:TF3J'UYM3S5%9@Q=2)V&!--RLA*Z9)E6M/;22RW 95I1?Z_L"K&*^==&QM M%-@8O'6_8&N]0_]C,)6E>CY+S M"FO%10T25Q/G+#B=QL;?.OSDN%4[,IA*ED(\&.4JGSB^(80E9MH@,#H>\1S+ MT@ 1C;\=IM.G-(&[\@OZI:V=:EDRA>>B_,5S74RVK6],&;-&:5%UP:17O&Y/]M3]AYV D?].0-@%A)9WF\BRG#'-TK$4 M6Y#&F]",8$NUT42.UZ8I=UK2+:,/D"42!"Z$?Q@?PHK[2 MR.)%[^#-<*EAQE56"M5(A-]G2Z4EO8H_^XIML>+]6&923M6&93AQ:!04RD=T MTH\?@H'_Y0#3N&<:'T)/[VCR\J:T?;EANI%<]NM?;P/(N_G?8], M8Y MK]?PK:$$D>_"8@;?A4:8LV<:06V; ,<2S9SG* V)RWMK_00C-XE\(R<0#=TX MBHT\@#AP@S@Q\A#BQ U#:Q]!-'#C((2%T*R$(P@&(W=(?GMI7%S-KO^+PQ$, M1V''P:6CI1"Y49MU2&*W, M6H5R;3>*@DPTM6['KK?V2^NLG=57]W;CT0M?\UI!B2L*]4^&B0.RW2*MHL7& M3NY2:-H#5BQH\:(T#G2_$M2B3C$)^E6>_@-02P,$% @ 3("N6"NWX"(( M P &ULU55=;]0Z$/TK MHX 02+G-]^Y2=E=JNU2 Z+T5+2"$[H,WF6PL'#O8#DO__1T[:2C2=G5?>4G& MDYGC\7*O]#?3(%KXV0II5D%C;7<:1:9LL&7F1'4HZ4NM=,LL+?4N,IU& M5OFD5D1I',^BEG$9K)?>=ZW72]5;P25>:S!]VS)]=XY"[5=!$MP[/O!=8YTC M6B\[ML,;M!^[:TVK:$*I>(O2<"5!8[T*SI+3\\+%^X!/'/?F@0U.R5:I;V[Q MMEH%L2.$ DOK$!B]?N %"N& B,;W$3.8MG2)#^U[]$NOG;1LF<$+)3[SRC:K M8!% A37KA?V@]F]PU.,)EDH8_X3]$)L7 92]L:H=DXE!R^7P9C_'__ @81$_ MDI".":GG/6SD66Z89>NE5GO0+IK0G.&E^FPBQZ4KRHW5])53GEV_5W('%G5+ M4K86GM^RK4#S8AE9 G"TKK'[/CXC4Q"R]9W:> M'@6\8OH$LB2$-$[S(WC9I#3S>-DC>!NG;\--*93I-<+7LZVQFD[%OX?$#ECY M82S7*:>F8R6N FH%@_H'!NMG3Y)9_.H(TWQBFA]#7]]0YU6]0% U7#';:VXY M&K=RU?K+5\NI.<3[*/)AWE^0:4!9<3H)[WJ)D,4AW&[@;V41KMD=M:#U18#G M&EV?5Z@=F98[>P9Y$B9YX>PYY$68IMZ_@&P6YDD* MM\HR 4\AF2W".<4=I/'Z[>;]_^+P%.:+=.00TFN@D(79L.NL)^!_MH+OF!M&(5S2 M0227%SW6^.Y0/8^B'ZXG"8.ZM^Z,,RG=QIWFLN0=6:Q5O;0&K((M0L=X!*^J?<>$VF.[9 M]7]02P,$% @ 3("N6'<#!V;4 @ .P8 !D !X;"]W;W)K&ULG57;;MLP#/T5PFN'%C#J>VY+##3MBNVA0]%VVT.Q!\5F M8B&VE$E*T_[]*#GQ4BS-PP##%B6>PT-)I,<;J9:Z0C3PTM1"3[S*F-4H"'11 M8E 31W$8=@+&L:%EX_=W)W*QW)M:B[P3H%> M-PU3KU.LY6;B1=YNXIXO*F,G@GR\8@M\0/-]=:?("CJ6DCV.PF<8KK&M+1#)^;SF]+J0% M[H]W[#R?HG+TTU\08>E#AGZ]K!G,IK9E@^5G(#RGH3FQVX5!V: MQ'%A#^7!*%KEA#/YE10%"J.8VR,YAT)AR0THKI=P]LAF->KS<6 HE 4$Q99V MVM+&[] .X58*4VGX+$HLW^(#DMCIC';7H=1;YO0PLZVBD5ZQ B<>E8E&]8Q>_O%#U L_'=&==KK3 M8^SY U5EN:9#L9K_2>*>U/LP>W4#N*$$I((G=XKPB"\&IK4LE@>3.A[V6C:H M#2^ B1*X,*B$"\IJT,RJF2O9 +6*5HL&IA 83O0I0CV"KI!M7!M2T,AU\*T MM=W-=IWQLFT(?]W;MDI;M>!T(#7."1I>]#./+KEK5:UAY,JUAYDTU&S9=FS M#21V@FUHUZ!)5PS%/M R;1&11)>D[>3?[T@IBIW(7MIY7RR2OND1QL MN+B7&:4*'HJ\E$,K4VK9=QR99K0@LL.7M,1_YEP41&%7+!RY%)3,#*C('=]U M8Z<@K+1& S-V(T8#OE(Y*^F- +DJ"B(>+VG.-T/+LYX&/K%%IO2 ,QHLR8+> M4O5Y>2.PYS0L,U;04C)>@J#SH77A]:]B;6\,_F1T([?:H)5,.;_7G=]F0\O5 M"Z(Y395F(/A9TS'-H3W_Q*:SV1YDMY+LTO;"K;,+(@74G%BQJ,*RA867W)0^V'+8"W#^#7 M /\E(-P#"&I \ *0N'L 80T(WSI#5 .,=*?2;APW(8J,!H)O0&AK9-,-XWV# M1G^Q4N^36R7P7X8X-7I/TFWDI#75947E M[Z$*X ,O52;AJIS160M^/8=9P1-H /#%^P-M)24PH3)-.=R)2A\O9A*)3!3_VZ+=<46 MMK/IZM672Y+2H87E25*QIM;HYY^\V/VES=''))LM\:E(-\WQN48Y)-#BO%F@XJ0WF9P#VXG>: ^SS- MS$9_,OH#P?ML="Z9C-AJ?5Q2010K%Y!KAT**_I1]N&8/"#V!)+1[75EDL#*-%]I,"L- M:X%",87QO%; Y[7NG)$IRYEB6,^??9)JPCE>!Z1AY+O.DEIJ8OM&:A+;0:3% M^[%O!TFWUIPD0>6@-]H^"_Q]A>(#=UOI%W-RT]DY6>-"%A3O&OHV\QP]146! MY]$C)0*/HX\OE^MV>EWP.G'W-=,,2YMV%R""OD9&G:X/[_ 3]^!=6RDX4C[L ME(*H*071P02YS;A0YUH[F*H -^111U>V58&**C94^AZX'B6)K\^8]79ZMUC% M&+)=J\EK*PPHQG/7[*K%+(HQV(W9CNJX41W_2P'49Y*]%:NZ)+ZOM_*CC;M) MK02VVAQQD/U[R^$QR28_0/;L!),MIY@8# N&T E^_9<9/*LR,/),,D7@>[X= M>I'NQ!#8/3_13

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end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 145 187 1 false 26 0 false 5 false false R1.htm 0000001 - Document - Cover Sheet http://www.escalonmed.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements Of Operations Sheet http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements Of Operations Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements Of Shareholders' Equity Sheet http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity Condensed Consolidated Statements Of Shareholders' Equity Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements Of Cash Flows Statements 6 false false R7.htm 0000007 - Disclosure - Organization and Description of Business Sheet http://www.escalonmed.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 7 false false R8.htm 0000008 - Disclosure - Going concern (Notes) Notes http://www.escalonmed.com/role/GoingconcernNotes Going concern (Notes) Notes 8 false false R9.htm 0000010 - Disclosure - Inventory (Notes) Notes http://www.escalonmed.com/role/InventoryNotes Inventory (Notes) Notes 9 false false R10.htm 0000011 - Disclosure - Related Party Transactions Sheet http://www.escalonmed.com/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 0000012 - Disclosure - Line of Credit Sheet http://www.escalonmed.com/role/LineofCredit Line of Credit Notes 11 false false R12.htm 0000013 - Disclosure - Long term debt (Notes) Notes http://www.escalonmed.com/role/LongtermdebtNotes Long term debt (Notes) Notes 12 false false R13.htm 0000014 - Disclosure - Concentration of credit risk (Notes) Notes http://www.escalonmed.com/role/ConcentrationofcreditriskNotes Concentration of credit risk (Notes) Notes 13 false false R14.htm 0000015 - Disclosure - Leases (Notes) Notes http://www.escalonmed.com/role/LeasesNotes Leases (Notes) Notes 14 false false R15.htm 0000016 - Disclosure - Commitment and Contingencies Sheet http://www.escalonmed.com/role/CommitmentandContingencies Commitment and Contingencies Notes 15 false false R16.htm 9954471 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies 16 false false R17.htm 9954473 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables 17 false false R18.htm 9954474 - Disclosure - Inventory (Tables) Sheet http://www.escalonmed.com/role/InventoryTables Inventory (Tables) Tables http://www.escalonmed.com/role/InventoryNotes 18 false false R19.htm 9954475 - Disclosure - Line of Credit (Tables) Sheet http://www.escalonmed.com/role/LineofCreditTables Line of Credit (Tables) Tables http://www.escalonmed.com/role/LineofCredit 19 false false R20.htm 9954476 - Disclosure - Long term debt (Tables) Sheet http://www.escalonmed.com/role/LongtermdebtTables Long term debt (Tables) Tables http://www.escalonmed.com/role/LongtermdebtNotes 20 false false R21.htm 9954477 - Disclosure - Concentration of credit risk (Tables) Sheet http://www.escalonmed.com/role/ConcentrationofcreditriskTables Concentration of credit risk (Tables) Tables http://www.escalonmed.com/role/ConcentrationofcreditriskNotes 21 false false R22.htm 9954478 - Disclosure - Leases (Tables) Sheet http://www.escalonmed.com/role/LeasesTables Leases (Tables) Tables http://www.escalonmed.com/role/LeasesNotes 22 false false R23.htm 9954480 - Disclosure - Going concern (Details) Sheet http://www.escalonmed.com/role/GoingconcernDetails Going concern (Details) Details http://www.escalonmed.com/role/GoingconcernNotes 23 false false R24.htm 9954481 - Disclosure - Significant Accounting Policies (Inventory) (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails Significant Accounting Policies (Inventory) (Details) Details http://www.escalonmed.com/role/SignificantAccountingPoliciesTables 24 false false R25.htm 9954482 - Disclosure - Significant Accounting Policies (Accounts Receivable) (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails Significant Accounting Policies (Accounts Receivable) (Details) Details http://www.escalonmed.com/role/SignificantAccountingPoliciesTables 25 false false R26.htm 9954483 - Disclosure - Significant Accounting Policies (Net Income (loss) Per Share) (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails Significant Accounting Policies (Net Income (loss) Per Share) (Details) Details http://www.escalonmed.com/role/SignificantAccountingPoliciesTables 26 false false R27.htm 9954484 - Disclosure - Significant Accounting Policies Earning per share details (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails Significant Accounting Policies Earning per share details (Details) Details 27 false false R28.htm 9954486 - Disclosure - Significant Accounting Policies deferred revenue (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails Significant Accounting Policies deferred revenue (Details) Details 28 false false R29.htm 9954487 - Disclosure - Significant Accounting Policies New accounting pronouncements recently adopted (Details) Sheet http://www.escalonmed.com/role/SignificantAccountingPoliciesNewaccountingpronouncementsrecentlyadoptedDetails Significant Accounting Policies New accounting pronouncements recently adopted (Details) Details 29 false false R30.htm 9954488 - Disclosure - Inventory (Details) Sheet http://www.escalonmed.com/role/InventoryDetails Inventory (Details) Details http://www.escalonmed.com/role/InventoryTables 30 false false R31.htm 9954489 - Disclosure - Related Party Transactions (Details) Sheet http://www.escalonmed.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.escalonmed.com/role/RelatedPartyTransactions 31 false false R32.htm 9954490 - Disclosure - Line of Credit (Details) Sheet http://www.escalonmed.com/role/LineofCreditDetails Line of Credit (Details) Details http://www.escalonmed.com/role/LineofCreditTables 32 false false R33.htm 9954491 - Disclosure - Line of Credit - Maturity Schedule (Details) Sheet http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails Line of Credit - Maturity Schedule (Details) Details 33 false false R34.htm 9954492 - Disclosure - Long term debt (Details) Sheet http://www.escalonmed.com/role/LongtermdebtDetails Long term debt (Details) Details http://www.escalonmed.com/role/LongtermdebtTables 34 false false R35.htm 9954493 - Disclosure - Concentration of credit risk (Details) Sheet http://www.escalonmed.com/role/ConcentrationofcreditriskDetails Concentration of credit risk (Details) Details http://www.escalonmed.com/role/ConcentrationofcreditriskTables 35 false false R36.htm 9954494 - Disclosure - Leases (Details) Sheet http://www.escalonmed.com/role/LeasesDetails Leases (Details) Details http://www.escalonmed.com/role/LeasesTables 36 false false R9999.htm Uncategorized Items - esmc-20240331.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - esmc-20240331.htm Cover 37 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 19 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentQuarterlyReport, dei:DocumentTransitionReport, dei:EntityCommonStockSharesOutstanding, dei:EntityFileNumber, dei:EntityShellCompany, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued - esmc-20240331.htm 4 esmc-20240331.htm esmc-20240331.xsd esmc-20240331_cal.xml esmc-20240331_def.xml esmc-20240331_lab.xml esmc-20240331_pre.xml http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 56 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "esmc-20240331.htm": { "nsprefix": "esmc", "nsuri": "http://www.escalonmed.com/20240331", "dts": { "inline": { "local": [ "esmc-20240331.htm" ] }, "schema": { "local": [ "esmc-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "esmc-20240331_cal.xml" ] }, "definitionLink": { "local": [ "esmc-20240331_def.xml" ] }, "labelLink": { "local": [ "esmc-20240331_lab.xml" ] }, "presentationLink": { "local": [ "esmc-20240331_pre.xml" ] } }, "keyStandard": 180, "keyCustom": 7, "axisStandard": 11, "axisCustom": 0, "memberStandard": 17, "memberCustom": 8, "hidden": { "total": 24, "http://xbrl.sec.gov/dei/2023": 10, "http://fasb.org/us-gaap/2023": 14 }, "contextCount": 145, "entityCount": 1, "segmentCount": 26, "elementCount": 289, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 558, "http://xbrl.sec.gov/dei/2023": 64, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://www.escalonmed.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCashCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "unique": true } }, "R3": { "role": "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null }, "R4": { "role": "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "longName": "0000004 - Statement - Condensed Consolidated Statements Of Operations", "shortName": "Condensed Consolidated Statements Of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "unique": true } }, "R5": { "role": "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "longName": "0000005 - Statement - Condensed Consolidated Statements Of Shareholders' Equity", "shortName": "Condensed Consolidated Statements Of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-50", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-50", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows", "longName": "0000006 - Statement - Condensed Consolidated Statements Of Cash Flows", "shortName": "Condensed Consolidated Statements Of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "unique": true } }, "R7": { "role": "http://www.escalonmed.com/role/OrganizationandDescriptionofBusiness", "longName": "0000007 - Disclosure - Organization and Description of Business", "shortName": "Organization and Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.escalonmed.com/role/GoingconcernNotes", "longName": "0000008 - Disclosure - Going concern (Notes)", "shortName": "Going concern (Notes)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.escalonmed.com/role/InventoryNotes", "longName": "0000010 - Disclosure - Inventory (Notes)", "shortName": "Inventory (Notes)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.escalonmed.com/role/RelatedPartyTransactions", "longName": "0000011 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.escalonmed.com/role/LineofCredit", "longName": "0000012 - Disclosure - Line of Credit", "shortName": "Line of Credit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.escalonmed.com/role/LongtermdebtNotes", "longName": "0000013 - Disclosure - Long term debt (Notes)", "shortName": "Long term debt (Notes)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes", "longName": "0000014 - Disclosure - Concentration of credit risk (Notes)", "shortName": "Concentration of credit risk (Notes)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.escalonmed.com/role/LeasesNotes", "longName": "0000015 - Disclosure - Leases (Notes)", "shortName": "Leases (Notes)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.escalonmed.com/role/CommitmentandContingencies", "longName": "0000016 - Disclosure - Commitment and Contingencies", "shortName": "Commitment and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables", "longName": "9954473 - Disclosure - Significant Accounting Policies (Tables)", "shortName": "Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.escalonmed.com/role/InventoryTables", "longName": "9954474 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.escalonmed.com/role/LineofCreditTables", "longName": "9954475 - Disclosure - Line of Credit (Tables)", "shortName": "Line of Credit (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://www.escalonmed.com/role/LongtermdebtTables", "longName": "9954476 - Disclosure - Long term debt (Tables)", "shortName": "Long term debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "unique": true } }, "R21": { "role": "http://www.escalonmed.com/role/ConcentrationofcreditriskTables", "longName": "9954477 - Disclosure - Concentration of credit risk (Tables)", "shortName": "Concentration of credit risk (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://www.escalonmed.com/role/LeasesTables", "longName": "9954478 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.escalonmed.com/role/GoingconcernDetails", "longName": "9954480 - Disclosure - Going concern (Details)", "shortName": "Going concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails", "longName": "9954481 - Disclosure - Significant Accounting Policies (Inventory) (Details)", "shortName": "Significant Accounting Policies (Inventory) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails", "longName": "9954482 - Disclosure - Significant Accounting Policies (Accounts Receivable) (Details)", "shortName": "Significant Accounting Policies (Accounts Receivable) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-41", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "unique": true } }, "R26": { "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails", "longName": "9954483 - Disclosure - Significant Accounting Policies (Net Income (loss) Per Share) (Details)", "shortName": "Significant Accounting Policies (Net Income (loss) Per Share) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "longName": "9954484 - Disclosure - Significant Accounting Policies Earning per share details (Details)", "shortName": "Significant Accounting Policies Earning per share details (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "unique": true } }, "R28": { "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails", "longName": "9954486 - Disclosure - Significant Accounting Policies deferred revenue (Details)", "shortName": "Significant Accounting Policies deferred revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-41", "name": "us-gaap:DeferredRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-41", "name": "us-gaap:DeferredRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesNewaccountingpronouncementsrecentlyadoptedDetails", "longName": "9954487 - Disclosure - Significant Accounting Policies New accounting pronouncements recently adopted (Details)", "shortName": "Significant Accounting Policies New accounting pronouncements recently adopted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://www.escalonmed.com/role/InventoryDetails", "longName": "9954488 - Disclosure - Inventory (Details)", "shortName": "Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "unique": true } }, "R31": { "role": "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails", "longName": "9954489 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-92", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-92", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.escalonmed.com/role/LineofCreditDetails", "longName": "9954490 - Disclosure - Line of Credit (Details)", "shortName": "Line of Credit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-95", "name": "us-gaap:NotesPayableToBank", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-95", "name": "us-gaap:NotesPayableToBank", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "longName": "9954491 - Disclosure - Line of Credit - Maturity Schedule (Details)", "shortName": "Line of Credit - Maturity Schedule (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-100", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-100", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "unique": true } }, "R34": { "role": "http://www.escalonmed.com/role/LongtermdebtDetails", "longName": "9954492 - Disclosure - Long term debt (Details)", "shortName": "Long term debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-102", "name": "us-gaap:DebtInstrumentTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-102", "name": "us-gaap:DebtInstrumentTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "longName": "9954493 - Disclosure - Concentration of credit risk (Details)", "shortName": "Concentration of credit risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-104", "name": "us-gaap:ConcentrationRiskCustomer", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "unique": true } }, "R36": { "role": "http://www.escalonmed.com/role/LeasesDetails", "longName": "9954494 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } }, "R9999": { "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "longName": "Uncategorized Items - esmc-20240331.htm", "shortName": "Uncategorized Items - esmc-20240331.htm", "isDefault": "false", "groupType": "", "subGroupType": "", "menuCat": "Cover", "order": "37", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:RestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:RestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "esmc-20240331.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "esmc_AccountsPayableBenchmarkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "AccountsPayableBenchmarkMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable Benchmark [Member]", "label": "Accounts Payable Benchmark [Member]", "documentation": "Accounts Payable Benchmark [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r11", "r462" ] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r500" ] }, "esmc_AccountsReceivableBenchmarkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "AccountsReceivableBenchmarkMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable Benchmark [Member]", "label": "Accounts Receivable Benchmark [Member]", "documentation": "Accounts Receivable Benchmark [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableGross", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AccountsReceivableNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r123", "r197", "r524" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r425" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNet", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Receivable, after Allowance for Credit Loss", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r375", "r424", "r468", "r524" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r60", "r462", "r528" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r269", "r270", "r271", "r353", "r495", "r496", "r497", "r509", "r530" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r124", "r200", "r205", "r206", "r209", "r524" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "crdr": "debit", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance." } } }, "auth_ref": [ "r208" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r177" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r22" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r89", "r121", "r147", "r180", "r187", "r191", "r202", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r281", "r283", "r294", "r326", "r380", "r462", "r474", "r505", "r506", "r513" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r117", "r128", "r147", "r202", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r281", "r283", "r294", "r462", "r505", "r506", "r513" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r20", "r120", "r442" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning of Period", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, End of Period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r20", "r75", "r144" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r75" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.escalonmed.com/role/CommitmentandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r82", "r213", "r214", "r426", "r502" ] }, "us-gaap_CommonStockConversionBasis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockConversionBasis", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Conversion Basis", "label": "Common Stock, Conversion Basis", "documentation": "Description of basis for conversion of convertible common stock." } } }, "auth_ref": [ "r122" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r465", "r466", "r467", "r469", "r470", "r471", "r472", "r495", "r496", "r509", "r527", "r530" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r59", "r367" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares outstanding", "terseLabel": "Common Stock, Shares, Outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r5", "r59", "r367", "r386", "r530", "r531" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r59", "r328", "r462" ] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockVotingRights", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Voting Rights", "label": "Common Stock, Voting Rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r25", "r28", "r41", "r42", "r196", "r425" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r25", "r28", "r41", "r42", "r196", "r346", "r425" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r25", "r28", "r41", "r42", "r196", "r425", "r481" ] }, "us-gaap_ConcentrationRiskCustomer": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCustomer", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk, Customer", "label": "Concentration Risk, Customer", "documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures)." } } }, "auth_ref": [ "r24", "r26", "r28" ] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Disclosure [Text Block]", "label": "Concentration Risk Disclosure [Text Block]", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r79" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r425" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk, Percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r25", "r28", "r41", "r42", "r196" ] }, "us-gaap_ConcentrationRiskSupplier": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskSupplier", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk, Supplier", "label": "Concentration Risk, Supplier", "documentation": "Description of risks that arise due to the volume of business transacted with a particular supplier or reliance placed on that supplier. At a minimum, the description informs financial statement users of the general nature of the risk." } } }, "auth_ref": [ "r24", "r26", "r28", "r33" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r24", "r25", "r28", "r29", "r41", "r88", "r425" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r25", "r28", "r41", "r42", "r196", "r425" ] }, "esmc_ConcentrationofcreditrisksAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "ConcentrationofcreditrisksAbstract", "lang": { "en-us": { "role": { "terseLabel": "Concentration of credit risks [Abstract]", "label": "Concentration of credit risks [Abstract]", "documentation": "Concentration of credit risks [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r40", "r444" ] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual Obligation, Fiscal Year Maturity", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r493" ] }, "us-gaap_ConvertiblePreferredDividendsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredDividendsNetOfTax", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Dividends, Net of Tax", "label": "Convertible Preferred Dividends, Net of Tax", "documentation": "The after-tax amount of any dividends on convertible preferred stock." } } }, "auth_ref": [ "r163", "r164", "r166", "r176", "r259" ] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockMember", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Stock [Member]", "label": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": [ "r256", "r257", "r258", "r469", "r470", "r471", "r472" ] }, "esmc_ConvertiblePreferredStockPercentageOfOutstandingSharesOfCommonStockUponConversion": { "xbrltype": "percentItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "ConvertiblePreferredStockPercentageOfOutstandingSharesOfCommonStockUponConversion", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion", "label": "Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion", "documentation": "Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion" } } }, "auth_ref": [] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Preferred Stock, Shares Issued upon Conversion", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r9", "r37", "r58", "r85", "r260" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods and Services Sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r70", "r321" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r69" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk [Member]", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r26", "r196" ] }, "esmc_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "CustomerOneMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer One [Member]", "label": "Customer One [Member]", "documentation": "Customer One [Member]" } } }, "auth_ref": [] }, "esmc_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "CustomerTwoMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer two", "label": "Customer two [Member]", "documentation": "Customer two" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.escalonmed.com/role/LineofCredit" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r83", "r146", "r228", "r234", "r235", "r236", "r237", "r238", "r239", "r244", "r251", "r252", "r254" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r8", "r55", "r56", "r90", "r91", "r148", "r229", "r230", "r231", "r232", "r233", "r235", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r302", "r451", "r452", "r453", "r454", "r455", "r491" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Basis Spread on Variable Rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note payable, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r44", "r46", "r229", "r302", "r452", "r453" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Interest Rate During Period", "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r16", "r44", "r247" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r16", "r230" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r148", "r229", "r230", "r231", "r232", "r233", "r235", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r253", "r302", "r451", "r452", "r453", "r454", "r455", "r491" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r17", "r148", "r229", "r230", "r231", "r232", "r233", "r235", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r302", "r451", "r452", "r453", "r454", "r455", "r491" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Periodic Payment", "label": "Debt Instrument, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r17", "r49" ] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly principal and interest payments", "label": "Debt Instrument, Periodic Payment, Principal", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": [ "r17" ] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Axis]", "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information about timing of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Domain]", "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": [ "r6" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r17", "r37", "r39", "r43", "r44", "r46", "r48", "r84", "r86", "r148", "r229", "r230", "r231", "r232", "r233", "r235", "r240", "r241", "r242", "r243", "r245", "r246", "r247", "r248", "r249", "r250", "r253", "r302", "r451", "r452", "r453", "r454", "r455", "r491" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue", "periodStartLabel": "Deferred Revenue", "periodEndLabel": "Deferred Revenue", "label": "Deferred Revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r485" ] }, "us-gaap_DeferredRevenueAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueAdditions", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue, Additions", "label": "Deferred Revenue, Additions", "documentation": "Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueByArrangementDisclosureTextBlock", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]", "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueRevenueRecognized1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueRevenueRecognized1", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue, Revenue Recognized", "label": "Deferred Revenue, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue." } } }, "auth_ref": [] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits Assets, Noncurrent", "label": "Deposits Assets, Noncurrent", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r484" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r2", "r184" ] }, "us-gaap_DividendsPayableAmountPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableAmountPerShare", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends Payable, Amount Per Share", "label": "Dividends Payable, Amount Per Share", "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date." } } }, "auth_ref": [ "r21" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r477" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r478" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "esmc_EarningpershareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "EarningpershareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earning per share [Abstract]", "label": "Earning per share [Abstract]", "documentation": "Earning per share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings (Loss) Per Share, Basic", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r137", "r154", "r155", "r156", "r157", "r158", "r162", "r165", "r174", "r175", "r176", "r178", "r292", "r293", "r323", "r333", "r447" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings (Loss) Per Share, Diluted", "verboseLabel": "Earnings (Loss) Per Share, Diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r137", "r154", "r155", "r156", "r157", "r158", "r165", "r174", "r175", "r176", "r178", "r292", "r293", "r323", "r333", "r447" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (loss) Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r22", "r23" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r476" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r476" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r476" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r479" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r476" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r476" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r476" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r476" ] }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customer [Line Items]", "label": "Revenue from External Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholders' Equity [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r5", "r115", "r132", "r133", "r134", "r149", "r150", "r151", "r153", "r159", "r161", "r179", "r203", "r204", "r261", "r269", "r270", "r271", "r279", "r280", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r295", "r296", "r297", "r298", "r299", "r300", "r311", "r341", "r342", "r343", "r353", "r409" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r81", "r322" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographic Concentration Risk [Member]", "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r27", "r425" ] }, "esmc_GoingconcernAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "GoingconcernAbstract", "lang": { "en-us": { "role": { "terseLabel": "Going concern [Abstract]", "label": "Going concern [Abstract]", "documentation": "Going concern [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r131", "r273", "r274", "r275", "r276", "r277", "r278", "r348" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Accounts Payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r1" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increaser(Decrease) in Accounts Receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r1" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Accrued Liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r1" ] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Deferred Revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r438" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase (Decrease) in Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r1" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherDeferredLiability", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Other Deferred Liability", "label": "Increase (Decrease) in Other Deferred Liability", "documentation": "Amount of increase (decrease) in deferred obligations classified as other." } } }, "auth_ref": [ "r1" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Increase (Decrease) in Other Operating Assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r1" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Other Operating Liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r1" ] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "calculation": { "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method." } } }, "auth_ref": [ "r170", "r171", "r176" ] }, "us-gaap_InformationByCategoryOfDebtSecurityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InformationByCategoryOfDebtSecurityAxis", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Security Category [Axis]", "label": "Debt Security Category [Axis]", "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r45", "r94", "r135", "r183", "r301", "r394", "r473", "r529" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r140", "r142", "r143" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Payable, Current", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14" ] }, "esmc_Interestportioninthefutureleasepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "Interestportioninthefutureleasepayments", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "parentTag": "esmc_Netpresentvalueofnewleasefuturepayments", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest portion in the future lease payments", "label": "Interest portion in the future lease payments", "documentation": "Interest portion in the future lease payments" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.escalonmed.com/role/InventoryNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Text Block]", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r210" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Finished Goods, Gross", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r486" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryGross", "crdr": "debit", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Gross", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r489" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/InventoryDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r126", "r443", "r462" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r98", "r119", "r125", "r210", "r211", "r212", "r320", "r445" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Raw Materials, Gross", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r488" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventory Valuation Reserves", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r35", "r489" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": [ "http://www.escalonmed.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Work in Process, Gross", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r487" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.escalonmed.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost [Table Text Block]", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r511" ] }, "us-gaap_LesseeDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.escalonmed.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r512" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "parentTag": "esmc_Netpresentvalueofnewleasefuturepayments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r310" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r310" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (reminder of FY 2024)", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r310" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r310" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r310" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r310" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r310" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.escalonmed.com/role/LeasesNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Lease", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r303" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r13", "r147", "r202", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r282", "r283", "r284", "r294", "r366", "r448", "r474", "r505", "r513", "r514" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r64", "r92", "r330", "r462", "r492", "r499", "r510" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r15", "r118", "r147", "r202", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r282", "r283", "r284", "r294", "r462", "r505", "r513", "r514" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r8", "r52", "r53", "r54", "r57", "r147", "r202", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r282", "r283", "r284", "r294", "r505", "r513", "r514" ] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lender Name [Axis]", "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r12", "r491" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility, Lender [Domain]", "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r12", "r491" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r491" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r12", "r491" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Long-term Debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r8", "r91", "r241", "r255", "r452", "r453", "r522" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r4", "r148", "r246" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r4", "r148", "r246" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r4", "r148", "r246" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r4", "r148", "r246" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r4", "r148", "r246" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remainder of FY 2024)", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r494" ] }, "esmc_LongTermDebtMaturityAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "LongTermDebtMaturityAfterYearFour", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, After Year Four", "documentation": "Long-Term Debt, Maturity, After Year Four" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt [Text Block]", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r83" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r17" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails", "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r17", "r36" ] }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtWeightedAverageInterestRate", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Weighted Average Interest Rate, at Point in Time", "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time", "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r196", "r459", "r508", "r525", "r526" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r196", "r459", "r508", "r525", "r526" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.escalonmed.com/role/OrganizationandDescriptionofBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Organization and Description of Business and Business Conditions", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r99", "r104" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by (Used in) Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r141" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net Cash provided by (used in) Financing Activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by (Used in) Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r141" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Investing Activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by (Used in) Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r75", "r76", "r77" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Operating Activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 }, "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r68", "r77", "r93", "r116", "r129", "r130", "r134", "r147", "r152", "r154", "r155", "r156", "r157", "r160", "r161", "r172", "r180", "r186", "r190", "r192", "r202", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r293", "r294", "r332", "r388", "r407", "r408", "r449", "r473", "r505" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net Income (Loss) Available to Common Stockholders, Basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r139", "r154", "r155", "r156", "r157", "r162", "r163", "r173", "r176", "r180", "r186", "r190", "r192", "r449" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) Available to Common Stockholders, Diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r139", "r164", "r166", "r167", "r168", "r169", "r173", "r176" ] }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic", "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders." } } }, "auth_ref": [ "r163", "r176" ] }, "esmc_Netpresentvalueofnewleasefuturepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "Netpresentvalueofnewleasefuturepayments", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/LeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net present value of new lease future payments", "label": "Net present value of new lease future payments", "documentation": "Net present value of new lease future payments" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "esmc_NewaccountingpronouncementsrecentlyadoptedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "NewaccountingpronouncementsrecentlyadoptedAbstract", "lang": { "en-us": { "role": { "terseLabel": "New accounting pronouncements recently adopted [Abstract]", "label": "New accounting pronouncements recently adopted [Abstract]", "documentation": "New accounting pronouncements recently adopted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International [Member]", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r532", "r533", "r534", "r535" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other (expense) income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r72" ] }, "us-gaap_NotesPayableToBank": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableToBank", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Payable to Bank", "label": "Notes Payable to Bank", "documentation": "Including the current and noncurrent portions, the carrying value as of the balance sheet date of notes payable to banks, excluding mortgage notes, initially due beyond one year or beyond the operating cycle if longer." } } }, "auth_ref": [ "r8", "r91", "r522" ] }, "us-gaap_NotesPayableToBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableToBanksMember", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note Payable", "label": "Notes Payable to Banks [Member]", "documentation": "A written promise to pay a note to a bank." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r180", "r186", "r190", "r192", "r449" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r307", "r461" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r305" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Noncurrent", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r305" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNewaccountingpronouncementsrecentlyadoptedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Right-of-Use Asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r304" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r309", "r461" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r308", "r461" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r127", "r462" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income:", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other short-term liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r14", "r462" ] }, "us-gaap_OtherLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermNotesPayable", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Notes Payable, Noncurrent", "label": "Other Notes Payable, Noncurrent", "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r17" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other Nonoperating Income (Expense)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r73" ] }, "us-gaap_OtherNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNotesPayableCurrent", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Notes Payable, Current", "label": "Other Notes Payable, Current", "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r14" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other Operating Activities, Cash Flow Statement", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]", "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]", "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments to Acquire Intangible Assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r74" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments to Acquire Property, Plant, and Equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r74" ] }, "us-gaap_PreferredStockAmountOfPreferredDividendsInArrears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockAmountOfPreferredDividendsInArrears", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Payable, Date to be Paid", "label": "Preferred Stock, Amount of Preferred Dividends in Arrears", "documentation": "Aggregate amount of cumulative preferred dividends in arrears." } } }, "auth_ref": [ "r38" ] }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendsIncomeStatementImpact", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock Dividends, Income Statement Impact", "label": "Preferred Stock Dividends, Income Statement Impact", "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders." } } }, "auth_ref": [] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock [Member]", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r465", "r466", "r469", "r470", "r471", "r472", "r527", "r530" ] }, "esmc_PreferredStockNumberOfVotesPerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "PreferredStockNumberOfVotesPerShare", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, number of votes per share", "label": "Preferred Stock, Number of Votes per Share", "documentation": "Preferred Stock, Number of Votes per Share" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r58", "r256" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r58", "r367" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Issued", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r58", "r256" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r58", "r367", "r386", "r530", "r531" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized;2,000,000 issued and outstanding", "terseLabel": "Preferred Stock, Value, Issued", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r58", "r327", "r462" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product [Member]", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r457" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r193", "r321", "r334", "r335", "r336", "r337", "r338", "r339", "r440", "r457", "r463", "r482", "r503", "r504", "r508", "r525" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r193", "r321", "r334", "r335", "r336", "r337", "r338", "r339", "r440", "r457", "r463", "r482", "r503", "r504", "r508", "r525" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r3", "r325", "r331", "r462" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Credit Loss Expense (Reversal)", "negatedTerseLabel": "Accounts Receivable, Credit Loss Expense (Reversal)", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r138", "r207" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r215", "r216", "r217", "r218", "r264", "r265", "r266", "r267", "r268", "r318", "r319", "r340", "r358", "r359", "r414", "r416", "r418", "r419", "r421", "r436", "r437", "r450", "r456", "r460", "r464", "r467", "r501", "r507", "r515", "r516", "r517", "r518", "r519" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r215", "r216", "r217", "r218", "r264", "r265", "r266", "r267", "r268", "r318", "r319", "r340", "r358", "r359", "r414", "r416", "r418", "r419", "r421", "r436", "r437", "r450", "r456", "r460", "r464", "r467", "r501", "r507", "r515", "r516", "r517", "r518", "r519" ] }, "esmc_RecognizedRevenueThatWasIncludedWithinPriorPeriodDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "RecognizedRevenueThatWasIncludedWithinPriorPeriodDeferredRevenue", "crdr": "debit", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized revenue that was included within prior period deferred revenue", "label": "Recognized revenue that was included within prior period deferred revenue", "documentation": "Recognized revenue that was included within prior period deferred revenue" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction, Amounts of Transaction", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r47", "r315" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.escalonmed.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r312", "r313", "r314", "r316", "r317", "r350", "r351", "r352", "r391", "r392", "r393", "r412", "r413" ] }, "esmc_RepaymentOfEIDLLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "RepaymentOfEIDLLoan", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of EIDL loan", "label": "Repayment of EIDL loan", "documentation": "Repayment of EIDL loan" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of Notes Payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r50", "r272", "r520" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted Cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r483", "r490", "r521", "r523" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash, Current", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r483", "r490" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/GoingconcernDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "verboseLabel": "Retained Earnings (Accumulated Deficit)", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r61", "r87", "r329", "r344", "r345", "r349", "r368", "r462" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r115", "r149", "r150", "r151", "r153", "r159", "r161", "r203", "r204", "r269", "r270", "r271", "r279", "r280", "r285", "r287", "r288", "r290", "r291", "r341", "r343", "r353", "r530" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r181", "r182", "r185", "r188", "r189", "r193", "r194", "r196", "r262", "r263", "r321" ] }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionAndDeferredRevenueAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]", "label": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r389", "r439", "r446" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Revenues", "terseLabel": "Revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r136", "r147", "r181", "r182", "r185", "r188", "r189", "r193", "r194", "r196", "r202", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r294", "r324", "r505" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark [Member]", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r196", "r480" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r498" ] }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Products and Services [Table]", "label": "Revenue from External Customers by Products and Services [Table]", "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.escalonmed.com/role/InventoryTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Current [Table Text Block]", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r10", "r65", "r66", "r67" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.escalonmed.com/role/LineofCreditTables", "http://www.escalonmed.com/role/LongtermdebtTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Maturities of Line of Credit", "terseLabel": "Schedule of Maturities of Long-term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r4" ] }, "esmc_ScheduleofinventoryAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "ScheduleofinventoryAbstract", "lang": { "en-us": { "role": { "terseLabel": "schedule of inventory [Abstract]", "label": "schedule of inventory [Abstract]", "documentation": "schedule of inventory [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails", "http://www.escalonmed.com/role/ConcentrationofcreditriskTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r24", "r25", "r28", "r29", "r41", "r88" ] }, "us-gaap_SecuredDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtCurrent", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt, Current", "label": "Secured Debt, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r55", "r90" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt [Member]", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredLongTermDebt", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Long-term Debt, Noncurrent", "label": "Secured Long-Term Debt, Noncurrent", "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets." } } }, "auth_ref": [ "r17" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.escalonmed.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r475" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r113", "r194", "r195", "r355", "r356", "r357", "r415", "r417", "r420", "r422", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r441", "r458", "r467", "r508", "r525" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Marketing, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Service [Member]", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r457" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Axis]", "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Domain]", "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeasePayments", "crdr": "credit", "presentation": [ "http://www.escalonmed.com/role/LeasesDetails", "http://www.escalonmed.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Lease Payments", "label": "Short-Term Lease Payments", "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability." } } }, "auth_ref": [ "r306" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r78", "r145" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement, Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r5", "r18", "r115", "r132", "r133", "r134", "r149", "r150", "r151", "r153", "r159", "r161", "r179", "r203", "r204", "r261", "r269", "r270", "r271", "r279", "r280", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r295", "r296", "r297", "r298", "r299", "r300", "r311", "r341", "r342", "r343", "r353", "r409" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r105", "r114", "r194", "r195", "r355", "r356", "r357", "r415", "r417", "r420", "r422", "r423", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r441", "r458", "r467", "r508", "r525" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r149", "r150", "r151", "r179", "r321", "r347", "r354", "r360", "r361", "r362", "r363", "r364", "r365", "r367", "r370", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r381", "r382", "r383", "r384", "r385", "r387", "r389", "r390", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r409", "r468" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r149", "r150", "r151", "r179", "r321", "r347", "r354", "r360", "r361", "r362", "r363", "r364", "r365", "r367", "r370", "r371", "r372", "r373", "r374", "r376", "r377", "r378", "r379", "r381", "r382", "r383", "r384", "r385", "r387", "r389", "r390", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r409", "r468" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Option [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r467" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets", "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r59", "r62", "r63", "r80", "r369", "r386", "r410", "r411", "r462", "r474", "r492", "r499", "r510", "r530" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://www.escalonmed.com/role/GoingconcernNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity Disclosure [Policy Text Block]", "label": "Substantial Doubt about Going Concern [Text Block]", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r51" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Schedule of Cash Flow Information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplierConcentrationRiskMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Concentration Risk [Member]", "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": [ "r26" ] }, "esmc_SupplierThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "SupplierThreeMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Three", "label": "Supplier Three [Member]", "documentation": "Supplier Three" } } }, "auth_ref": [] }, "esmc_SupplierTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "SupplierTwoMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier two [Member]", "label": "Supplier two [Member]", "documentation": "Supplier two" } } }, "auth_ref": [] }, "esmc_SupplieroneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "SupplieroneMember", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier one [Member]", "label": "Supplier one [Member]", "documentation": "Supplier one [Member]" } } }, "auth_ref": [] }, "esmc_TDBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.escalonmed.com/20240331", "localname": "TDBankMember", "presentation": [ "http://www.escalonmed.com/role/LineofCreditDetails", "http://www.escalonmed.com/role/LineofCreditMaturityScheduleDetails", "http://www.escalonmed.com/role/LongtermdebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TD Bank", "label": "TD Bank [Member]", "documentation": "TD Bank" } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r95", "r96", "r97", "r198", "r199", "r201" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic [Member]", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r30", "r31", "r32", "r100", "r101", "r102", "r103" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.escalonmed.com/role/LongtermdebtNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "lang": { "en-us": { "role": { "netLabel": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average shares - diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r164", "r176" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.escalonmed.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails", "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares - basic", "verboseLabel": "Basic Weighted average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r162", "r176" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-8" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482836/275-10-55-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-15" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r439": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r440": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r441": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r442": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r448": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r453": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r454": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r455": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r456": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r457": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r458": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r459": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r460": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r461": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r462": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r463": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 57 0000862668-24-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000862668-24-000017-xbrl.zip M4$L#!!0 ( $R KEAM.]J+*+\ !;9"P 1 97-M8RTR,#(T,#,S,2YH M=&WLO6MSVTB2-OI]?P4.9\Z..P*D<;_(W7R#EN1I[=J21Y2WWSE?-D"B*&(, M AP E*W^]2>S / *4@0)D !8'3.R1.)2E?7D/2OKU__S<^)R+R0('=_[[6]B M1_@;1[RA;SO>\V]_Z_6O[^[^]G^Z__'K_]-N_]^/CY^Y&W\XFQ OXJX#8D7$ MYGXXT9B+QH3[PP^^.R\6]]6UHI$?3-KM^+9K?_H:.,_CB),$24DO2[\-K@1! M)9J@CMHC63#;BC8RVP-BDC91]*$HJ]) %43^^8H8(V(.!:TMB-:HK0P$M6W* MRJ!M# Q),RUC9"M#WK[2X"Y9'0G#H4V4@6@81-)M23+UT5!2![I,WSN.8,XP M;R^\^NDZWO??6N,HFEZ]?__CQX_.#[GC!\_O1=,TW]-O6\FE3N@KDJBO7/QS M$+CTD-^*7MS*]?OE9['W\Y?_;/*/NYC@=#($CZ]U%@>2%2UHI@ MK> IDM 6I+8HS=\7.EDS@=>)[__OE\_]X9A,K+;CA9'E#?9 M?WF??(DWR>D--G&R+X8O5BX$&K?ANY7!I-?N(K.HM@6CO1AA&"S6:F2% SIW M^'#M9=MH),I+;TLNWPY A&KZS%G8?K:LZ>;+DR\6 [AR+6#?%O':W_JM[J]C M8MG=7R?FM=^UX$K-Q^>IW"<@WCOWYK1>1G])Z^]WWW/_[C M/WZ-G,@E75S'=KI8O[Z//_SU??SH@6^_=G^UG1>;Y' M8 #.SRN\D 3QKXYM$X_^"M_?@SP)G&'\_I_1(QG]UAJV@=J>-<$G$>?JUH/7 MO5[#Z ++O?-L\O._R6N+<^S?6J.V:+2Z OQG:)*F&;^^7WEJCI=,V[:U&(/9ZFKO9>'PMZ=R]1\S M*XA(X+X^DJD?1*LO'SD_B=V.@AE)7RP)K>[3X[?;XU^\F/I_[1Y LAF-_ M3%SWVI],+6^. TEI=>G;MCS\4V -4:IP,\^)'QV.K8"$K;77@4BWR="9P*-^ M:PD9K.!/ (/]R!]^[],'/,PBE-*HM5:/UJEH "X1)7WO M)9F%-J"4TG5]793E=;F[_Y0.(A' 5TOK\M4*'H)^A#;2_UCNC"P>N;X")H!& MZ("2WD;]"@Q1S3W$;&#+F<#.&%L,Z]XL&ON!\R>QTB/DLA\V(#- @>*-5$ #2>=1A@7/'"UP('G MI_A!$DX4M+-2^\!!ZSL'_7[5;:2O)=Z0A!G>+D8@KD(:[(!)<#2&,4H2_VG#RWY.76?H1%\(BAG.=N!;FHJ9Z]C/OO<FW?3($H6/CE_$C?GV?^>0Y$>8#.!N&-$;I$V%:KQJEPR "F]&W9\,( M'!X2O#C#-2HGWQ9/X16%!V@63Z_P#+8<6^V/?9=#+FXY3+8<53('18&M1_9Z M2/NO1X'L(9;NIA2_'LF'C=0>8NG^4EW7XSSJ0RS=RZOQ>IQ#?Y3NF]9U/,_MOV=QD='4]^#/<-WH74[Z MU"46(E;.WG_2"++\8A]:P6>XSV'M2%\Y7RUBLGX0_T%N-1<6J.CTH^5\]^JI!"JL$"5 M<^BJJCVJL%B5S9]61M54896JZ(N>@PZ5RXQ63#^OFD5F4691W5W?$_I@A=&\ M[G[OF7RPHN@OU]T'/K4/5ACAJU!F6=+4F'N9R\00A;U-#%$J*,PK,_>RX@O$ MW,L:+19S+^NP2A5T+\]"!^9>YC"+5LA^E%G$W,O3TYRYEV>EO\+5GR!F'M9H\5B[F4=5JFR.TJ2/K7W:T]J5M5(.'5NONS)Y3Q4H'=+^I>*7PJ&5\DS>ON9I]#QA=) M_[J[T">5\442OF)=A(J<6MT=R9.&SG)LP).**_Y4Z^Y&GBYT=J8%JKO#>9[0 MV9D6J^Z>ZHE#9V=:I=+]V7K006/N91ZSJ*B"58VYEZ>G.7,OSTM_YEZ>B?#5 MG.7,OSTM_YEZ>B?"5[,G;-=5&,WK[LJ>J5U78?2ONUM[ZG9=A1&^ M8H=F%CFURFX%[<$3;,>=1<; NN2\/;GT)W9Q/X4^!.$V0R0![<]C%), M?4U.%/[XFOV =2GLO9 @<@8NN8"-V49E?>A&+_9Y#%.CLLYXTQ?[# =,&95U M[!N]V.H;&#@)(M-%_9ABH]HII:N;$2A8<^C>\W28S YZ2 :;4%JB\H>=%B_]"@Z5"LDLCZU8T(B9A62Z$= 72MH M/Y)9V6C!9]][CD@PN2&#Z.EUNG9P[;T?D?"K]6J!-_#D?[2\[Z4&&A%Z6ELR M"X%>97WV"I"\"LJ]LF[V9\6),Z M@6$]&EX0_U76L[ZT]5UG]N45?M/46UQZ%+-7U@^_=# H^X-!*0@,HE!9M_W2 MT%!.-_&!"W?*/K]> X&<_>'T8X1(D;OCKFA..GQ(;+Z@/^2M; MW% M\F\J1OG4,1!1J&Q]?[77Z@P>BRA4KL C#**K+]:__.!Z%D;^A 3ADK9* M/WOP2%$JZ]KWAC"R@*+BT0F_?WS=U%SI>S$C^2%>#-R3\H65N>"9>7B7XV"95U56.6B;HU"1>V%U;E@6;E@ M8:-@60 JSE#=(0J5BQHV"A5-$%;G@*58V?#E>>&R%W,\_? 9+,N!966#KF\O M%(5(;SCT9UX$"S4DS@O&O>=7-=/J$2L7IV7Z;;<@V81H0Y%9V:@T4W$7CLS* MQ>";M59R<4W819%%QIE^JR8R*Q<]\CDZGKOQ+2)\&+,R3A4V!YH36,D_GID)9D7_J17ZKLJX1[ M?BX85R[$70J RC5^S\!>#,:K,*Y<3+X&FO-,OI)4[T UTYP5$SGG@G&- ]OG M%#GG2$)(E0MI,Y%3?J$B%+E\@A, M&C,8YX=QC9,.*P4ZR:[4?:MSJH':NCJ_=J>C&"8;F"*5*YM;8IBL B;/XHK7*5'$,'D1R4NY3GFH*F$R M'0&X2M_>ZN!;>W">R["L4UZ)@?/"+,PZY8D8."_+U%3JE/5AX+PLFU.I4W;I MI."L.F#.9 .S^O M A+ZLV!(POC/,;%L.GC;>>G^"C_H,CJ:H@]E=20,AS91!J)A$$FW)CR_Z*ANK@GC%Y=6,Z)X[7'Q'D>1U>*U-'5:?3AAV-'XRM1$/[?%KVT^VLX MM;SNKX/@/3P@_CU^SN;3K. 9'ACYTRL#GH13:%NN\^Q=X;*0 !X88=5'>OW M#V J[:'ONM8T)%?I+Q]L)YRZUNN5X[F.1]KTI@_)TP=^%/F3*QSJ"PDB='>2 ME]#WQ5\O9M$1XIE$0++(3M^)1H=1<[^ MJD&/RKXE?=1[2OL@_3+!FSR-6O0>6'5$U6\MN;4&C&2IX4K.]F<(G+\(]+\/ M4\NV'>_Y2N!$>,Q[]IRWGD/7X#UEI-V,*V]A7!Q">CF,R ^NTG>-0%BU1];$ M<5^O_O8$0CSD[LD/[M&?6-[?^-#RPG8(XFT47Q@Z?Q( #;R%_ODC!H,.SZ&L MGH!#E)!IO]W?/=W>[Q[NKOM<[W[&^[V_U[_ MWKO_^RUW_?#ERUV_?_=P?\8I2'M-X0\K' -L(M_CN9O.=8>3!%4Q$-=Y0,GGC/_\B:L*'=)CG$#"?'AZ_<+^"">CYWOUL @\9QZCGDU#^^]1Z?;A\_ M_Y/[>OMX]W##??WVV/_6NW_BGAXXD,-/(&PY4>8>'CE1?6?_4GG!^_")>_K] MEEM2(7/UT;M^XN!KT905)HB9(&ZR(-Z/5S[Y 1>-"?>/&;C;)'!?N:_4>^; MJ2;V 0(ROOTV=LE;7'RD++C4/Z,K&SYI3^ 18[RM;5NO[5=B!6WBI1)5:G6_ M6,%P'*L'6>0Y#.<=(F#-"@G8:W\R<4(,QG"?'! , \,T0AM21 EGV5_0W-* XB-Y=L(HL+SH'KY)Y8?PM M04YO'V>3X]WM3VL8T5ES_H@+YK/EK) +IV2(L6";]5>@9$/,0T1D6G@O^!S M%H:*TNI^)9X7OKHOEN=8Z_)EW\'O_U_>:3Y9/^^2G-&03C4V.M+QJZVN++<% M29<,V3S0@:U+ @)X5I7E7.R__7-5EHH2)*JL[B-(MG%\RM32]">R]:9T7B=H M3,NBV?G-: M=L'>4TSAP-GSP-@+N7[/ "4%!(S)!P5$UY"QS)KTT> ;F^I/^ MO=!MD?T61=X0E?4BW%WGL=/O<+?QKNN 4FJ5L[E[O[-*GCSB_01>TGX"/Z^$ MZ]EV0,(P^>G>L[[S,!X+UO;@%3B #+]S6"#,_1@3ZA#B#)>BG._$7[BQ%0+O MN$ ;RW43%D&2_7OF(,& 3@.27 #/G--,1M>1)JI3RBT1_/9GS'U(3?P:$\&< M#=^"$L=+IP$9$JK218FCJ:J0>P?/ U;FPMEPS(5C'T.M7%QC"O=8T?K8?UBK MH\0AQCPPX7Y\J6?^;U :YG00 O>*2C@[>BPS$+YW:OSSWC\_8?Q+D!#(.< T$R>*@,W -A]&@>^AZ>J^4O:: M@DL+W_A)BB0)+1'N#S( U1L1JHLM[Y7G"!B]K_!ZX&OL8P<>XHT567&N=DW< M+-ZX](IET?TX@YL4047A D[$S(U#-/WV$_<.,:%_D&2IDUP0C1V:O)EB\J9L M,10/?3[NN9@AX2^= Z+H@_JWA$$0& MR@.;\D" *CGS4PX W,[X(IR I(%W!*G6!*:9 "%>.VA_P,- :2.=GKGGP/\1 MC1=?]PFA([/)R/$<% \T4M7:-K(6U\KZ$!FYM744R?=;!M'"S#$55:(T:$NI MH;1L'75R1<(<#T/25Y)"M[WL=E;/XJNL,M?&G-:V[8" I MS%1 4X"]D8R// MPNFG?"$L;K$&X/G/HLU;WMK[$_\@BKID?5)UPH#GIL\3<6/SMN M+ZH[ O<[J:$=2K3S7M8@:9?7KT2?.[@&IGCV@]?-:JQX,SGEE&%RT:(F2U1: MW?LL8WUK]K$23%8&6ZV8>J?EZ)^K9F8E2%Q5M/?1>_LX"^%!8;BZ5V+D_"1V M.PIFBUR]VNKV8WF':91F7[:GXJGR7.H@ M)FZS@S*7QJEYI65*MK]3JEVGD:Q-J3FRW' A-C5J9>X0BGM72VY$NZ3.^0*@ M=Z,=04:L33Y-(+PXCR[.MP XY+*MW[&VY M;_F=-<_@9IDR VOX'68]\^QV0O,1_>_#J59@)5K*<=G5$(>,LNB8?J6H]D8@ MMK+LEC_3$(Z)ZZ83(2L%JI/60+^)J6^22$(^C"SE_%E$=@LH$/B76<)SRD!.&,W2/ MDI+=H6N%(:'9-6##B8_3\8??>=Q$F=SAPFO""%01)K.'--EA5U)NPCBO.)U7 M1)67)7-.B]%9:_#V-^&2&JQ7$'E/3N0NS#,=3W%97IN_8@I(Y*96P+U8[BQC M'\4R .*5_&*]QIPCRG'+@,[1M8$'[IM^X[;JY!GW[W6HSWL='I&;U*7C$I-5 M*5Q^ZGW\?(LM9*X?[I]N[Y^V=U([=5D&@R9K:+M#\:E5F+-PX0!OW M+WLTBC9;W6^>-;,=#+!=^^BIA?%O%*LT2[E@@?D!-.&O[ZUUFZB4519UP5B\X!665&SQELG8'RW7PDU^_3$A49@XJQ0,=9TH;<]7 MZQEP25O!6D]"J?7HN7>S5"7^0NO4_VOF$4X6Z+K(%Z#Y\MK+9:YTSK'D6^EM MB\DT7Q,TGRQNU7P+0Q95WL.4Q*]9;&*-X"U)-U@J FHKT) (GH/]?FH\@60A MXNQ^F#;_K?.,ZFVHX QJ;ZC@).IKJ.#HXXWZ=5\#N=:C7S86F6G8#--P(1F8 M:=A0TU#9TS3L8R'#V'?A%>'?N-M_SYSHM8%&(NY-J;61J#3.2%02(['>4ZB] MD:C4VDA4&F$D*K4V$A5F)#;22(1U59F1>/X5+H]S]3V-Q&LK''.?7/_'(GY8 M7W&EUSU>J#?.%(09?:GUZ*D=BR>BUW@.-;=C]5K;L7HC[%B]UG:LSNS81MJQ ML*X:LV//O\*E<:XB8.>9",84^=0XS5'GR;W[QCB^81R/>#".X_@Z]+&@5>@2 MJT*OOH#2-8QU>]8SE3E_"[D;)QS.XB.)T>CK>9;[&CK4UUX(*91B<=<'O.:1 MA#-WO9R'2:QF2"P$B'BDD5*/73-R"?)JO@.+":LB=DS@B1/_P'XP3D0W15/Q M Q^XZ=\HO5P_G.$.>&O@SR+NBQ5\)Q'WZ(3?RQ1)N[;:,7E4- 8D\1($DL($ M4N4%4KS#)PI@8:@P^AKX0V*C_#F5 <06LJB%?$NJI/-*7W[&7I%L._E^8,3M MY-S='?= >W$=LHV\T3O%XYWV&G/4:R"A)!T;"XZ=@7,16\ OPYB51% [.S>! M%W40[ &]WT1]M046_IVOF55IG:P.T$"EMCL3BVBGA0UISWK6SWD:9\4ZNL-Q MG^[N>_?7=[W/W-W]IX?'+[VGNX?[38SM24RSM2_Z3WDFU9XT2=JX<-RW^]ZW MF[NGVQML*W9S>]^/?^L_?+Z[Z>''"Z+UG^"#+]F=Q_:CF2050[-U,5!F3[NJ M20*I"$F &Z0K<>I759KKW?:O>Y\?[KDOMS=W\!NPP./7#M>[O^'ZWS[V[V[N M>H]WM]L[[E5E&EMX^&/O,_#P+=?__?;VJ;^]0>6!K27W."/]Y!T(=4'/VX%0 M4SN:J!;3-E#MB'J^1Y5_V!D=E%Y$+\/#W?X8$%7JI/02^@ONU3/OS-3:,[RQ4CQ3%& *[2FXV3AZ."0$7-8*AI"R(=GK M]V^7K,T=O1C?FNI;=#_9_;G7+&GV7<$UR^:+Y$!N#ON?1^'508NW-N?1=SVLKYV>:8I<'6H(_OK45-3;^@[OD7RP7RT=[ MT;45!'@*S_]@L_S5XY"\V:1M^S1^B4\%%@&J$/KLN/N^9+2ZJJ;P8*>G;?;3 MD6[IV7P(D^V]1,5H!L8@3640Y?0,8K:ZAF'RFJY4A$$*,EUJH/T>21@%#CV8 M; AKNM6&D?)-/I/EZ\T7NQ7'@H[(&HEEF),/9*'5E52-ETWA6#[8@<C/#;G&: M$O-Q3LN_!_[Z\EAN0&PGXEP?#R2\,%/V78'"-R7J)S^X\6># M:#1S-UDI+Q+-G)Y MSB/1,8;NUDQ@'?FF3!/XGN3V!W''*2^K)B\)1WN$N9:K!J;QQ>(NK]%\ .YT MQ)T&\EG'G4 5Q]WE&--WW@OQ(C]P2'BXV*ZO45.<<$X)^7H ;QBQ.ZGPIG2T M.\GLX0I"9[=\/08Z)D)'-73>-*H"G.-C\.5HA\6X#U0@%)B]B@-#TMU M8/LG4=-X33@Z6<8BNQ6$SVXA>CQ\,%.FF+Q^?*ZU@B%=6:^&(,VN=7WR(\LM M0I F%-B[U+IR;))-GP)C",=PB-3J*KRH8O)LT]A(U^M\*8&\ADZ>@ORJ&]"7 MC/@WHA?'(%Y&Q&NRSBO:9KJ8(;X,N[\*6BJ;YE\#?PIC>:6]B,B_9\X4VSJ6 M%^VN/.N6[1*D!/_J6E[4\^S;E.;Y'64%3S61>5,O/?C8I+CW!2!PM_(H$H%X M+K?""UI1)\?>V/VK/0E* T]%P1GDC>A/W)O:>/Q,K))2R M#Z-O(:'65UY.T< 3US5>J$Q(DT7#3QC(*1)).FA]0>8UY>ABS[H$Q^G?#IZ# M$%VU12.C8\39[.?/SA!/9Z#F\]2*BK"=&\XINV7N)P=N)9^=%V+?>9'E/3L# M-V:3\ #S!/ED;K%(,EM=S>1-0ZL(DAK?=B#.0[J^]\Q% M))@P6_8XN7I#:&>T,&$ WQL>%#Q4!> #B=>-JM@>S(H]G40M"D-BQ3#4Q.*. M73G);%%:;D#MC(&2;%+D;H2P__RK(@].DW?-R_TTX:J:)B_(FW'K&J6?:A(S M9VS-V/J0Y')>MI;!U>9E0>=-E;'UY3AOV6#\?-?[>/?Y[NGNMA_WW/V]]WC[ M^\/GF]O'_G_^Q9!$_0-W^X]O=T__/*:=W-(:R; *MC_#;@1;NRN>N-E=3D[@%*L3?V *D-_Q'E^ M1+BI]9K9L>1HM[]R>>#][:"L*5;%U#E)?3X];OMKC(S#2NI4I=6595[2I(I$ M- I0=8PEFLH2>^PY*( EL#)(YP46Y*N"\KN]N_G,N;[EL;ST@9JB3X:S@-@W M9! =R! :, 0OZD>K"):*KB!X=LO4X\&C4_ (5:ECN!Q/8MX*)G$=6 +ZR$8O MQUD5M*N *!J\H%;%L& 9Z-,)TF) 1/L+2(+*JV)56A!?CG4*2QC,B,V1GU,L MG&2]!8X0J$C(SXMPZF'LH FMKFJ8O*&SYK%-1-&;$K48%&%1CRKR9D:G0F:C MEHN&1SP=E6#].=W(F0A8!T]8(V%T6'ONR[ VWFI_%5/P*&M#P^[2TGNM=.Z&6V M[E$[,5-CY?5 =E):7%.M2E,D9O">:ROFL5#"+)=D\IK,K-Y30^*&C BL MF5E :W450>8%K2K&";-O3[DEZ"CLZ( =2>.E MX\\MJI9A6P/Q&>^O#,=@O[;I!LLE*_8W=SO4Z9B1LK=('LW(.IZ6RVO@ M8XI"H_O3ULWLOUC [U9?QP,>6Y;SA@H>I;E&$G-YQ'#JH^.;@!GH[G%:N\J1?5-;]F MIF_#P710_+&PHZ]9J+]AH7YLHEM,CO?28Y][!_L/9V<#V-E4 M>%W9[#3-@I\LVE_9:/_AB#=;7542>$%AX?Y+*TW:J;6*J4>Z6,[=6U?EY%># M9J1-2>:-C',U:L2Q+*/0$*3OK:/R(EW$KBNRCIU7-NO[&=(O*(-Q#5? 0(DW MQ-U<[VA:6A1^*:A[[?8.PQ5H7KO'X!K?N[8_M@(R]EV@2?@W>DQN]'I1S6OK MS\%]N V>UD/=00>%?6"G0;J)*(S\X7>>^ZO0$001=])S+Y8[(Q\XB8=QX?^Y M$$$0'D.9RBE MU:5K5)'4%DN4GDX<'PL=M5K0:;R!W8-Q(GTM%^2O8[<=CQM:4R>R7&;1'MKB M;T[2KT#1.^\ZIF=>3M#HV;6Z -Z*263!B^Q;*_" '.$2E6]B(N=E M#@.8P^ UW>0E8[/%_T90AQFJM8+5NGP]&:Q,"BM%-'DMPY(].:R:V%UJ5PU" MN!3W3\\MC*/_I93/74"N]HU35M#;2^A]2^F&-#-.,4JNK\*II\H+ M%G3>5)E,*<0<>Q]ACX^3$TV**\,(/1T\Y"(?0&;-; >CK0 P&T^HHK_1*=,@ M[,CQ+&_H8' @@@\FQ(O"SFI[_Z73"I(7*5)'5V$P4S^DD?BK (]L<5[(AQ^. M'8U3P"_=F"R&L+C%&L @9M'V6Y9(/B1X[L3I(VN4GO+:80=+/W&TR$..INA# M61T)PZ%-E(%H&$32;4DR]=%04@>Z_+\R>#3)3>,@G<'4>B;M04"L[VUK!!.\ MLMP?UFN(*%JBP\3QVFMT7R=93)CNKX/@?3=KM'M0->OFY4%8P3., UE&I8=4 M4( O5IM?US5Y!*1W- MJ-R@Y(XJ%C4HV5"*&I2F[WYYIA\M*:T%MV[-L<6<5"EKX[9_W?O\<,]]N;VY M@]^XZX?'KQVN=W_#];]][-_=W/4>[V[[E.FO'^YO;N_[MS=PT7W_X?/=3>\) M_N@_P3]?;N^?^MS#)^[AZ^UC[^D.+J#WO/MVW_MV3 M>N+8MDN*)K6Q%Z4_^0$7C0GW- Y \WZ!Z\=F9674_&DF"I!P+C_I.7;[Q*EQ_J$ M1^VS*F>374&;L-C@3C.XQI?>?@U\>S:,-OHD'%T56;FV=_M'2[.F6)5XY_$% MG_K.>&=R&M.GP)_@QF5\X!].-+Z>A3 [$MS^'+HSI$HO# G\SWZR?N8,@8H" M]BGB54WG9:,JAS<54,_ .*:I'&.[<6>7&& MA)NZ\) +VYV3BSW$L[,'GDOM1B),.CO"\-P9Q>!-L2HGPC.$%8JP MW=6KIT"8@@>NZ[PI,!G62(3MKF4\!<)40)@F\8I\=)RB6OL.JV!"9B>\DE6- MSVYA>PL/Y)S=1V6E-,[-#AH]@M=4>56H=;DOVU/8++CO/MGK8+CK&*=69(67 M,[PD!G<&]S/!O1RT&S1@)IB\+M>ZQS=#>[/0OE>&/S_M M% 'W!@6NLP%Y[8=1O"><_)SB7B=6;,<&5XUBNTIU5]C6>CBDQZP^^[X=(EEL MUNCR4-\<:?DP^CM2$G?HQ@FUL \TS:OA)-H!2-4-7I<:5)C&H+2OWUL@E&A7 M'5T2>$.M2C*=0:E0*)T*2;0+B2&KO")L=H=D2&H DG;[:P5"B3:?$"215_2& MG3)1 YOOBQ5\)W@2&,\]$X\$EDO=)\N>.)X31@%MZL!*@ XU _O$A><__STF M+7!*;X6PM[&7FIME%-3CHJCSZO%UI"QG7D58[38)2X*5VNJ:LL&+VF96D(&J M : Z!Z8TFGP31-X\WE!DJ*HBJG8;BB7!BN9T10&$E7YT4*1:-3TU,!H?24AH M]PXT%6WR0EQ_BGW#6+CP\%*>F*+ 'S<+>A[*' :8AZK*&\K1);O,-:\BEMZJ MDRD22R9@R5!Y7:V*;\ZP=#J;L% HR4*KJXHJ+XDL]MQ(*+U5X5$DED0\F%;D M9;$J.\_?L/[2/I@P4+(=>I=XU4F+4I8:FB;WM_'B*UE+G^!@D]SHJHV?G/64 M@^%&+@;XI@"^7+PK6%6O@X!7Q!/.']*,'WC']@= MYJV]#G7DW5S'[VZX(UO.WWV(Z>P]WU'BXT+D9F0-DP$:KPF;R8#]C]O-M6(U M",4U"GH%^@5% $YO=57#Y-6,C$&-] 9#?(41GT_8GD[68@]A10*S:3,(Q&1M M(Y!7H(E>!.!, )PN\YK:Z+/!JU+/75T;_2$:DR!-%!RSY?7<>S/9_?FVGYX_ M?U?5JQCA3I60K6T=XQT>C$3"Z$W!V_YJZ&\ M3.$R1'#"DPJ#/TW,H6%05^]".@W!O>5 MAW[9FZ**0[ZV'?E,\%XT -_('!:&0+U6"&Q\J1T>$__.72JW8^5U99;7 ;D/ MS[TKN,M>DWA18<4>#05=@>;R<5 SJS,6%3,UALI+\F;,O<[V.V/$"C-B&?5^ MQW&!V.I*JLEKVN9N(";\&X&Y NWUXZ"&>XM5@U>T1A_GPFK\WB+X-P] XEH! ML3G;>7%LXMDA!\"$4.H=>_6*AB/>T:6.6LZ=6%H Y=PD0^3 MGDP +^$8[,NQ[X*-OF%''FS:[^4 9I'KK/[?7\N;?U5DR+E"[;T7RW$1>4_^ M-<4=%3$)[#Y:H3/,+5!TL(%TA3=+W7E9D9 ,8\3+8,2R0OXEL)_1ZJJZQ$M2 MK;O?,?YG_%^AB9>>]2A!$."&=).>/\[T,./#9O!A69F@XME/$X#]1!,S@%W0FN@QDM_T91A J>+0W&UVYHRNR38"L5YF3J"C> MEY>.WG]9?[U?(]6^T\3^2H(^+O'NF)>TU=:^M0(/Z!"FSTE4^J;6%EM=H9-Q M/%X=]R(S_-<)_P?!7UN#_X&HERCJFU#4Q-B.L=T)U$[!6D>F_+=Y>@/3.E6 M2)/A?Q#Z]6*TCD)1WX3P2$4B(#5PX&X<=Q81^V@7KI"=J366-+GG7VTQ=%+G M+\%@EDA2CW;_:K+]FS'693#6";S*'>RD;;%K:Z3A&3\S?J[0Q$_IKNY@;/UH MAY7Q%>.K"DW\!'[P#G8RMIB=3$]>UM: /^@?X!Y;,"3KF<1.<9CT!1I@(*64 M-C1[":L:,6U,MIQ;3E/B]V+:W\\F Q(\C"COA@^S*(PL#RET6#F0V>KJO"*J MO,P*Y7U5F(WG@(,LY<7@W6"$W M%\B%FPK%UNDRR!1E6Q8&F;@1BZ(;O"EO/Y"38:9:F#DK9%0F9>J'F(.,L\(@ MH^TO9:A]]C["/6;PK^V\='^%'REY)U;P['AT!=>.:1P2/";I]#UL)%R-/B&< MYT?PP,B'I;!FMH,6&*R!C>W-Z6_4$[#PXY'C6=[0L5P89M*3)NS,B; ^Y>1% MBM3151C,U \=I-I50%PKBJK MU%C^B:-%6#F:H@]E=20,AS91!J)A$$FW)CR_\J@VY*;QD$Z@RG MNST(B/6];8U@@E>6^\-Z#5':+,,,,+9&]W62Q83I_CH(WG>S1KOSDAPDW^IH MGD#2T+6X[5_W/C_<[VWY]YW?] M<']S>]^_O8&9W?> ME/Z!N_W'M[NG?W+UG?FGAT?NZ?=;^/_C[2U=T?N[^UONR\/]T^]][A;(_\[)(L])@J30B^ 7N;Z3?O?MOO?MY@Z6^)?ZCR M6TAQ:K, >5QK&I*K])JD.])VP9EP$SDBHU)[^A2U<9D=)3" MQB1KQ8Q)Z\B25#$ZB4+'$)2*$,T97\UTOLI3+L81 MV8\=D\WT=,U]:!(KF(I1)=M5[<-=\+ >=^U[=+RHW>:M.CG:0831;)5F<7.5 M8FBS%X_5B#8]F 2ZLY9+[:JOEF.W'8_^?FU-G0@^9Q1;I=AP.)O,7 P^4#+= MD)$S=")&IE4R/?E1@JG^4D_9Q-VCG]_^>^9$KWGRB4RM901P#TR1UPA*<6W+*QG%N^N_^T^UB.X[/) M>JLK\4 "_'_99T#7>F]=I3?696.ON(UUU=Q55\ 9.$:.,W#^QW)G)#>#&:VN MIJB7PEY,SN\IY\TWY/Q21^CCA?S.?6 -1"$3\DS(;^.U#2&_Q&D'27@CW53& M.*O:C?8*XI^&5T ?T/9;,!7VR,E&4O4B25R M':HC[7FJ3@',(0%S&*!%3%[+T"2Y6]PPOF!\49JJ4,K6%'A6.F_*"F]41E&< MJ W,B

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

O^WRT M!="J_)@&%4E^##JIRJBF,?7E:D\Z!IWJ&Y,\5,^8G^JBT[C,DPI*>2)M" J: M=5>EKSHC#+LW5##@!/",J9<#-4O*B.6VP=>-2I6&?@HCAP3T('!L(.$CQ 25T0 E;(>W5S9#V832M),RBF@26\-!75-7\F44+01(J MZH)J[;TKXE?M)X0GQ(SKXOWU5CUHXZL;;6^(GH,S83-K\W,)D[W5(J89O;,P MG87)2W3_(!9FT&O).&2T=.->OLBZ]5JG,WWM,GW]6DW?0&E^""I8WWR?J-8+ MQJ6;XXNVQ>=KB#>CXNUL +%D053'=8&'U]T%MC-VK31V]=98#S2P-.UOA](9 MELZPG*%A&1S&L Q ID5%&UV,83F<5;D(DS*HUZ0,@?U:SGOMM2?-'_6U]:I+ MZ%?PR7'A3[MK5K#!: X/8S3YP9LV;$E;@AV9O+(!/$.N66?FZ@6/'-1R0E8' MM[37F'7LNJN2&QU$R0TKG_T<:!QT]J.I^8*R-LA3IWT/H7U'M6K?X2Z'-#4/ M0;VZZ==_2--9A(L7H4)-/#Z,)J9#"+D ?+53O"?&->NT7KTPVD,-&&;OZ$ZG MY"Z>78N47+]W&"5'_6B'HVYO?_)I(N[H9 MB[T#Y#EUMK:SM<5"M+^M'72VMCOZ;>SH]Z\$BY_NJIQ&Z2_Z9%N;!6)L<] ? M&JHVZQG&E/4G\FC$E.%44<;#F:%HDZ'Z+TKO/EIOAARB)?5F&$LE>R1%POV9 M>1YC][P%@OWXF6%#LWS'A5%!QX510<<%?O_FO@DU]SSFPR@8G%*Q$_(19+QL MPV/!(CH*!J@FW;2%F6Z8ENF;\!&VLF!_!N82NUL)U$\DZF!A/X;W20(E"/"_ M!/:R9+;'Q/#BVX?WPJBOB,*S[@FF;5@!(BK#2PS'\[&AS*/C3#U4I5-ZV4)W M?S!\N"@\,AM>9-''^G1AVJ9'9N&)T_!OG8"=>GR&FH..QJ5; *&PT5(V6P+D9I8OXI( MPZJ_A_7XCHJP0);'!>(RSLMRN18FR>"/W,-D(/6Q7<=-I1XFBBHIXVI-&=;V M,!E(8[7XJQUZ*?0&=0U*5?IU-0S1:NKV,I &2FU=)^JBU$B2^_6TH(%7R-K& M.RX03/XHG0U.G#9[-C;(D68?-BO5'J1]I*P#O?YTI[YWSX+3G7JWZK7JAA-+ MBRZFS7UV'\0W)>_V.;[8$?-HWY!F-[)3']E%P.68+VRZ3SW.N1W2%4VQW?'F M2H=_J9M07Q\-6X+K44RG8B! MV!N=BWFXA @%GI MU;73[ 2Y$^1.D!O;(P]JVR-W@MP)WNA[7M[L]"DM=D]J=SS'?-K3VE M%/&'8+FT*'%:MP1#]^;"S'*>!=/FW(5LBUG=:_./UZ70CPM3Z,>K*?0MS (> M2]J@>A;P2!IIFS,V2Z>1#B6Y-ZHIMU4=U91PJTGR>-RV00VDWJBN?.D:*=4? M;WU4>XN=NISB+J>XUISB.KGL=#,LN^322YQZM^HMKSN^A!/"]^C5+W78>V$M MI+Z Z?C9.DW4\@O86 8N[02P@I*G.UNF/@G+1+N%O/JZ%7:[N[?.N+22':?'[_,'=<_SMS%Q1D_*J_4CU]Y4#CZ.IF-!*5+LFT M$XD3$(G-)^$UB<081&(@JNUH+]N)1"<2NY\IUR(1@UX/-HD#153/J8=7)Q)G M*Q*;3V=KD@F9G]".1FJK9>($MV\G&+7I&G)UN2=GM"T<])2ZMH5GD7[2"7,G MS">[H1WTU+HVM)TP=\+<"7.C6_%^;5OQ3I@[8>Z$N=D@@E9;$*'%TMR2$,0V M8/A#)I"?>N(Y8I/SS.X)PXQSEP'M#-."-V,Z"O"AZ1F8JL*FPBSP Y<)" ^^ M"!9A;LHRE!#A3;@V<.'D54"L;<+-#O-:],='ESWJ/GO;?EIQ.'5@,4.W#681 M=59/ZX5GTY\+/N@)0CI?."YBF\-8@3'YY'V' YX38/O*[>F,'B+YHPWCF\+- M(=6WP*Q/= N')GASQGPJ"X Q'!D^?= ;E()/7ZE4V"B>X3+T%6F(50)+QS/Q MFGN(R_<>U/H/!OM.M9_W50QV8KN,P[>L5&JY.?Z/:.L27VWH\*(4]'M2KRN#X M^7X7GT,I>_U=!\T%_Q8#YP]ZPTT0^>VHAE$&XZK5,(,1KZ&I!0E=5NJIJU&& MTEC>#&1?;VKZ:23T5@7"S;B/(<%6M*@,K'5U7"*>*>1/\:8#C9WPQF6@=*E7 MRTSX]$^R@&_W2=+=92-\ 5O9,]V,;F[638/I)"M@_X0]S_=GI[) MC6%]947LR_D&G\WDD%R(01[4;7I+2519,]Q)5"A16.9;5:;DWM6-*HZ546>C MCBE1P\Y&G8!$?7("M[) R5:.[W/F,HJ(=W:JY6)UBZN4R%9>?-2KFT%GC8XI/*EFTM$Y;I/6:7M)>R=@ M&P2LLKWJPXZJ-Q1'6LTI9UL6L+-EQ1R#ZRR8>.;$/+\,IE-GS^H4-^8MC'=W M(?F7CHN/@=68,Y[W0FIRN6,^F(Q W.)8;4M)V258MZ^PC@BC\Z1; :L=3*?V MA-5]K%_K:%]OJFI9TER$AOK"_"7G;&)L9V:S9^)LKJ9VUE (,3X&'768]67M:HY5NI8&HZ4VL!OJP$.;\BQ&@WK0^2M<5";*76)B5_ED!QCJ-<+ M1;+\+;"9H/96D&X[?NE 3[>#GE["7N;7NNAU7?90C?MI." V_\WF,/O MU9Z?6.7^4F5*KZML$Y]VO@['D_F/=P:O] MR-O:36%QD8.ZN?],)/2AI_\M$GGZ$DL8Y-A M;HMTJ.CC12U@_P@+.+JZD:7!Y@6\2!.8V>@V:?):=W]GN(YON"[LU,4.%A/F M;@QK5E..'T)I_@;"_)6YN.^(HYA80QBIP_'5C28-]VZ36,/YN8!T_I,FHO!"]8."=0<,R ;FH#\T5&W6,XPI MZT_DT8@IPZFBC( M7N9)=TTG\,#=>=0M8>DZX!VB9HB/A9:!3[ ?NB_ I1Z+L#MLW()80/_ ]>@@ M?1)X,!;/DP08 7P$&Q2?N9XP!]<[W='&9Y;%##_@KP/5Z+_&[Q%I/5&UI3YB MBZ7ET/EE,AX0M3!ZZQ'1_Q2TSVQ/CX<=@N(P0(7%H8,UX+ M__@K \;_X/DN$LLR?S#K%^MO+^Z_XQY*!8#]U]__B[H( N$GZ__7+[MX^_?_SR_2\/PH>[A_=_/#S< MW7\1;K]\@/]N/__SX>Y!N/\D?+K[Z MY/[KQV^W^,7#SF0S0$N-_F3. MQ-^#"M)-'$XT4=)"\!'I*Y$4@6TX[M)Q.=#.*PCMC+D,T7;P G]N(F(/IH>! MDF08GD$27ELA"5-/7NA3)BQ!9P8ZZ+,0#LC39PS4BSN!-X%.?#(]U &A9A*^ MNN83W"\\, /Q2M"&?89_'KF! IL*FEBX-:@UF#P>:Z+P/#>-.7\2O WNB"E1ZO\ \3<-!OYCYWG7\7C,&;%\WC MV;2L^#.T8IX)K*Z[PK/C3FE98$9@$H@#,D;M+]XFO@H-K&"$S)QN$LV!DN!Z M8#?P@L#&6+%9@F<@4S^"KP ;A6=_'GU@LHS)"JV4"/;PS\ $Z_4JILT=#"Y, M/<:71$X9)DQ.1DZVZ IPHL]?L72\9%E809@)G\0+A8\/4"PKEG80S690O;6 MPJD!G5TZ.S/A49Z.D&B&#M>!>A/8; 9\8,(8<\1QV6, B^"XKT!3B_PKCA4& M5WWZ<"L*N@%DY2A5'M$HPJP*!Y.:.D[TWT!37T!A1:EUEJAZ<(]*JU;L8^&\ M40KA/OC,9YQH'(UMYJ)_G- 5/&[2"B[J UC':< B707L:?(E0V;E#QZ_L7B_$;+9,0T@S'\^D!B8QX7+G"PAFO$W3K^)^< M%W5?!YJ!%C9 \YO>#UPA, #VE(0J-3@8L96HYLBAQ&=DV0$' -SSA/>;N&P$ M9!;*.TP*H6,68"R!M\#2!);U2E!O)GZ^00D0:R/N#'Q&[P2GUUO1Y*'S#W*) MKC_SR0&F286WAVO(6>F'[3S;X1?TNTA_@,9$L%ARXT(OGNFF MA4P3^!CX"%!HI4$+C9HKUFB,Y>ZZX,:]>;FDE,- MU_/:"'SBO;!;IR?&"\]W*GR*4]B;NN8D:>Z9<,4G-.1R[_K_QJII9F(DB$,' M,FKO'.>\8$:#!#?;'OLS@)5%G6,[Z[DC,N&/@>["&C D/XY/YVHBVH7@R@)C MO,;+9KU*PIV/.R'<3T4V$&F'1M9CC-PC[A< %U@6++P!BLX+N6-%1#9:L81B MH0P@W="_05!#M*8TAE@22%.9'ND58O/HS6GWC13UDC -32-RTD X\\1>1^5P M4&:R0/\C_ E4!/I8K]$3@1XH$& $7N8ZNKE/+$5[W&H"94+=D9$Q)%]LI"Q4 M(:#& C3!:9&2UKK7%XF..%C9'I\E.N+6#5:Y#>=(*=JW;X]7K8T='VLC^O$% MC# )TOT347&R\E&-)0L+U0;..$2$)![7>+/ )8,S93[:8'0TR=:D-5C&U3"1@!C) XDA MXXN?KZJ\4)6BHG(9MYZ/Y.MQG%MRK\ Q2SD@.$[<6H9:FPF7FAT 8SY\T51-AG&A4-6G\LXA<^A." MV/7HXVG@1OX(*A&!E$BD/8X-E:PHI:"2171H4;I SJ=)Q&C!0N5'16PZ>$$I M9U$22+PC,J'LILEGHI]GVD PV*& ,QJ$/K>>N8/O;N'I#X[M+-@47#=P$5W= M0RZ)]\IXP4_]P7"5OD5,=BP^I[5M(9=?W33+<&HIAMNJ5"BE:5,*JV.\IY$:VR**4:V>RFX^>48P OB0A(N=C# M=G[*Z;*$P6!LCRP\F>,'6<"J@46!Q *-U/F1[?,C1[OZD25/.+2B$XYL6F3; M#C>B$'ATM+'+T5%;$NBR)Q/A400E5?!#VPD_:."[3?O?@<#*TD//"&9)RJ#1O.=* <.ST8\YB/'PLM@ '=PFR#SK7R_D[(UZ;%Q ME;!I,2/FY'D0?%^/))XSW?+GF),2^JJ"MV0&Y7;P3);55"7*J CP "APF9@X MN%%R.0\^A_9DP:98:X+WFT:8X[V)A- M 2<'UD]RNC@K!!-,U>-'7)21E>1 X53HSS"S\=.'6_Y$^ 6N_C,PP8R!Q?&! M,=$/]S$ED9]PI=/.0I\:WH 1$'HV)I3_&RR4!_/CDWT*LQVU9^&\49;%T3*(,"1J3=S5OD/ +\0 /#^7\"2]G$/.TI @;W1E)')3!V57'_DD\@DAX5R MX66$PDNM7.9\Q7OU0%5YF*HX)2=Z:NJ/MN.9E#$R,>$U/EIO?;FT@'=XMA*( M1T8DQ$TOC>4/3WG"N^"!7@!VT^"9@YRC@WBRWUWV0_@]E-.OT?7&5=;,3 MRSEQX?1*'>_*JE3FA'?80BN/^=I(J]LD-?%CF,F<3Z>O<^K'S$I8(L"@&R>! M[F;&8PV;8A+*'OS!A"CYF_-4+M,P+,#1%TCBR*:S*?<%3%L2[C%+@2M\$!T= M9 C\ TQVUZT $ZUX_4_\EJB"*?5:4,43VHU06F\(:B#P,EUM? M9VG:E',:9<]2FC(E\<*T333>P*XI54PYVL'TD6?_N?%]/$OF)5J/R/O@SBHO M?!#,67Q&XF<>DO C;=NQE$1,Y6F&"9>"$[B)#"2R%J7YB<459Q2_,71O+LP0 M\E$4,+4SY5<[)60X5>7'7:C2.99'.$-H+YM^V)254K!QSA07@$_G+'%%;A_^ M@&_EP;6LBL*G>'GN;,ROY^MS+;QWP7C[PF?'HRCOW'EF3U&>+>5)[LQ MYE/N/*$X3G0L1_%;HI+O8Y5<*?7QR#FJQ=.@'GX"[S=+.N,+ZK/P[X_K]5F4 MJ+O>.3G=3-T0L!A4K9=5>JF,O,S>/BJFH)O!"9AZ/(9.5R9E:YFC-]+/Y6Q' M1&OPU:W%T3&90.%*/*YTJH,R*(BFJ6@MJL=R3 M1H-Q35#*_=Z@KD%I@VJ/.LJ@6D@I61JK=2%AUS:HZNQY')[:CAE>@"45R;KM MV.STKRH)*=TH(.(J#G(QB%(Q6E0\)UD[37CG3Z%-S/@?'U?24?:%OCYUXJSQ MQI5.;]YY_.(UK@NR&_? M61X_ 7+R\Z7T*JB&UPWN'8,KGG- MV*B6W0U)_QA:=ET359[YLP_J]+FU+"V:8KL!M151&XR:Z31< P!]QVNGQ&NJ MJ(RTD^6U^/[S;';P1I&E4:[_VT'7I0TM!#HE=&%*:"3*/>5DE5#':Z?%:]KH M='GMW V>)@TZ>]>6[7(7X*RPI ]8+FHP 0'J<_OO4F);,.,3$5M9J;I=+5[= M@VG4,A&U,UV:_KA;FG8NS1NY+\GEK5T=Z])>:]%;=]Y8ZWVUCT*F8!I6#3N7GWQ9Y7I/T M)0[&<=^,)A3*;M&PTN0_0JBL3Y3:QU)X**M5 M#E(?;D6;H<+13VP[C7P>&IEZOG0:N?-V.MFJ?>)CL=?7.MGJO)T:O1VM2E#M M@IV=YJ-D!XBX15]'U A11?8I2DOQA@JK/W4"A"BI6);0O:M[5WN%IW9!_"M! M\JR%&6\<=G<=9'6-D'^-S[%ZR\NA.HI:7F+((&R_0='>U7XOZ[JUY""B=FQF M<[1^D\.>7#BW)IL_G$##R8+%;B7P9N-4.V3CV:Y!R=8&):>IE+HFN*>CD[*@ MG]O@)-NHHHI )I?8: FQ'*D-![ K3,7@G=4=%VZ.V+DF"$F%"YB_/XQDO 99 M@A\75W*L2$-E6!564NY+?46I#6VO5Q7J;]WG [D>","QI&K#FL8T[M>#OUGG MF.JCDSSNUP7?J-5#IX$TK$CQPX]I) U[[1N3UJ\-#[2F,0VET7@K9[8REM#6 MJTI"$1:'Y.75Z%%H6;8&GML-AW44X,QS)UZ;@34+%V1<% H]\<4H">>W.UK1 MF1)M;R# ,Z5+QTP'8J;6.P)U%0DW6KWQ(=S]5RU4.=DMDZ%.;1Y6;D-K4 M1$7;$8.G4YNGJC9'DMRV)6^OVFP^6-S6JXX$5M,HAWSB66L[P5R>+CJM+*I: MU3A>'1BUQZ]B/,'%T7I2U?A0'6O37@W=,4=:4 ?2>YE\(G+TM5DU#.6W*;CQNT]:I+ M2,JKAK^;#?N%*?,%@!4G>QJP+ZQ6_01JBX(Y#P3?VM?G"&<9-1U7'$I:V\>4 M\%,Z):#%YIFRO>!BASBD[NS6Q=NM4T/';EY%=':KLUNM8\K.;FTB[\5;K+*D M:3>[G1IN>(TKTUFI]K%C9Z4Z*]59JE.BMU8NQXJ5:J^9/ MEY5 MC)$>7;T!S5+I2T.M)K3D[+..*&?;04>--&BRX7@^HN(^.L[40\F9$FJH[@DZ M(O8B>HW^R/"*$(^W5E32'1%)*R]:S:LPK@"#'XWEN!BII.E)EU0#21U+2D74 MQ_58C?V^5A=68Z\>[,]N3.7&-)1&ZKAE8VHCG=HY)KE?#>;X.'3:S$\E41(; MW0>OHJM5<7&3;8E<9E+M XT[-@#I21*G-,#HQ;![10S&DUCM@X-.GB/12@5> M.XIEV:P,3&='M([-.FW6L5G+*=9IL[W9[$B5%T"W1L+>?%Q39CBN[IN._0YF MPER\"ON\\2CEWRA*^>!8TW?['.36PF4[G4IU@^L&UPWN8@>W+QA0J;+WN:%>E:6>V+LIL#16Y4Q&=V6H34V)H ML^/)UNN.VLU6;4*Q#UA"^^A,P=PSDX<+008X+T;$P'7'ARU>H$XC'TD0,$C? M24*GD1MG1$WJ,(/:O$ %AR@YN)$27IE=H*YU(/.QG-NF5LB!%*VJ%O,/D)6"BSUZMR)+:.K72I$8ASFGE M$K9 JX3CZ2N$QO7+TO%,*N)SF:7[YA-+<*D0DRIU8^@P]I);] GP5^"OOR57 ML]F0OI)'67*D?\[=:#1+$([K"4C5CVM]!H-]IUO/^JN'>Z T+)UI7Z_0<'7Z MN[N4.WYY*/BTDN3E/)S_61[<;J&[/Y@/5XF@6FSF@G(B<+LI4-OT?))@2++353KUU./W?':*?':6#U=3BN5 MH'>ZE?_8[>9"*_\[-71A:D@5^[TFF+TS>9?(:W*O,WHM79SQQ:+=M'7;?L2S MF5./ !P"T:=KPGWF3;AIM]\5U!RHL*MRF'JO>5<*6E^BR%8C4+L%=ZR>F]A6 M/7-IG?"6($XTD=P[9>K>Q54']<<]?YIF?NFU)8[LQT1N>;=K[IV?NF M%.,\,\'MO--S]D['9X41?K$ORLHFD(-B/ '3KCR= M5?@ ?*G+# ?$]17?.-&GPI1-? __^$F659I9"BQ@"6-S:3 P??TE?C2OUHV' M!F]^8E;T;0[$I( ZPMZ%]1TKEV5E9=R/67E,J!O(R;1ORG#R;K@>C3#R7GS, M%DO'U>'.N4D7(#('<'1",9OYSX[[(WD_CBW+XYZ0?GPIRE7A]')<'1:(H^4> M9WVG\DQ^+%XN#SF 'Y**0*I/&1#=62[@LE64 ;8_TD ERK:#C!6A$0HFQ =_ M$K@$0.M1;UQ+S;:L2.JH7U,A^:@FL 2Y)RD#M:9!:=JPINKVJC0__)B 4'UY M:\E]R<_K@@&0D1'JHE1]V 3C08=-4++ NKBB?73:%>V[E?MW=?SGQ-AGB!QP M!A66QZ\%/@^B';G6]PR(5E#+6UK>+HY8G5AV8MF 6)Z15])EUF^IK?^6CFE] M2&):[XZ:2+4+T7>]OQM<-[A3'%SS:K)1E=M5D):>8ENR(-94YFN#DZT?[3CM MI#AM=+J<5BK=[70KE=_( TE^VY4I=XRQVB!-;J*$O;,.EV<=!GWY9#GMS)7 M&WDL#3OKT):]6A=J:Q3$HM?5'EU.[1'LCKM*CG95'G7"VPEO2>$==<+;,N$M MY2E?:ME@Q2A,\PS3WKJ]EIB;#E3BS$$E-/G<*GT[2(G.,SQ[SW#0E\],;#O/ M\+P]PTH1V.89IKV>8?,QU]KCMVL1'?:I^SVCDN+WU:J&IRRNB%=3V ZP-XNP M';3!<9 =BFQ4XV #KB1\VTK#9^92,3VP"8P@52#O>8YATD(\F_Z<:&#:ONM, M P-S89$(-HP3*,OLN6X;<.&2?^MQ=(!H=;">>?M:Y@ !DL6%L3W"JNDV_$,W M87%Y8"'80'*_,YMYS!:9^_< *Q51X$L$.N1)1\X-ETH2;D%?F);I MXY4Z:*0GTW]%!02;GRF'>8&!D*;R1-02CDMZ Q28Q;]V0%>X8(EU+W!9")*R M6#JH<,#@PU1>X?H ;C#QVT=X*VA\/AI1^)59NAN$[UDRPYR9!CY")R,>#E(D M=?2LNZC<0N\!E!2H.'TV8X8?*:Q'RYF &0$.M9W%*SUS9MHP>A,^Y1A('MFD M9V99^"][T0WF3G1Z@F,_.J0)Z788!K@6EL7L1\;1BJP -W*":Y+W8=HSB\2 M7A.^V0N62^OU&FX$50V;##=8XB62< [24%4GW'FNSJSK_]872/$#:(1P''V% M/*U?@.5,&H/++ *T2L!P$ @G=6.XE>\EM^@3<)<"?_TMN3K'AI2//,Z2(_US M[D:C68*!OYZ F/RXUFZ]:R_>KC533NTX,VNT'!U^AO7X1!?5F?TQG4M MJ-I[PX?=ADLH5Z+ .1[([CJ@+! WRO=AD* /N4AP1"Q06';X ;IH%OG(J..X M9V> LX8^(^JUO^G_JPL/H$"7W"%,P6?C18T/ZKW&VP(5ZCWL?L']S-&>PYR$=Z:&K'ZZ&R4F5LH_V-"0:7!;X MGCEE1,@_;!.YX<$'IO#(:.NX%P#G'6P3K'EH@%(O03O,>8 ;XH@11&$).T,* M-HHI^PW?3DU^9[AVL-6#^:0'!U\\STW8?)@8 X4/)K@39YZ7MJE_2 \2[.J> M/9Q'8'';:J+*M&ED,$IB%WBYA4AJCYSYTJ2R'0P)^+AU@H>3$.@^7N61%^#! M14\,?@"3"R@E+MIWQOD=&!+ID=C]2,4TJ>" M.?T_5^:@/S14;=8SC"GK3^31B"G#J:*,AS-#T29#]5]C^6IK7*,1-^+JYK/Y M9V!.43TA2[[7E^"06KCK=@+78%Y%+9@MPGR -*W!'_]A0P&*.F?M &/U< =V8>0;O% EDDG\.]FJW]#3N($S;1X?6CA@6QR7X[+2&L:Q),.";9S%97*AOPHVX_P MNS(8,IYLA1K=" 46HX/Z#Q;:%)UO&_&.68"6)M&YNR][>K5.>>'3_@$2'#TW M(%1Z95:()LQ<9Y&7.'_NDA6-U@ 7A\+G7'4*Y@QMH&<2DBG>\Z2;%C*'&%IS M7-D) X\/=D"( XS<\P+,1@_Q'>/'W+%@5^>)\:MB1J,1(>N"YPDL0]OHV0HO M1\%,"BE'3R#08?!SP"^U+!.CGNC5Q QE<5[%D7F,_< A>>1?)"S'P&" N8!G M(A0Q?&VT,A(3N-S+BR;N@/*#,2_ N4(?VW"93X#>MJ='01:*!/LH/P5D K_. M13@;C-^*X(#YL.XVTO@)747;0:U:T0WZ!2S$824,, M,EI <3%KQT)&P?7!7W#QP>9XD6I)[V<0<)H]WUDD_GHT+(RQOF-/G!18[DD7PFF=@JC&S903PF\MA#,: M^#[XUCM?=A(0BS'JA5@5X#=7BNBKQXSI^9Y[T3(@FS3!Z@,=EN8E:3_CLMME'$@3+NR%6> M7"-M3V^IO0:LV#_\A^/^H' H#U#MHY$/X[=4>7C;N&Q-&;(L:N5Z0!S*]IT7 M,8>C_KD:QN(Y1R:1=C@U;6,*JF%KW"IL>/IIL)DL:2,\")*;-*;G1="!FB?H MF9O;3<&)#WAP#@0A@,8D;V[W4$5>U]:!VUB%JC<:\)Q=_HI+EFIP2I MSOFO!R-]1YGK*+E*R;WE\01-(9?',/NT)7[]9H2YEC.1+ Z&6BL)>8JT'*O: M&9O(#>CT<;)<*W5[:_EH37Q,$945W=X62IXD,4?*GE+9:D.Y22JG88#"WU]& MZU7WI?#\3CY@I@RDT5Y(SQVU*U!;E27MY[R@KT46O$0$"R4Q*SD$BPJES/VX ME/DL82]:490=G?)&8>6O(;.==YW&RMEV"C]MM5)Z(*?*FO_+?$$\T2_! EYK M4/$0S/4;F\%Z7WS.9$WYKT#5 MB/"@\_FOG!/"G.DCLX/:*\\._)+\4HI8:(25R&!ZK-<5\$%@\6)?CM,H!SO( M#PF6^BL5O!5Q24E-/VPM:,5[+.O[9#G/PA\$KV@+]W$=XFU.31*HXF M&PDF9$GP.84UH,?LXRN=B@ +6R18 M"(57+2N\B3H'$786(=-KHTBX,I)=*+/J6D$,L<\B.4&( <>^+I ;9903SC4O MSDKGBJ62>P7#)H2,E$+ZB>\K1()X"QTH_)PMEI;SBKA]^DNH0A!R!V[HJX43 M1)@SFF"AOE&':]0&3,4-6 P#Q"^F-QQ)3'9U%6$#WWY?T8NY_0X6W3N0L]C. MK?7[!+8C(H(9$R'EK$7H&$TCD(?JJY4F*]2I1]]GRJ7VF81+%RKP90"7A_J( MX_>D%*LJ<\52E35P>?A0HV8"138F/0R\*\*/BOY>PH2YWLWS* M2FN]B#MPCP156N=[_T^ R%8^Q\A"*L$'5O3W!]-#/$<"Z;^=.(&/R_0#G-EO MIO>CI.!NQCMKQE!_<6R65\9UX.7*LM9N3A#ZDB"\=U+-&+YBXX8IKO$N1U/' MGL2;V[=-NGC;<,B:(,G')]T*] A8/9'9>I:YX#"X:/N@#AJ+-7_/8(>WR9AKF,J93%&WT_-QF8A!=F<#C3>\3'96Y(-]AUPYU6Y+W ;_CY+=^] MHT4*+QZD.'S?8T;DC&)@4,7M= MH4P"B@[6TW%#M%\,L80M7!83? #B_3/;1)32I%54=(KXJZ.[4\Z:+B-@Q:JZ MM_4L^"L=BSJ$@F^Z LM()-* 0\T#;Q&@:8X!2_#)&_1U&*P']X>^!=@S05;U M:UE[P][2U;(V#?^B<0@1#3M> U799;#UZ;%E6 [24XF+'H%CVRE!T7-V;A4T7-, M!+3%946TW6"R0)DN7DF49Q>K^V R(A\K=CT0X;8%=I/[7Q9!J^/CPSYR89,& MWXR[Z7E1 R7.4P\?WPLN\17U07((L)=+,8ZNS SC)AZI::6G7&%^::!8CMB[ M6 38N-%/.@,6J_VL5JQ+N>,F Z$XB8!X: V4\RA$F<#!QG1)V$H2_@'<@0J* MTSG5?^*9Z3\B@..PW845<2'7^-T5PL+9IPK&AB!D9H4$*1 MQ6 (OL[+F9",ADIBR13,P%D2OC-&3@CQ=A98<;A:C+MN$1POO8N/,"0(/C%9 MCO_\CY$B#W_!$3R9H&U3IZJH)W#[5Q>^?\H [))K==$I=G)1=MD99LLUM&OY MM=NUY'I@A0HOW*5P19*HX6]D0D!5G)NO"-L5ER4].B:,V82XSZU?W$LI,6TY MTT"46O7,4:FBCTA>#8+MTWEHUF&,_,796@]1S+8_-L%Q_S. S1-SFXID]LM& M,L'3(*)&YC7N]8A^$;8=<-$OT3T'VYR\"I;Y ZTX8JZOWB#NN@ %IJN6H)*2 MZ<+4C+Q^!2X0[NXD0;C__M\?OPEW7S[=?_O]]OO=_9?=Y]5O?EX4%=,DX9XV MM'>)D]NN:-B&0.;N86NE,%$2!F-<@U"[NN&_XQN*9EJ%AHLS:'6[M48B?B]S ME46\S?GIYB/;Q6*GI2YB<="*1[D_:8S0[#VELP@OY+ M+U0&C//=+XT/4)B[Z'$P;V'\"]T!596OY=Z?[$6596GN+ZBN2A;>4TR30@:X M*5T7">"^4.(@]=_H;T'GZ*M[B-H O8& M)T0/"=Z1>ANI/WS\M(W4'S!D;':4WI/2GV]_W4;IS_J$61V1]R#RUV\?MQ'Y M*V^7V9CJ6#E45GJ\'^01FP)F1Y0#EJGE@$+=5$65"BBN+TG*G'YO.=O;^;G' MCM,^P ATGY*(=IY,0Z>4Z\+>7P/7PY3Q*(\DTZ(X]/0?L#$SS]#/)/7 U_)8 M#6O]7?9H8DMQ&X_M,(W?>A4,G=+]J6\Q/U0+$XPPZ84GV&%&SX3-=6L695.1 MCQ=>@&'OASA[*A=BJCC7GG)(+J2E\:J,5?5>UO.I0T1:OE20A_ MHJ@UQ>?[O5$M@U(UJ2?WRX3Z5[2WW&].>S?B"1R\/6V17[$PIU.+-83']M&# M@8">^9U-<4C">\==2LV[9.>\$,4.WIMOL8%X>W0W358N3-!/P>7'_*%WPN_Z MJR#WLX@[!VVUZ^(06D6(7U_+-&HYC$YH=.)_]?XJ?#/!HW2GPF^2\(%]-77; M$87?W*R*;D2IUG/9KB#&K5NK,U^G4UJ*-0>(14O1V<'V+V=G!SL[^%>JQ!?^ MH5N6;K!S4:H[]4)HW>J- M@SJ+)FD7 =PX2-+M[M."ED8V49G4DE02[U]_I'[8LF29HN->OK_6?GI/7+V9LW'_[E.+^? MWX[0)7.C.5")+CA@"1YZ)'*&Y S0-\:_DP>,;@(L?<;GCG,6BUVP<,')=";1 M8>>PGS7+GO+33N<(CCM'ON/W.@.G?^P/G D,P('^>[?;.SJ<''6Z_YF>PHD/ M [=S['2ZV'?ZD\Z1,^CU)\[)Y.3P>(!/?*_OQJ!/XE2X,YACI(9&Q>F3&+9F M4H:G[?;CX^/!8^^ \6G[L-/IMG__,KJ+F[;2M@&AW]=:/TUXD+7OM?7C"1:0 M-0:@W!QP.@KYNUUVAD"SZA0F+J+O$]R1VY"$%T-PNI MYVW]7"OJ*,,XA]V2J%GRT.GT'-U)+"4GDTC"9T7?)?@X"N2P%=&_(AP0GX"G M?", S?Y:@]QCB?D4Y#6>@PBQ"[5L<_8&(4T:F8>,2T1+PCX6D[C3@DLMUFNA MA. 1<[&,_5:W%*II/+Y2^S8$4N@K1U\=/ FOU:ZO-1+.%./02G->)M&>WK'I M0T3^=[J$BV$)ME5O6UZVNG$QN'WU8A9Y='S*Y M9_9A8Z15^8)),KX6S^W&,FRMNY%*6G4C!A+@'DS90]ME$95\42VHU[4MOXFU)LTSO QQY8)G MG?A?%SFKQ-I!L=2'=K%M 242X(WI6?R[&-2I<-IDBV#!++7EUJ-HHUAZ,S/? M5J-2#Z@25C\$"XBG"XMS'.C]FRLUG+/" BT]_140N]LCI!G CMT>[<)M7 M]&^4J'IE>47$!1:SSP%[W&? KC"-G![OPJG&1[&"!C$YYE-,R=]Q+S#U+A4S MG(3ZBOGGD2 4A 6'M=",[+W7B2D1;L!$Q$%=Y&&1PD4Y8,1\E$$WB+=?&:%3 MEZG\@=-K)L&"I+*HD9&3(B,Q!DI!T-L8IDDIRQV94N*K1(W*CVZ\L*3L<:,F M%I?84+$=QDC+H$A+#@^M %&&V"""KNB#ZCSC"\O@*,B9*.AVBA0L 1H8%;<0 MZ/>J*F3DXIYC*K!KF;57(AB)Z!:)2*%0C(7R8 UB1$$ \R\X>$369V%-RFCY MPZ+EM;A^+2< 3;(VHU,)?.[!1%K..V51H]U[);LK#*1!D$9IX/QSH?,1*I.J MF_EN['^K02""1QFP@3R/ H1MA.2$C P$0.W2U"T81B:.R[&0@<6EW!I<@WC9FOKON9*H4U$, M!D?]_OM2%F6H*-#;[%>38BI?0=_C2;!K]9W*&EDI95B%\CO!:1(#6]W=EI(Z M8$:.2MF8,7*:Q]JR-K9EJ"AH9*.4@>7*\N;9?92KYVQ-OT'6:/UR]K56$3:2 M@EQ]9TU!6=9(02GM*A:'S:.@LJJSY<,$9"2GM,&QO3YL'E5)M68=)WDI(PFE M/8VL1&R>N:OK._O0," 9:2GM:6RK%YM(5KZ N 2)2;!C]9$)FR@Y*>UQ%,J/ M%*A))&PM&9:YIC4]=K!&XNRK^:6.=Z^T%NV?WA&WX )YT//.?OFMQC<275H@ M,!*=*4,K;:^4ERBY!GE%%7N@#"MN@,>??>V7]:TJC,3;KSHH?2A1B-YJE>^0 M4II\S_;J "5V/F%.U64(7&@+>8EY]NL!VW487:"TU&%R@50?4@I1K!&E*E_I M+[]R=:!(_+3O-WD!UDAR:47%1'(:XDK'*ZM%\RM-P%6@<5#)3K3G^;P"W,AP M:<'&Q'"F"*6:7GDNOUH?\?)FR!E5/]WD>U\.>KTE6&"/A1*\?;_2;?4:O:.T M8F3R#M4'M.H$6N\%RKJ!TGXTTG=V+]/L*['28E-N/Z*!IJ_ZS,^:"1.0D9C2 M3L(F106FU:538/&HX"U^PC#B1"WV&C!?ML A1!\S( M4FEIJ<"2@S)HE&$WD[G6P)7D$ MK?C\HV&KAB E0: ?9(+Q"7.G(7#"O/OX4!,O2J:S%A*1TD)DI*]^Y2P*AZVD M.9$P;Z'D#)35D7.G'IMC0J_40XVT.B^I-, LK6#*KFDM]3$=4-70MHKL?5#) M'06O?+7&>*Y!ID[Y@(-(]9'"8Z"G)#]2B12$>!'7[OFQ^3@0R\'5EC/;+N';FCX(CSR_O(<4T-T MK;=Y$=V^B(1D<^!C"MO[OJ'ARQA 54XF3!-"'&Q8:&/XX>BWDZ MB]89!X.#;6SZ$L90V*(SN55E\Y_M2YF!F2G4-S1\$:%>?VG=Q-$N2#^;OBPU MN\&+'1*Z*JD70>P-3[>S[B1SOU]'NFMC_S?]UWK91Q&5F4\MV1_$':$2IL!K MC/ V2\'&_J>KR]&(85HYHHUM;4;P/TW<] +3/>BSF2?+!<6/O@3^!V#^F46\ M /$4QOXXDMJZ^F3V M.)#T.4RJ&F>-^( MG!%ZHWK);^*^7J;DI\VWS'_/!7[&9+D?D\7K-,E!T6=O_@M02P,$% @ M3("N6&1XFG5:%0 !<< !4 !E/[M[Q^/Y@>GN.J[Y>+7!_QG]N %VF9N\7[ M7Q_\^>X9N =__^VGG_[V'P#_^OW-BX,GRW1RA(OAX/$*PX#YX$,W'!X,AWCP MS^7JW]UI.'@]#T-9KHX ?EO_V>/E\:=5]_YP.!!,J(NO77RZ^H4QC8;I D4R M#\H4#Q$] BJ;N-0B:L;_Z_TOZ KZQ PP'@JHR#1XJ2*XZ(3QP96LTOJB\V[Q M[U_JCQAZ/"#Q%OWZY:\/#H?A^)>'#S]\^/#SQ[B:_[Q)L.\2A M^B'L$CU!GWW2[]^ M\\4RA6&M]>_B.KCU&_457'P-ZEO !4C^\\<^/_CMIX.#,W6LEG-\@^6@_O_G MF^>7;HE]"O/EX@CSSVEY]+!^Y>'CY2+CHL=,O_3+>9>KJ7\/\RK#VT/$H2=) MUE<>/AWCKP_Z[NAXCA?O':ZP_/H ^Z,$U>1,GN'YSPVN^O +9D*53N9K%;V@ MU^?7KO":P\>/ ])?G&GLXO[S9;KTI7FUUW)U\9?S$'&^?G=VTL/[$(YG+[H0 MNWDW=-C/>"JH#3&5J11 )6[!H\F@G*6W@]+!L,OZJC+U)-3:P"7T<6WE\VN3 MM85\B/.AOWBGJE:NU7K#[<_TV$22QR>K%8WW62I6.$N#4P3-02F-$*2EW[@R MT8NHN/#C"72.XK)<7S'DT2H=+%<95^3#'AQ\P.IOSMW9&:2P2M>HU@VU?6920E\0YN_7"[2.910C(G&,T"K%2@I M#;B,"H3AD0GG#6=Y/+-_ ;*)Y<6/:_DM-=[,^&^'9?KWX7).>NR?_N])-WR: MH;:,N:#!N6A!H4.:<*.!4J?D(#7-QJ6QY:^CV%6NUP0,2:]Y?>G_#O,3G$5F MI)4TNGPV2((E,ED6"3#E$G-,D1?36+ ;8$S)E>UH_:N\WE7IS5C]>'ETM%Q\ MA2+D[&)D-#P]R:(D%G!:T[@-A2DE8BPF-#;]50Q3:= LU8SL81FB@;V_X6*)M00/Z8 M%&BA_&9,>(-#Z!:8GX;5@O+9_E&BW+6J&O,3+%WJAAEC45E!'BE8:ZJLC"(M MX2%%01FF,\%RWI@4WT>U"3_4C\F/QB9IYS126IXLAOX-)NQ.0YSC2R0H1O!L MB@2I2%P*[@S4B X<%IF-Y"5AZYSG1B#MI?O':MGW,QU<,%Y8*%Z0DY96 +U1 M('@95!#2%9-&EV\-94K1T.Y52,%#L9X"MI(=!6Q207#2.U:X+-@Z_-\,V1T#*/C1N-+>/&.4"!XM\@U3 M@]2!'#8/P$*=YJ66$%7AH!42*I$=VM:D^1ZFAC)3LF^SXC:#=>A!*>8@%N<@ M%8[9,.ZL$O=5U)M,\6MW)GRC+G(GE8]9#5'":2Y%!)L3#6E4#%S6](/%A$DH MYGWKJ?)[7)Y,$:P] W8T0+NYLN]QZ&$G[Q_@6&'M]4-;XJ?_:X%G;& M90@E53$Y#2T59(*@M0/E:71Y(646KC$;O@EH2KZN 1W:*;\9'YYU"Q+[17>* M^?EB"(OW'0669Z)6CM*]41OO((A(2(2FO,1D!*81K96$6,?&A/@VHBF5S1HP MHJ'ZFU'B"1XO^V[HSV%\692B1#0DNBTP50HH73RX2(*RHEC(V0C;/!N\#$RJK6*V67 &QB:OWC MF'I[Y8Z1P5_@L(Y[HX4%S)(RK. 3.,D(![>!*^.0V]9AX/-R$8SW7KQ[SJ**86T MC0FPH\J;K^-DP>H$\TU;ZTR)@6$";A0'%0V#@"5#TA&="5*33VK/A)O!3"F2;4^&!@9H MQ@=*L'"%_7"%FTX+63 :J"O:=5=" >\K(*]+@$81,"V!^3 M +LHNYU#J'G+#8*I*'TB_P1>!PG*L@1!4.1"\FK%E#7$P3&RQNUB!/=C,J"% M\DU?E7-IZ-/+B'9H@7/+Y4?LA;.)0(V:XI"9EQ<$>+X@ M6/CTXW$%-%-&>AZ04AQ>=_3;N@F:R0#:8"A&&9MTZ_+ZK6 :[3^Z3=3B)'I6KG^7HE<0DH*B< M21(B7XBV@. LYQ306-UZC?GBWHUD>$9VH[ED6(4T_+,;#A^?] .9:O7T8YJ? MU+Z!-?&E?_E=^#@+7FOK*>Q75M2##P?[N1.]V M-%-B_4X\N-Z'J(D!&E8EYO31^W_@@B:W.4%ZE(^Z1=6&2PFS! MF-HC2<0,D4D!R'DVBKOL5>L@<3-D4ZI=-"7*"(9IN2:+=)FZ9/R$O/E\N3X\ M>@$IQEP\6@U2$1!E>8" HD!BB5GO%8%\FM!$AJI1=%!16NL&JNJ]05&LRB9.6FU]!)T80B*>TT6 MRQR\+;C^R,;6:\\W1\G[G15WM?0M8>'=]#M>K.\Y_6YM[)X4W,_M+'+[(\^@T=/.Z/O1N^56WR/-.'[^' MODLSQCR7T=#V+8I[9/NM,NXR/T9A,^E MV>='QY2VS3!IFX.28/"L1QB'*(6%6@\I7DMFF_=HNPN^.[K+D0M((U+MVTUN M&QIQG($W8VBB3ES7!5A)$'*$&"F;&^%?:]T MU7V)S^;+#^,L='VY^CVM<]TB3J-EKO4FSLM;>R_O\*1Y^/(;7WUS%I76+$H- MS.8"BF'=+&$1$B48F&FJ=^VK7KL OI_]Z::4:+5AM4LPY6VL=OLJE&S5K53, M:L=2;+T\\L/M3[\_WFVWG_TN-AQI/_M,"K12N0)1>9(R!07UZ0SDPXVS7O*8 MF^]TO(Q@2G/?_@BS@U5:QD3UYJ]7RQJOY=\__=G7]DO/ND58I+H@D@:*Y-:= M)PWFA+YDR#F9>@0Q0G ^@PP!G5)1*M[:)V^.;O<16B=?=V&96JIQ1C$N3Y&&MAEY]%2P[DO4%Z5I\^? MO'BQ#(OJS77PA0 X&JXJ<1JS2%"DBHA>V8R*?R\RO.WBDRK%C&SN)@IN5YC; M94IXC:MN2:I)J[J[[PF>_4^OSU:8GWY,AV'Q'M]0(/ZT%*1DF-'\7TQQM04( MR5A4 6^X !Y+X"IHGF3SA[#98\A*ZZ:RFZ/[RT3EDZ#GKN;?1XB/P9AZ\@J8C_6XI:H5625 9JEU M$#[ZYK7U;4/\/2^I__#TW-7\8]/S)N]NC _180+'*?!77&1PF7Z3%/U'R8PO MMO5NL6TG]RT6P<[SG'?+1XFXLL);&Z;/9 J:9C0.V1O2@\X.7 H)'0F[62I?82X2B@O!1$\B?JX.F4X>$>!3G;,E>1%BLV= MT[8A[C8'5JY.VA>M#*KHC/D@;8Q "B#3%+*Y,TJ#238'+ZRRIO4@^B:@'\$5 M[TJAZZ=;6EFHX2FGJY"N]GJKZ^9)^ PBA;HA4W$(R7M@E+MZ%EG0.#YQMFBU M=X_[$_;#G5T,-2)_KG>3G6EK* LP#++65>[ZB#V3)$A1M+@W3X$O: )GB\BL^.;;[S<% M-Z462_?$IW$,URX]K>+WI*T;'O$Z0QY44CZ"\(H0E5 ?,(,(T3IDSE,Z'5HW M8/L6GBFUH+XG]C0SSX@3V16&GZ7*3 ;F5'"U#Z\Z>U8J26HA!.:%T2GKTGK' MRF;([MC&^B^:F.ULLY%VAGOC'&/H(=:#L12:*8@J%G $S1J7$P^ML[$[[PR_ MKQ;7]T2.[0TPMD^YR _MVF:*6<\L\)!BHYH:AB%[O4!:%D;X[-$[D3K9^=L MBFT3YOB_%G-&,=L]9%Q?/;K>),LX%QILX 640 M>*Z*[$R599P*WK3NP;8)K MH^HA^\O/4CL:K.6C2%>8NK6NZ/PE^DIKM2Q M_:+VG0!.:6?QF%R[Z@S'LV+;V;;65L/\_#CU&MRC85AU\62X.&B]( EJC>U5 MN7R0?H99LQ@T0J8L!916F9)AHR$%;G1V%"/D46;@[2%/:>7X/LEXGY8>>;:F MO\9E>4S0NN&/,)RL*(-^FPXQG\QQAVEYD\NVF7_O+$"CB?92QW<4GA=$ \Y; M5MO+9/"%7@K'#7D?6TQIG=C?WF)_-UG.=4C!R])_,*R> M+4]6,U%4IG%C@8++6L7% $%H#SPJZ3G7OH364^560*QZ!P[Y:YK#T8&4022/0AIL7>'8#NF49L']\>ON1ML/ MP5Z2_W_W >>G^,=R,1S6'HFH6;().+/U\:M<040:'3(6ZU,VC/$Q??>= 4]I MH]5^Z+:3"??!NC=X%#J*.2@>?=;5&*8.F)G'$FQMQZY<\J ,YQ!-75_/CA6= ME"]RCP[N1LQ3VJ&U#^[M;L@]SJH?EC,E#*(BO5A1VYW+VE.QQ$!#1C"4N=ZZ4<5+'(XIL2?S MG-:>3LNRP _S>LMR0@;\;+I9T,78$LA,OC[C$%E]IHHMX#A1!)&Y$O+WU'.7 M&^[4WN3BL2#'=7EJN>AH"CV__/I.GX5*,MH0HX'BA:Z/9,T0Z@,2HM?2)R6U M\G8CH3:\X20.L8QF]DL-4,8P0;N9I3X8 V]Y=MG%L;4G)Q3L^WHHK40HP0O* M)B,2NJ@A<*^+U#E1IMEZ-MD0VQ1RLM&I-*K![I].RO&@D0=PMC8-O1:3P=7,MLT$IG&3.@E9*@"D65T8L +$LC23&2LIL]Z62; MO/3>RFQC<&[;8;>34>]]&%Y$GA&#-:4(H(#7U^/K"#%(!DYB+!C(6QC<$_/N MD"7<6]UM2H3;QH3[X=E9S3")Q)VE5,K6I"H+2J\X,I \!D?Y#9>I>1WDKB G M572;'-?N;,:]L&V] L)BSCD:!>ACJ0^W]^"E=I"#5Q;(V5$T;R)]ME>J$<9)%=HF1[6[ M&O'>J?:H#+CZ#)4RNU(84_4YF>2 71;@3:*A$;RW&M%XNZ_\Z1+0*1VLG!3I MMC?GAJ7?\_?KCT@8?OOI_P%02P,$% @ 3("N6/Z"'9*;+0 %_T! !4 M !ES)S].,,PP/_E]./OP9/8!G_Q[//EM^"D\>7T6 M9F4\.0?XV_S7?AQ__#(9OO\P>R*84,L?6_[KY"^,:31,%RB2>5"F>(CH$5#9 MQ*4643/^O]__!5U!GY@!QD,!%9D&+U4$%YTP/KB259H_]&PX^NTO]8\8IOB$ MEC>:SK_\ZP\?9K./?WGZ]/???__SYS@Y^_-X\OZI8$P^7?[T#XL?_[SR\[_+ M^4]S[_W3^;]^_='I<-T/TF/YT__^QR]OTP<\#S <36=AE+Y] 'U\GGW]Q:MH M]-/+?Z0?G0[_,IW__B_C%&9S!=VYA"<;?Z)^!*O_WSSQ\F6#:B7RZY@M(5SG_4ISW=&],' C))%Q&!OHNC2O&&&-<]?7_, M7Y\%&4NX.)LU1+SZ[*9XQ^=AV%+ *X]N@';^(#C'\XB3EE"O/?<*SB7(FPCK M(W&:PMEX=([YSVE\_G0.\,?Q*-.B,=-?IN.S8:Y[[/-P5C>/MQ\09].[4>/T M/$'=:YF\?+O_8XNG7L%,Y!B.AG6_^86^7#RZHFN.'C_/D'[CP@%IG ,:=R8%H$]+W6-$=P?3W?:/)LLES9XCW; MZ;@HD_%Y4WW.QLW$>*DI OW#D_$DXX0L)/JG^3\!<;9._J=9Y^'TT'D ;GU'K1Q 907 M"J)SG 3CDK9&Q&1:7OK[$[*+"'N ]'!LU53H0"8O86E-4!0J*M,1).&:TB MQRI\QR2X9E >CP.[2+F#[M]BNIA@KJ#^,;\CV@Y;]X]A^N'9 M*-?_^^G_70P_A3,"-WTV^S%,)E^&H_?_"F<7./"8A752@P^V@&))0% "P1C' MA0K%2R<;ZW\K8,?BPUY*'/?60 >:O$%:Z3#-<(YSL?Q!U"S%6 RD"D5QK)8, M#^"LS#I8SK@1C6FQ%L@IT&!_":^J7>Q]&J0TOB VOL&$Q$QR8O\^&4^G RZ% M3RZ3,5,M#U6L V_H2XG&2U&"EW9-G'*_\V ]E%-0?0LIKRI?[JW\L[/Q[S4N M^O-X\F)\$6?EXFP5ZL!;+"WA%?5 MKO=5^\O1)UK?>/*E8C':9><9 X%"$?%2HLV*2<@V:9>"<:&8QMJ^^OFGH.1[ MRW-5MV9?W;Z:?<#)M24.BE-6(3D[.O"ZR0ARWOXIZ/C^$EU5K]M7 MO:\GXX\XF7UY?19H>:-<_4WD_&SLA"[/AZ/TO&*;XIF:]O2K_G.)<"H/B4Z"%6;#" M1]J'K"#*Z@3HM&*B9&M+ZPO;6P&= AO:27Q-8&?O@._/5:+XR_ 3YI>C61B] M'Y)Q>2F$RE8R*E,RM-*2"Q);BX00"X/@8PRE!*::9W3P M[P5^'$^'L^D"T7B4%L<84T*B00=,,$=K9AR<9>1KIN2ED$$$[1J381.64Z!! M$SFO(<#^8;\YH('Q+'AC,Q3E$BAAB8?&"["Y&)-HE?!6(Z4P'X<"%3!Y,X?0J.$8& MBV=%2DP9@^U'CZ-? _?1X&::["/^#L281RQ^'<]P^CI\J=''I6.;-/MMXU-F$Y*BGVTM>Z\-"^PNZ;Y;5$Y&F)2O$"2D?: M%!UMBIY'"])+J7W20L;6ZE]%<3**WU/ '>]_;Q QQI(#([N(T^E'9R'39"$9 M,E=C-M4Z#:J43C<[)_K.-Q!TCQO@E"87F%?7/) H>#$A@3$^TS$7/&U%9!R5 MDD20W"4AFJ?];0)S2B1H(.X.][LO1S. M>6(Q*DLN;/,KOW5(3H8!#03=X9[W>@!SN?0O7\FIN++9DZ&+NIJ\B4/4S$%A M,4@LSF-SS_%V1"=#AX:"[W!%_ (+$I#\!C_AZ ('TK&B70B 4G!0H48LF9)@ M(T-C-"T]M[XVO 'A9!2_CV@[7 _//9(UQU*Q& /+"61F!(L<7 @9+5A70A1< MR.1:7QUN@'(RFF\AZ@XWR&L0,6)AUMZ"\Z'>:2L#3FH&F(I*2G.96.N;H1/6 M^YX"[G%1/&?B>/3^'4[.KX8C!I:'[ S2PH23M$[C:P%; 1Y"*1*]"KYUQN=& M,"<:"FPC_ X1@46,8@FMQBH&GKGL(\^0#-%31<$@2A_!>.51EH54Y,7124I&2W>2B=,Y"PTOSF\$]2)\J.M M,CH$#ZY(X0HHSY)S"@-DXTQU:1&"'"Q7-:1A,@0E/3#/"^UBV6G;VEF\\O&GK_6=!-PA.'#+"BUZ+U'5 MYGB>6%B4 OJ&!YM*3*RD[%1K\_$AY18"F\ MR@9X\F3/^!K(XEZ"1$RV9)&U;7V;L ;&,=),VFAI)?UX/Q'W*#,?GY^/1U?P MH GDP>I8&]21+Z.8 EH70@@NDHLC/#8O)KF)X63TO9=P>]P:YSP79#A['8;Y MY>C'\'$X"V<#:[TV: LM*M.&YKFH-J@&DP1SA3AI??-\PO503D;U+43=P4-\ M@S,2"N:?PF1$KLGT64H7YQ=GM=?B"Q)V&LX&,ZC$'+@B% A?0M+6&QU;=QE9 M17$R%-A3P'W]O[66[T#K3"L3&2)B;7B0)?B,"0JFH"S9OBFW#B3>A>E$_8.F MJMAXW_2?3V]([1?ZLG'GX:^IVM-791$+HW^]#FV/%L0;'M^O%_$VZVG4E/BG MT8Q4_>]AQI>CV@Y__E&+*^>?B9<_T<=,R+3X\6(Z&Y_7:\EE,KSQUBCG/&"I MEQ#H O@0%63OK; F*\E:1V_N#7;O@RI]P'QQAJ_*KA"FS[^\GHSS19K-7S*< M?!HFG%[V@M7*9Q]$@>0+O;R,6X@E6^!:>VYMY)&WEF"7A1RJX?)AN+IRAAY= M]\=N[SR=S :+A;R:+)8Q[V)J8Y:H/4FT%L4H9AEX+CC*K0 [;![J- MCE85WDC !]-^C47Q6J:2EO?+3YW1V40>LU2IV^F]^%SX/E$S:*XW@,BHRI%.!((0& M[?)E,B+*UN&Y>\ \?,#F.*Y);PUVV%,6D*<#R5+@@6D(K-1N9RF"Q^A !AL4 M0R'I=_LPZ0B9'T>EQVZR[G+Q.YUOI#]]_EA#7=\ZJ>=4^YHH!(&*N)B(BY%K M6:=@%.9"J)ZTT=@:&C00=Y<. V?T3^__CB.=HT;KI&R"\YS(RJ1(VOR?<"MF)$*2# M&CKL&F]PBO3 .COA!>V<9^-YA\4E.!54T5X82++.W*FM%ETI'EA(%AG/VNO6 M\?5; 9T(-=H)O4/6RIN(GA M1/2^EV@[9(]\K7IX.4ID(/U2QR6$A,YD4V-JG$PCSNJ8K=HZ19IB%"KRM)OW MIUZ%\5B,R7TUT*,NJ1;-7<)9QW\9!"<@ HPGNT8992$:+R&%2*2US&C7.N/L M=D2/ABKM]-)C*[ELMS4:7R?T\DPSBI%10\<9YD#H:+N#*#D'D33C)=7Y?:W/ MD-L1'9XU+?6WOM=9"^%W\$>6[5B6<$3VF&NAI5(U9=*)&IU/"HS!1!M=BBRT MCEO=@'!2RM]'O!T"8#K<[3IVM/VU!F$$1MS% 8RU['()H/.;T&X+1T?F_1=CC\ MKY=*O1A^(M-HE*>7 +^F8KX\_SCO[R$"G3=! L=<8V*10]"FCEO"$!QW036? M9;T+OL=B3G;368>4]VMD?_8I#,]JSM>[\962K47>]?,P'::!S\GD7(OS,JNM M_^NU<,0 ,C ,=>FJN0[WULM#G-4[>?@@3_-:4R+#,(H]@ M76T=5H2D%Z .$W,F*&YM<**US;H)RV.A3A-=="B]OHGKDKC)Z,1R-$ K+C5H MDVI.2]TPI27.YB*:=V)8"^0([&BBISN4O[N0.SBR-T&]&)Y=S# /BLO12EJH MK 7A"A.KTRD4P7+HT68N1>N\K@U03E3[]Q%T!]?VWUBG3F%^]HF2LUR\W7@N"U<^%B4;!U(WPG@ MB7"EGU(Z.,0;P"[XO8)Y4$(*03%W67:NHO#@DB:;*"G.C0I%E-;=(7>$>-HL M:J*8C0[WH0L[Y\NX7I=[#6*C L\U'W.80L^[UM>HX'/-6*-YKT"I:B%X'366 M2XVYDKOL'$KM> @R-L_L7D&Q?R^!Q1,O*ZI$$MS,WZ18KR&C)=L]UC0$1\P/ M*24E6E_97$=PJ*+(/?6YVC'@WF(\=IGBRA(NWR)RUC^.1_4=FQ?A2,.]R#+5 MU@>1_B!_SDFMP8KHE:?3%7GK..ZM@(Y6R+B'HC=Q9F^!]W![KF-:%'%L VJ7 M8W M0!S!&]E?.9O[T-U#LAT*CJ[?%"TP::.R+BZ"L;&F+==*7%D;*\FD,@J3?.I[ MBW[PT=\1;@G-#)%Y-!\#I3(00")Q@#I[0H7-ALL?GDNML G0(+ MVDF\2Y7 ]49X"U1)V,!+5A!%R76N8@:77"'M*9V$L_2OK>]9UR,Y!0(TD'&' MB.7US6DU$"8\^3TUHY#K&I)WT8(WD0-'D4Q.*>OFXZKN@/0@YESO$T!H*?(. MYL"/X]$GG,R&Y/.N0_IR.KW _$]Z+2Y_L!K/ V%YD5(X"**0;YPY!^=Y 1:8 M\2P+DE7KD,$]8'[WS.FMFA[%BJM-$T5)47!#OI(UY"OIVE)5DO5;?-&Q1,9+ M\[FX#Z%C9?,PY%Z"[9$9?"UED17EC*8#4M@ZC+4X#63@,#",>Z44EFA;A\R/ MG W:6,'W%V<',V$-VXHKB0 5L$%9\EJ#@&@M BKKM% !2_.!IG>]QON:/Y=] MX8,Q(K"@P!E#"S.H(!2RQ253MDZ:EI*UWI\>R)R%CF;.[J+MD&>Z,@+ !]01 M X+ACM9G$KE=W"5( 8-4/AIE3W&^0F.C9 ^A=LCQO()GC6VM)8M*2O*NI:T# M0B-X;=W\VMX=K)6M&/F.8)/05BP Q,\MI,+GGM6H_36@/C4"D/+72\ M.FU[/ZD^E.2'Y5M6U_..?F=^?R>4T"%;!L*S4+WD ,%S3])Q 9G2AMO6-M\Z M',=*==A;MS<')^PKXPZ1B)N8%B'=;5!URG-8C^@XB0[[:^P."NPA[L.1(::@ M@W8&C%4%E&4"O#$(.BF9:Z<>[EK?>AZ2!'>D.!R* [M(N8/NKV]V\T4FI9$V M-PY)8@(EF8'HD-;,T26T'$7S21VK*$YE\]]3OATBD]<1_1K.ETSGS7\3 MIN-L__OJ[%8*["GP[EO %7R,^XBN.(B"VUH_4C1;/=#_0UF//]89?H:)\-Q MGB_8FVQ,<1:"K/TXM=;@4',P6DB&M?\$,UV/]W6H3F7C;RS_#GV,;D>X8/$V M& _B$ZS']Q#\@_UUNQ-U]E#,P;>9I7WK:J1$1#"AUJ$;2?:M-PPBLRR:PNM> M>S+DV$]_UUN= M/G?,>/OZ@=_[P7)_Z37,'?D*8I&OO0V,AF,:KWSTX0T,WCD%-DE!4'@2)GX/"KQEQF)C_>T@L$Y7-N^6EPGX>?:< M_O&W043:NZ7G$'FLM7/10]"U?$+&$'34BF^WI^YX8[,"Y/"9/#WN^/>7\<:" MA/;-4!*.9I>#W\?:1[ZAC_K&%)N1 MUY9:8+ .SRQ*0.#&TA'-O?8JUZAO^ZJ-#6@:E*U9R+A%8X8-) M-O/8_(KQ.'2Y(QQT7+;LHH6#L.3+UTPKYYR))4K0*98Z[)J#+U* L5HA0Y$< M]B?(5SBG?>+<2^@=,I-65_LM36X;:(:M?O)_Q!;QM5L6JM] M%DH!C^C),U<,@O<1; HEHZ;MS+6NP3PX-78_3KHS8Q>Q'X(1+X;3ZD!=3/!; MT,9H9Y@O=++1T48;IO$0$O/ N4HU0$0@NSOW:W =8]+G81SB?95PJ,C9V^'[ MT; ,4QC-GJ4TOAC5L5*OQV?#-,3IUZ)S6LFW]NRU<\W9O8)J]_^P)O&V1FMM M%(I[1A^?:\?IX2=\B^EB0FO"Z4^?T]D%/;Q.VJC]ABYFK/GX ,A M2X\&EFN17:DPV 9?)^_Y+FS'<:$?#!FV(NF>FCP&XP*/7'O/@;-J(&YM!)6,@ M&C3@DE=&6K2V>37:"HC#.^QM];2N;=Z]A7S(=IO+1M$L^VRB %,#%9 2!&=<]%NE::V6QSG-D@GQHB6"NBP*UQO VA=YM[G $4I N,S[7^.(6'# M&)+)*'7K=)8C=U5\$([G_9708<>X!N92 #6N=4'+?G4Y)GX\6C.+]\KPK,M9 M>3'JPHL(H+'V&0X:P4M3P'B!.6*B[[2.(C6"_@<+#Z;XC3O:(:/2"W'2&J=U M,?DR1MLK+'W[I_6/2^^PVH<6F%;16\5JG$28FBDL%;A"?YAD/(].!=$\G'JB M@6FG4'MI/6T1F8%27- 90V]K$!:C4I9;W;J [)$'IG?A;N? ]"[*?PR!:<.* MS$GE>M6>0'%KP&N/H*++/JB<@V^=YO!'8+HI20\8F-Z%+,<($VZ#[X_ ]#'( ML&N\\#Z:/ ;C=!0)BR[@%,_UXJB0O5\=#R<,^LR*CX?9/D\X,-V5:+LHL$^^ MV:T1,J%D5)'6KLG'HA77G&IO-:!0*ELCD\,.]3+?68AR)QWN&*+<10$= E*K M,?52$!W+&LR\8I0L!%IVK*$.;[DP7KCM:JM/[.)B'P[L)^3N@>F@%!.,U438 MPD$QI2#(R "]1Y\D)VNQ=1WVJ02F]W$\[Z^$WH'IU3CDE>$]+ZK<, ^RUY(3 M]2'I$D E[B"@\T OA8XA!RU-ZRC'SB#_8%8'91[,#-Y::L_.:QAV$!(W0FH& MGEZ6&I\/Y-"&"$DJR;@J(F/K 3%-@#]2EAY>Z;T'Y^UQKQ.L"26)#%$I"&G?_&X?L/9%L\(ZCA M/?YZ407[JJR,&KM\#91-=08W0F3)@1*6'").N[HT+ABO4&#SLIB= #Y2IO53 M8H<1D;0?3^878^'LRFX[?3:;38:1!+78AY?CE5^5ZP&9@><64=%67%P(-1/- M@V=%@ZJ-MPQRJT-K/WA/R(^4E8=4=(JH4OMCJ+,0K/O=.UY46-2G/) M(3A1P.3L?-&&L=*:ESM"?*0\[*G(C4,U[\^[E4N1^:;M5,(@G ;Z2\TH8QE" MI#\T-U9X9S53K>):,V49)D)BJ)/204R^@-*R3IIUA6 Q MZXUC(L76,;\-4/Y@R[T5L\H7WW84^U=7Y-)!_CJV^.7YQY!F Z44MRXA2)<8 M;84\0@C"@O1:)U.\4ZQUHN$N^!XIL[JI<$VX^("W%8L@2XF*698@R4P'KRP9 MO-<"@C$A"1ZELZTIMR/$1\JZGHI<0[P^^>]5%./RX[PA\!Z)[>L>TV8V^5WX M&J6BU\]YM?BI<6E_^/*0)YHTTO,T<\UTD MW6D.PKJAREN@>JQSS'?2V)8SK.\A[L.1P3J9LC,,3-89E'4:@DP)F"S*!"Z= M=*TS,A_Z'/,.'-A%RCT2\.K,B-?ARZ6U^SR,?ILN,@,5-XG33@>US!,(2X90 MFQMJ8V(H4GJ96Z=?;@1S>*>DA;9NNAA-1-TAY6[=L7?9* 59$=8J8GKDH$KM MEUQL!F&R3,HSX9M38!.6$S,)6DB\0Q+16N.Y>F2391NE+?#U,A#NP'8D4Z&) M)K>@Q]YJZ&$XW(53YZ BO0V0:^]]Q21"--X %TD7YD*,S2^RCT.3NXR)H[!D M%^DW9$<-* W>O:@'W.)\"[1%FN(BY,QHJU12@ O!0R(+"C,F;_2=0:F5IQ[! M)F@J\'$+:?5(P%\Q4P8.13",.\C1D=EKDX'HBP>,UA-Y<[:V>9.7%10/1-]- M0DE[RKB#UJ\/ GPY(ML7I[,ZEWU^Y9)?D\E4\US>XR KXXO*'HJS-;F*&7"" MY*"]2"XIAYZWCI]NC^Z46-)))QT,@>M(ZPW)].W'"8;\:O2O,!E6FE?8?)!= M*D&1Z\1UE*"03CXO)0.?A:"#C]QHU;J*>%MLI\N<1OKHX&]L9OB+BTGM9C0? MOSV(R1HGG )=DS@)KH&02P R<',P#NOP[8/M.%>1G2YGFNBB0YG =90D@67Y M33&6\20D.%XS 8KFX&,.(+C4O' ;9/-YBYNPG"XK[BGO#DG]-\;#X^2\]N_4 M9#$7**G.2>$^@0].0'(^&)^4T:PO RJ*T]7]SC+ND%A_'='ECC1,9$C/OZ1= M*@T_AK.!=#P+1Z=:FN>X\A A6K*JG7>H!4G$\M9AA^V0G2X[FNAB8XI[QSR9 M?X19S3CZLFQLU2AO9M-CF^?1;(7_('DUUINB9%(@S-P',0JB3AQTKD$N3#G( MUKEMMP+JEU>#@MCK7 9I0]T%"P*]/PF<=JABIG35; KU>J23TV0&*:E BV$U.)@+J=I%(W2T0K5.6=^$Y>%=INVDZ6TO MTW:1^#%N1[;!]\=EVLZ:W/6:Y#YJ. 9=K$F:V=HFT]6B5AD%>,$B>,]EB#*1 M+76(V_B'>YG6E26[2+_K91IZD41DY(+EK&F5M1-8+:[/4J"V*18G[%V6ZO=P MF;:3P#=>INTBK1ZI->NRR% 7ETQT@*)>$]8A$,[4:2,!BS?<,.V:&\K?19;M M7E; OI+ND4ZS/HEL&U2/-R)\XQ# M,HJ.*^=4\,UK-!YXEFT'#NPBY8-FV48KD4XFVNBBHZ,N>P[!IUASBPT:S;%@ M\X+ !Y]ENY.VMLZRW474G4R!=XNU+H)V0YR^P8^7$=-I;0ZR")J^'/V*GV?O M?L>S3_B/\6CV83K@)HA2!\S;8"MX0^"5$* 17<9@6"RM9W;M!?B!&)1M E0' MT]RQ:?=_,$S>_3X>F&B<,DZ#*([>0N](6B)S\#R0Z6U0H6L>X+P'SD=+LOOH MJ9-)LQMF(@L.DO&ZU/'3GM/.KKQ.X"TO@%*7S+1G2K5NCWH_I(^;7SOKJI,' MM1/JG\<7DX&,.5D3)&0O0S4@);BB,CBKZ+!7C/G )VM/=>T)J_6>D@A,31!99Y[E-,N/_]4R;"37#>F)+5.,%GXM9D [I-0 MLN8Q;1)([L+7*&'D>H[0-^7GG)5D.4/(J5H5*M+?-.F,^^"Y9]&PTC5!ZRN4 MQGF(\S!V8E$7%0*DZ 2MCB-X1C93CHRL*1:58:WMVS4P#I48TD+'=V0>[BS5 M!Y,,LBZ\:8HOVOL$-B$)QM5DN*PHCU(X?3RYBD'\F=R%A"XJ:,5\]Q%B<"YDL+II&-L_:H__$N^?73? M1M0=WO>7HS*>G,\[E3[_\F.8X?OQY,NK4I>^:&VZ2%7C$KT7\M+G5;+6T?B2 MP!41,PM&:]2-&;$EM%,Q"WMHHD. ^]7L T[>?0BC=WC^<3P)DR^UL_%P4H5P M&3JI#6EKI"N-WX^&_X/YY6C9 7>QJB%.7Y67HT\XGBX#N=A%VT M<\A>BS(7+1FAT4R9VEG20=#%@=<>%29+4F@=$M^$Y51,P":R[G'K?%?IPS;X M_B@,VUF3NY;\W$<-1RD,\YB=Y Q2$!&4TP@AFP#:*B589EZKUL[D<6ARW\*P MKBS91?I="\-LDE)E[J&PK&BKK$,O:]64*<':H&TI\8;=\9T6ANTB\(V%8;M( MJW-AV(WI?5=;+PV\BX'./PW96EMGVM!BF4Y@K52)%:9];CZL9#MHAV=&CYOF M'GKHWIYQWHHG6ILL3YDVM9C)D.5$8*T9L&)-B9:1!%KO^@^AW=$!T@UVE6[W MAHHWFNL,="FD&SK%O,_D$3$TX%1@4)3C]!>++K5N)7$KH%-DP3XR/VXB]!NL M(LQU .S/PYK\5=,A!XHL(%&L@.!BH@V,1\*/''3)/(3J^;HC%A"MQ7P:M#JH MYHZ=([U2_>2+,:F*RG@Z/)5)Y+][62=<>VZ+,K3-]K!?OJ.ZM2-S;D^==/7%!VC8NWH]+J/ACJTCKQG_9/G M&F.FB$B(]]3\Y@]YR+KX]=Z'*E6[6$P:V>@J-:9BXL85 M8$)5BU)'\)@"T'%>:!TY6GWT+>LX56H/@ED[ZVB56':OX-X:Q%^>E1E.OE7/ M96,1ZZ P3?8@.2(&/ $ER:#5/"EOXXTR[0T1OSL_ZOOF0 =QKBK;-:T6XU(X MKF6$XB)97LX+\%%:,*$FN"F9>?.6]\>M%NO]SN\DT57M^BYU8C^.1W6"QV2> M>S$N:1[TG@RGO^U1-';G,YM4D.V&O%$YV;4/?4,?]HTF+LG:C9S>6,7)22Z! MW.5B9;T>(/_98Y3-6_)N1K/O3K#RY,N[<&E$\-H8B)H3@UEPEZD+WM"?3KB2 M0NL]83V20Y66-=+WS6VA@7@?2H'9VP]A@L\#?=[?Q^,\?3;*OXY'2-O$^ OB M6YQ\&B:1X@0W"@-(Q@R,*@"A&E\"# M4Z[U.)[]$!\K-:4%96ZF)AU.=3W2WG9$O\2^3*W8 GVG#)?]D!\G_^607-F3 MI@T4_?#H2J^XCG2D0 Z"@1(V0U2E3CY20DAK+)FECX"F=^3??+\LW46_K7-X MEE ([R(UQ6<1'HYWM*MF$ZQG0R M&\R'KU;G[>\X?C\)'S\,4SB;GV BQ)Q1Z3E5Q 873:*,,CQ, =R&RS\E&@LUOY!P]+]1O,_4-K?A?A-M1X MJF-.)U\&_WP["-QH94KM2R*QGEP6(I<<)'DFQFHOF;FM-FN*Z<_OQY^>+IYX MJ>'%%]\4_.WS#G>R-Q3\>"^I=6G',?KGLBL$)]-/>Y4AJ=I8)M.Q%C@C9G+' M8O#1^]C:?[_R\=^S/O>59H=8SHJU\?S++0N'JE6&N M364EBQ!*G7*NO,^Y=53[+DPG8)EU$7^'?-55?$MTRWDP6^#K%'N^"]MQHLMM M-7HG71JHXR"[R@VZ(\AZ7 M+;MHH<<]0CBK26.?<'2!O^*RIX 37F*M2B^I#JV1GM?45@[91V>5=<6XUDFB M:X$[-(R2UC83M,#J#8:-'GQ2G,Q> M)3!GIUC<;C3C[9]S(FIN+='6 =TEM#>81_"$?R"D0B?73,*R@8 MZ]"31(9-"@:8X>A+(+,VMF[R=7!J[.X^=F?&+F(_O!69@TV%[%D0Y"&3O\PD M>)EH\Q6HZ1"UWMO=O(:';$7>5RN[&9"[B+3#U<./%]/9^!PG*ZM?NK E>K)E MR7O5-7G=TKD8O"?#*?N ,M/?L?DV<#ND[Y\9/63?X73X=BVS"2#W4BIT$9SA MF0 JITZ-%6_AV_H=U=K4' M'X0E,0CGI,^T)[:>'G0'I-,A1TO9-W1&ZZWN/\+_'4^6>]MT;BTY:Z0,ENA9 M,AUR24@(Q$Z(#J4RCKF\76N".Y).5C_Y!%S-!B)MV*.BHODUG..K<@W3,JZR M!:B&^64;@1P^OVQ?#8U[B;=Q8MDMX)0,T?D"R2HZC&J&JV.U.-URX:VV2=BM MREH?ELYO22P[C,IWD&IK?W )Y=77P@243#"=(B2L(4YN(^UD6@)WEMI MD\/MJCA6'GTRJKN?L'I0=?IX]IU_] M;8 Z)Q%#A.R+ $5J@(C> >=6ZXRQEI2T-K9WA_D #/!?FA3F]U91CU#/34DL M>3](R0ME4JZ"$(ML2Q899!M+,98LT]!ZZ-M&,"?#D#;B/D34_S7Y-?2-\![Y MP$LI3#(,C#.>O,5Y8R'&@:/"DF4BM-UO"J_@.5TVW%?H'>(X*]B6P86!L#DJ MX33$I&L:MN40D--A*#W#R$-RLG6 ;R.8TZ7"O<3=(8-@D;\V'3"3E//6@$F6 M<(AB(!9/QJ#GR&B/2V^7?^(88I_^]/_!U!+ M P04 " !,@*Y8#S9C)[MV "_KP0 %0 &5S;6,M,C R-# S,S%?;&%B M+GAM;-R]>Y,;.9(G^/]^BKC>,YMJLT07$ %$ +T[LY:E1Z]LJTM:*7MZY\K. M:'A*W&:2.213*LVG/R#X)N,!(!"1M;>S74JE(O!S_Y'N< .]__ZWWY[7&1? M]7HS7RW_^0_H3_ /F5[*E9HO/__S'_[V\!;0/_RW?_E/_^F__E\ _*^?/OZ< MO5[)YT>]W&:OUIIOMABOOS'G]U_!-_HS*JWW-1__><_?-EN MG_[\XX_?OGW[TV]BO?C3:OWYQQS"XL?#TW_8/_[;S?/?BOIIQ!C[L?[7XZ.; M>=.#=ECTX__ZZ\^?Y!?]R,%\N=GRI70 F_F?-_4O?UY)OJU9[Y4K:WW"_0T< M'@/N5P#EH$!_^FVC_O O_RG+=G2L5PO]49O,_?FWC^]:(=F/[HD?E_JS^VP_ MZ/5\I3YM^7K[,Q=Z8:6O1]M^?]+__(?-_/%IH0^_^[+6IGG8Q7I],:J3DCDI M4>FD_,]M8#\.$#^1O-M;61,(5ZO[2RH9NSC])9FX#]9#Z/$%/H,9+/+N"_5F MJ:;Z[AZA!HL^OL2IOA:K+5],\+4XP9R)O'"_^-G^M(=Q W4XTQIG[[K/1-6_ M;?52Z9VWO!@ZFZM__H/]:?:\ 9\Y?YJ]6TH[Z6WT:[W[\]WRO9WXUJ^UT>NU MY73.Q7PQWWZ?E4+PG+ *&)AK.U?E!6 DY\ H9@I92(1R-ML>O^LSO01_^W00 MJ\:. _Y# !/;%HM>Z\WJ>2UWZVWX1M3*[\>T M).3%CWJQW1Q^ ]QO:AL-AOWQYLMPOS[HR->RYY/8/_&C7-EXZFD++CX4LUX] M#B-CNQKV/=I]2%;(/V2KM=)K&U,W*'SS[?]7OK8C61=LW=WKU2.?+V>J,KED ME0*:" FPA@B(O"* $J*-0((60H0XD5N(D=W% 3!SB-FO.\S_-\PK-/#B9__# MM VS]$!%@PVZ79=$IML ,*F1MBMX;8X=3\89WKV4Z^>3'<_UYM6S->SE=E8) M3@4L]1TAMFK6"+[;,>9U$Q[U;VVUOX7XHSV M,/M^U%_U\EG_]/U^O;:?OG8;4Z_G&[E8;9[7^L&&]C]9^?\QPQ*K HD*4%64 M "." (=, HIS!@DM*(-!4VD@_LCS[#&6W(MSEXGOV9E$=]E)INS7AWJF8D1"P_S&6%P&NY9(1A(YG%#T2=U0)#77SBEVF#"7M5EO9Q_= ML'_5CT*O9SDN:*D5 E )!#!6 C"A-% <:H&TD$4A?5S1U;@CNYA/6[Z=;[9S MR1?97^TRR!)3'P*$!?777'3[A@$:AME\M'+>1MVB2I>QVE?.#-7^[62DUZ-- M8GPM*AR,JNV?(X/RS49OCT&F,9118QC(BSP'N.(Y8%Q60$%28D:Y4)3-MLWL^&[5.Y>9W&%EO$8.#+XON/ ,N&,U# RR:Y@QXNHF^5/% MTA=C3QL_-ZEU$S,W/A1G1^^6=FJS5'__5[YXK@\;/^J-7G_5FQDV[CBUR($T MN0V)<(]2,VF/LT2[:EW HT\29RG\*WV\:];\29](?U/FS]M+5! MZ3Z0LG&CDL:N:J5B-JC4@@)6< $HL>M;H3@3@H:L;YM 1HXPCY!9C9G]ND,- M7)TVLN-GKD-U#C/48'6#C;1+GT3FV0@QJ6%V*7EMDIW/QAFCLVG[TI?[I7IM M5Y&+U9-;.+S9;;+.5"$+;8@&E#$(L#5&0(V0=HJ%R'#.L=1YB%5VHHULG@?L MC"]5ID[H8>;9S9>?G29C(FWG\N7G5_QI;M=U]V*S77.YG2E%-164@IPS;N=?SH'@A@"="Z1S M;)#!:&"^1POTR&;_ZHM;T[NTA=5!@/TBMK:#Q6EC_\^#LSW:R/6-ML>@+#3Z M;L[X.%*WER3[]2!+POD^G(#Q\C[:@%\Z\Z.'$(_;3;/6OWM:;7ARM6=8R1(5L@2J*.T"7BD-6%E)EV,F4*[L M(K[0(3XG0H:QG<])HNPJ7K[+=E)E.[&R9RM7=A(LS!?%L._GE$;F-,P[C4!G ML),:0$@B;Q4CP:1N:P!%U_YKR%!QCLQ==U#/"[UY;UXY=9?;=;WY\=Y\G&_^ M\=-W]]^WUE^NUJ<38E%R7!))@&05!G911 #E[H ,$F24X*4A*L211<@P]NG9 M0:)L9;(+F=POG#SU,;/[(=M)-OB8/N:#\/-I(],;>'0W*K/![FT -XG<6XP$ MD[JW 11=N[S.-"B0;COF?/"I M]U\:%&O8<&EZ*CKW=O6\W&X^:JGG7YU;_D5O9P:5DA)&0%E "C"%$(C*4/L? M"5DA%6$:!AWW-Z&,?.Q_P,Q.H'<9-S9VR.X7B]4W=QF5#LODV^WFU M"<_);>#.SP@',Q)FBTG)B,G1;5K$ M*;YPON&M_63?+=U%\'I2/F[GR4*6E985R"NW;V&C?,"1H@ *94PA">,*!X7[ M?KACA_AG4F2'P*0.2JU(F9,I.Q,J<+/4EUK/ #X]88%!^SE7C?R,LD$:J'>J M@-P3==H@/(R*F\ [\/44F0[WC\YCO3?'W[Z>?YTKO52;=\M[^W>^WLR4$!4D M2@)60 DP'#L)^'&96W,%]SL]&YD\9YYM,_G7B=+[.]2&,E8@2P,4J6A@_^"Z9P M!-#3G=\1,E#L)231>.-%B%((2"D@FFB 524!%[($S/X_B$NL.2O#+ALUXHSL M:WZ>+W?Q2QV3A]X1:F;&SWLDT#?,1SC RVL]XUSHZ50KV<6=9I2)+^ATJGI[ M$:?[\3CSK*_I_[+:ZLU^LCRDT$N!72"0 U@)"G"AN5V V/4(P@07;CN/%%6( M?;8!C6R@NSH2->XI'.C+Q ]CRL]>4^@?9K!1J@<;;)]>B2RV%692D^U3]MIF M>Y\?9+3+8[;1NZ5I#AF#%=8%*F@.#75T=:;"[DL\ @EH3@B6C1=#>03?< M1 9\0L]V\-D/>P'^&&7';>0%67,"2N)L.H:-6-/N43*M@;>!O829]RC>8NQ] M;X69O-+SV9OE=K[]_G:^T.M7=B'[>;7^/C,\KQC)(8!($H#+P@"6$PZJ0D.[ M@J>:YEYW]5O&']FH=XA9#9D=,/W,N(V0;KM-H&:8H89IZ&V:/7HTV.)&RS]] M7GW]T;ZY,T/[P\GZVL:;Q-QZE#G85]]CD1OQ6SN.VYQ[;^J5\)?5PKZ\>?/O MSQ;HE+(,.:L@KH#,F;1FQBK *@SM?T15J +ABIJ@;7@?U+$WX0\RN(7KN13_ ME.WD\-E7'L"IY_Y[:J8"=]]3D!2^^1ZB=*JM=R_,:3?>0VBXV78/>GF@\ZBS MI&8Y1DQCJ$'IRE]ADAL@&%8@5WG."ET0Q,-R\RZ&G\P=['*^8FU^1T6@<0Z#-G:O]$*1VN!&V*Y;*$AL0IC7'=A5O;++CT?!5YWZKZNU\(_GB MWS1?OUDJ=XXZHQ0*H3$'B)36,I&A@/*R!-9$$3<"$8*A[]*S#61DT]S#9CO< MS %G;]R-50OMOPQM9:A_+9I"[S"SC%(Y:%W:IU/4XK1UT,E6J'UJG2]3>Y^- MFQ_?\/5ROOR\^:#7]9V4#ZO%7'X_G1C"BI5$(@5TR7*WX9L#7BH,,.;W^29D(S +:0]\$G]NVP' MGOVZ_W.4(UA/A1--L'UHDTZVGJI?3[R^KPW+_[XZ=N1:,]?1!X@\M]-P455 M(!LJ2PFU+GB1%V50M=9FF)%M_9CT_+1#C=Y(S6+UYE+O4SKE>KY:'(IUE8>W1KDM!7D .,+0K56&,!H23 MO**"R\+OGGGS\&.O5/=XF04,+"G50D>W"0Y7,G!)FEP_M>_O5F?RCJCG!-\!H;%KKW:?VYY:Q)_T2WQP4_T/!5=K.)TU]+=L;3!@?L% M_ZS1K"BPH 7'@/&" :P)!$+)$DB+=7>(3>G") MB7;._&;U5$P$+J[C2(@I#-&K7;H*$.U04Y=ZZ%6ZH:9#_SMQAMV>.B2%D?7T M7S)- 3:E! SEQD8#G*)2<8U7;L!>\)92F^+=5Y):WTI1C.2P181S*7*D M() 0V:D:41N*ZX("DD.CN;8V7P:=+C>BC&S>5\4[(J\U-//C9\N#M0XSX6"% M!Y8M&6?_K!GC!8N8].R>=3^<;A9^_[QUW=^5G?!G!!J[*#845-#MIN78 ([L M2EEJ(R&CO%0PZ$"K!V^R>?ARZCF38/A$?$Y?_$P<24J:J=B'CR1S<8.6(T[& MYV@O/ALWJ.XS'3>]%IGKY<;[B6^T^LMJI3;W2V5#??WXM%A]U_J37G^=2[UY M6//EADNW>/_I^V%G[OZW^69&)@;E<;%$@P!F7M.0(=#IJ,O_A[GPC+,D"J=*3ALFS+1Y;$F(NTEY2S-J MG"O[66\V6A^+7?_LBE\?.YU_X-_=P" RQ M!-P(#&2N.+%AC)\[S6(^FM'5V]973 MVS)UN_RC&5=&04&L?^$$NN6*.:F? MOO_-!DAG;3GN;2STM>Y',ZLXSG/.&*B(%@"3@@"ABP*02AC-JY(5*.S,TAMZ MY$-,ET5<5TT\B.(JG/_@I,GFRS^>3<@GB0+/-OU)]CSL'(6ZP-//A*R%GXD& M$Y#JD-0?>-I3TV!";HY1PT<(2(XQPN:".FFYINGY!,X3#S#]$UJ*U[ MKRX#FKRWCSU9R_=>]40@)(00UC2B/!@W*7;B%&-NOWZ\]\.?^/71+MKH'L M1J[G3X=&13\];RQ[FUU3S>-?7JV6EE\G7F#\?LN@9YP^B)? >+S&?U6/;GA:X+P"_5_>-JO=U_XV=* M&$-R7 !="F.7XF4%:"D@H**D&N6P,"BP(G(_Z,@6?2Y";;7\##NT6K('A7X& MG)J8,),^1[_+CO@U/?<^]$345/;7-UF!90_(B:LM^Y-P6WHYX-U$UX5.T2?5 M&E&3*Z")RTDVV JI0&:$5*5JC*P)(,N"TT5MM_>DAD0L7<0YN<%TM 09ONQ M# R_*#16C-X!]+*7A'JC5DO+J]KQY!26J-%!2@*6+KVBQ5@.2N MT-! B(PT&(5=(.A!'-FD]_C9F0"A]PCZ*/,SYZ1$A)GU@8-1S]"]]4MVW: / M;^*K!Y[JWUY#\'TQ_ #KK_Q_K]:OGC?;U:.UG/IX!N:<:<01P!RZW!F* :\8 M!E) 1G.7J^=W0[]Y^+$#[3U6\'%5 Q']YU3#U L,H#TU"SJ<:E=@P*E4PZ"3 M'4>U*W1^#M7Q5'RKKW?+S79=ERQYM[3?7+W9?N1;71]YJ=,=_%FI!48X+P$Q MPA6OX@HP3JR-%]>V!C$A>Z(I>(LJMU8F/H).Y!Y D_>E"R,D*8^98$C1&>Y[2H#N$[8;ZTF M=D6_G2^?Y\O/IXW[^Z]\OG K@H?5J]7CXVI9WQC8UX3_B6_F?GY^A>X%,)\X*3?B QN7DIZ4N7N)=$JJFS^E)2V9#R MEW3XV&2DW>6'N=[LKXP?^[]@;KC$A@")<@$P-A40E:8 DHK(0L/*Z+!;4*U0 MHR^S=B6U%RI]8W![K+?S)5_*.5]\6&WFYYWK9Q73IBHI MPPO=\D@0JZW 7[6Z,A44&= MY'U 1[;IB[Y/1R&R@Q0I6F.U\^EG\ZE9"K/^! 0-:8O5JW'ZKECMD"_5%*N7 MA(Z>6/WO1M1#_LO*1A>U'NO3MSEG4'-**:@*E\_$J0&4H,K=032%PKQ QFM= MU8HPLBNH(;,]9K#AM_/2;>5)M TSZ;$4#2B2/%3AN#K)P8J'E4KN4JJS6G+C MB],53.Z2^Z)F#*2I#?>#K]^O=MM&_\L6S/C18F$'#I&9* D64]2VE=)%' M97\2!HM22%2&==SS@QW9X=S4:WSBZ^RK$V!(>:A6#OVBC?3,A#FGFV)15@3[ MC3IL"M=2>#2(&5@WJD_O4?J)V[_*0 _9 M0 HI."O95K\4J+IRK44*^EN=8_ALCUEQ=/6FW MGK #;.?NV_ET'=+]W_!/$*)39/=?LOP.0NC^=UN>^[^<_FV^V3S;4=PED56: MLJ$[[B6QJW B#2B%._R$1 !.1 Z$A"45.2)E$73X.9#Y%-55:]"[[%W-V'"& M8L+D8+T'QL1^*@^,@2^4&B7@W2&\8'1[H6)W*'OY:&S"U&[ 8V[C>8JCM7\T MXR6G!@D(#"X9P(QQ&] ZUZBJ A%H."Z#=MA[$4=/C]I_8\B)2(E"=/19-E.O7A39S@Y*G^;5Z3[XMQSN#=TJS6CWQ7I?25 M72)_7JV_OS^KO)15%78QJ05G9'=P M['V]3X4[:X&]%V!8*_ #6U!RRB260/&2V*5G20&E!0?*"(1T97(D6-C2,P%? M4(80&1'TT^H9""['O)Z[XJ9+M?E%;]^;!_[;3%0%SZFKD9(;MZM9N9(I7-@@B"@E M%*0BK)22%^K(KN%,ANRT 7B4XBYS%PA6)K.2!%=2\:#4ST4D)RK,3:3@**;6 MBK_.Z&!.78'%GX:&8BP!+R)&E6^7&JK)T MAO2R999N5>ZML]3P2N19\KZORL/J7O[[\WQM@XVM_1XX)W*_V>CM9H8)TI(I M 7C![/( *0FXA@4P#$M8Y)6Q"X394G]V"4D/ 8>WVVV^V[?P/L? ^[% M<#D0>T&RDR393I3 ]!>2OWL/@U#<8>C@U@)/R/UU335B6DOWK3GI[[JWYRF M>K\8<1]AOQWQ9&W*[4:$0X$H]=H<[0*9 M9F47M[8ZD<<$TA@>IQ-Q6B* B[K="C6^>%A;9W MI[NST"/]Q;6%OF=39+;MVN;N$G)FI%+4>AP.((,*8%X0&Y 8"$I<45-2HLWP M=M8[J*ESK?:=FX?G6EWPY1EC)&$A,+B((R!)U^I+W49L6+T'>O%>U9<*^[2I MOGHC05V9&6(E1I@S4+IC0DR1:Z)H,$ 4J4)H0NL&:9'5848V5[?;]<.B/@Z< MUY@#"K3$E%D9SPYOBJ6,5.DDL;5=COUR54?:;*KYH5050&:D$*IR50)R=_L$ M&X(!+:3K=5 @)"#DN80AEW)N(8(,*O92CKRM^S&T[$=TN8_Q3*RIS,>8M3T2 MFUH#P O7\F@SNHXGPRQ/Z?GLS7([WWY_\ZC7GVV(^Y?UZMOVRZO5XQ-??I^5 MB&H)%0<5K>Q45FH$A"ZUNSDK.3DV- O?',JE8TTJZB-+5WO+I?C*RD04@E *)5$HX)5.BCH[(8;V6!KM, ) MLIL>S\DRF=*!$V>->W?6+'<'/5+?+C\U4\VJW6#3SK!>BM_,MGYOQ2:L[:J= M[KL0'(([@W'I>G@!(HL2X()QP(B=@BD5R.0:F4J8L"RU)IB1S?A8E/?8\:(O M* RAR,^DARL>9LKA.D^P&.'S>_N?WKW M\[N'=V\^9?>_O,X^_??[CV_^^_N?7[_Y^.F?LC?_\V_O'OXM>MNIF]'@S:AD M/$5O4=65$7:X8]>B]5(V_2Y6-^Q+[6UYD=&QX^7W?D0*R*&QR<.WU5_UH]#K MF3MEY87U#D36R1]VAJ>PTJ#4G)XZ:QSDN$NVTD1E1CNP:5?#)&6H3#?DX"<@?V&NO0=I<]0(^ + M]A?J(J"[KU#GFZFJ2!X#8B.EJHI2 9IS9D.'P@!AD $5)KG298$0#MK >[%% MQ7F;CWTYR<"6%8.7#2^Q4.BN'#A2S?J)E@B_ET5!^#(@>>#??N5$+^671[[^ MQ^O5(Y\O9[*2I9+< "E*=Q(N)& \1X :^TN5ZSQ'044R^@#'7AS<7G@Z"I#] MNA-A\-6O*PK]C#TE,8$KBT&<)+@+UJSH:!?"KN!>^%98L_+]5\-:W@O/@WF] M7YZ]G6\D7^QBA+?V=YM9 0N%J797/>TTCA6D@ I%@%T?"02A*DK(?;-@6E'& MCNOWN-D.^!"MUM#^&3#M''4;=S+- ^/U&*6# M^A\>>/I6'\K,"BQ$:16QD;0[%">T )PHN^(N#"Z(Y%R*H,7VY?#3G;8-.5W; M,>$WE<;K%V9FWJK%GYY=:)#ZU&PW^,N@KTP\V_)7KO+CF+=N96S MT';Q/%=WV;]IOL[>+Q.67AK*R8BI;EYBO'@27 A9/NEQ0>-%;LX?:KWL\WWN M'U?/R^VQ51'.*XFT@C92EQ3@0FG7R,4 (A2G"N:JT$5$'8=N5"\;&US$X2C# M*<=L)X9'4Z,8*CWWY82\E4&_'=8--NPGLI?K,![_=6Y.:[ M_*+5\T*_-]>E).MNU/=+M2\I^5!WK3ZF@C-$K N0)="\0JYMCP!"0060T@PI M3'(>5NDM4HZQM^WW4KDXIJG2:2U;G0*SER[[M98O\\DX3_IY>)X!C,]RF-\9 ME>#PLX-A]*0Z6(B48MI3AV%4W1Q)#!PN]KQBLWUOZJ1)EP^EUU_G4F\^K19J M5JF<4G??'%** ;:+,\!A"0%34*"RT(PIK]W*?JC1SR@V=>G%&KJVI -XYM!# M3R=:"?,]ETA!0^B)1!P#$6<1? MZK4[Z."?K6-Y?VK?M2M:\=Z\6CT^KI;UDW][6BUWPVQ<_IJ@%4*8(\#JW1I- M-. %K0 RB*FRS$5NO*[LCB/>^,>:#=5<#VU@CS)G[TUV)O6A)(O][4[PW1N9 M$ST[R1Z29)C\8^UV4B__804?M?[_]',*229]R<\K,AGU13ZWP.S6L6CMSHY- MCCIA=NU8C%UFYXZ&$A="?]0+MP'W@:^WWQ_6?+GATMG";H_"XI[];H8)I(+2 M$E!"$<"%H(!6G )8=V[I?;N7([ O.O M>M_<:ZXW;WZ3BV>EU5NKG*L7\KR;F!LV%;XW#U!GT&/&=4&Q IQA"+#0'+"R M%(!K1 LN"RA9T$GMB+*.[-;.@;,3X$E%\[Z"D@Q\VK<6D/;ZVQS(K2*,&+'"#*H-NAR0$K8 4*B2E7 MQC M@SJ0A0HP?AY--4[&S)%!/Z\Y)B]AKC J0\:)-'V*S#49$Z?&'.%_ERDQ MU^3$IL+M^H]8XW=Q/,"_9Q/U&V9[> M[;?/QYKLTVHSWVYV#4M^L;+OJYF5DE3(U3@6T+45UM3EJPD-."[+LF#($"C" M3+89:'23W<'NF^;<92?D4)-M(K'VJRX9I'F&RW6LE,M@5F8I/M5O;6 M9'N>C\PSFW]>SLU<\N7V7DJW'V2G]@^KQ5S.SRN,EM)H214#18DJ@$O.@' U MI7!I(,2*5.3#_*]D7NG<;TQ"- FW(3YF@J]9-DD?=KKX8:+(+U4WBG]^A M;OSWV&X>=KEJ/YW-A]5FRQ?_S_RI_G*4 D-IR@I4I;01JLXE$!(+8#"OL)&8 M5*8*:^;1!#.RF>P;6NR1[[(==F;! ^VF@ZA^*TJC?IA-Q6H>T7:K>-/#J?CDCW_:CERH:>_W'<5WKXPK=_YYMWR]TYUM_GVR_SY8?U M?+7>55&XVH::(2Y=D@7K;> M 69;*V#VC6]<<[I:Q.Q;+6/VY(1TO4Y=?0]UV#W=OQ:0$#KX ^KV'9/3'N9B M_H]D/"#C=DKFXQ)LQ_\$PI)I4S'6F3L[&&2Z5-E4?%QDQB8;-&Q&VJRWLP_K ME7J6V_?K_866.BFI+"HH2U'8^<6=14"E@*AR#+0HGT#;,74K M['TNMEPLWVHW)^Q*5[J$I=72I034WZY<5]:\H 80&@.PP,9EFT- .,*":4BY M";JWV8DV]KG! ?ONT&'A!!^5@]E-G>>102I" M=MH01$%([U4"Q9[=@NK(G+ MQWJH?5M!UN>EV')U,8,R%Y"1$G"AH)U<[5J. MREP#(4E%A&OC: );1_6#CFSM!Q&R'PY"N.[AV5Z.[$R0T*)W'GSZV7YJEL)< M0 *"(DKG^6N!^3$9?;\2;@MOA?P;F1 \&6UWC[H]6.=*7A($)P57. * MXPKD'.< 8TT!EP99CZ$19\8Z#[_XNQMF[!# @0+[XN,NV34[X 9._,T4><[X M@Q4/L_.=S@\!.H?/]9TJI9KDFT&FG=T[%;V9UKN?'EH->I>PZ^H<(U)09;A= M&T/JSO"ME7*I2CM]4Z%)A6P 7\35@CYBC&R8UT61]\GF ^I G]CI/SE)H'.8 M34:H.Z "](U"">H_G\9\H>K/-TJUUWZ^?31\3^J3_NP&_(M>?5[SIR]S.^R^ M@P!37,F<5$!!=PT;%G:)K!$$%<=8Y@4CFF/?C:E6E)'-[QPPL--"-SG]NU-) M5 ZSOC!M@W:G>K49L$75/O9D^U2]ZIUO5O4_''FW;;7\[&95UTGIKWR[OS3W M43_M)]CWYL-ZOI3S)[YXMW2V__!M->,P5P*:"E!:*#M%P@JP(J<@9T*Y HN2 MP;#NJA%"C&S$]LM2!MYQBV'2+\H=FY\PBW?2[$)@)\]=MI?H^_Y6VT.*+H8I M-$]UL2U&A&DOMPT@Z>:"VY"Q8I.9/CWRQ>*GY\U\J5T3"(&9R8T""C$"L%T* M UJ5!!1,$53*"FGL=;>M9?QITI=JR.R &9JT=$E(?\P]4,W [>X@#2.2DQKU M&)"5=#G>Q.E(CK-]LLOE^6HY7VZ_:/-L#5DOW,+Y M8,@C:I@BCMMM.QB K=J'Y9C@)R>4;@*BYE)PUG86DY@Y-*'OQF[<[^H[:W4H"/O+:JD?GQ:K[UH?:L.>U8SZ]/STM)CK]:&9 M)")("BA 0:';2=0YX(I3("7%E39(5SBH3M,P<<8^"-B#1;:5'$BU[T'!5 0& M'BAXZPMYHBPE M+24#!CKG9# !C!(*[=[?)Z\)%=30V7U7C9#M!_:77#0_^Z:HAV MH9LJWHH%K:C:-(A:3MT,-ME:JDV-\X54ZS,)M+K[?#8*E<-N*36YG\HK>SDA"&A!+ ZDT 9EB[&5@ C:&B7!70T*!2(EU@(\_( M!^@Z1UT?<.^RI0ZL!]1)F)\G2$5#F Z:!C MT3:@D2UZ\-S>2I"?%:=0.\R"&S0>H2Y(GUZI:A"WP4Q;0+A'V9OJOWW/CY[> M\%&[=;8=^KTY93K-H*!E)70)"EK?V4'6IG-2@E)@)+&0AJF@3-VA HV?]K!K MD2KR?KYB2SM %?5N6Q,<+=D\YBR^2-=')RO09%,WB_%ZS*3K)&Y!9 MT3WNP*N)[\TKOOGR=K'ZMKD7F^V:R^T,E0CE+M%"YH8"7-6]M)4!"@KK^PS* M$?8J.N$#-O9AQ ':69<#SVKT[-<#?NR]Q";>/,\>$K$1>+(03T3\_<0.#5-? M3VR">IG;B1U*MUY.['HG)=:\$4>V MM*Z&%;&5O?M9]#/.I-R$V>M 6H*-V%O51';=CS>IJ7NK?VW]_B\.+O'[KRN' M\W'^^8O+GF25+(FT 3.GW+H!5 "*J0%2$Z)(47%- ENP-^*,;/SGA7#OLAUP MMD..+OI[09.?G2=0/LRZ8_0>4@:X2:OTQ8 O4%ZJ)'"3JAV%@1L?CS/571[U MW^=*OUN:U?JQSO'_&8M9,D7KYXWV]6C7O\\7^IW-AC?S&C.&66$ M HU+88W9_H=6W$[L"I-"XYQ1$;3ZC99D9'/?BY"Y#S [")$=I,A^=7)DM2"! M:^1XZOT;B#,C986UL.XJS^TZA.<*"!>/5*;4B$O-4%@CV%N(D9V1 \SF1\2[S!42 M">T@=$.+GS\9IFR8HZCU?'>FYT.7GA']@MI42=8IZ 9@XAY!;0K>=@=J?3*% MV?W"'_4^Y3Q'-L(7N0!2X@)@A!%@4!L M%?G"I!J?65*Q2JD"D #G*[;I>NU8^%3> V?E4 M&XU@KKUVS0=+,OK*_RA;=A+N[J*$SD% _](EP[CO]A23,AJZG>!/9O9K+566 MM'E8,FX&%%09AC]9T94D-)T79DDS8%R \HO>NE/$#^O55[LF43]]_]M&JW<6 M?UZ8;7E"[^0 MQ1\ZR),=!? V/BO([G3[($HFOF<_.&GLZN*/V5&@["116&030+)?K#,.=6$N M*R5KP2%1. &)@J0 X$G#IG!"K@.IB!'B#T3FVSIAZ7ZIG/.SH^NE:ZOXVCJ] MQ6KSO#Z/IQ2IB&02<$@@P*HD0"B#09[#BAE-#$3!#1']X2OUEK-MV^YK ][ZY!J9E2.)*HH@"6B '-7L96Y_T"N6$Y0:0JORI&]2",[ ME?K@P&7LU)-VG6ZKLYU:<:=.:^]2] MR5?N?2'.A#_J+;=#JS=\O;2>8K._&R0JK*O8&U=M:2_&/]5U M"7P/,KQY] VAT[$3&DE?4O*FFX2( -I/LV1Q= _Y'&KS<; MK5NRH@]G$5?G;CFJ8%$A8N=T3FSDK7+ 6(X!PP7$B!:22Q6T<@Z78>PU=2W1 M7=:5U1]VVCF$;T^_,2Z+@:[$@\#M*A.N'])]/M1.G,M9 4N#=*$ 0P5W'6(@8)PI (O"8&U$7I9!-R\: M44;V1\=E\@\_KS:;/V86.ZO![[(:/C#[NI$G/R\S6/LP/W)4W%OC\!SI+HU2 MY3\W8DR;V]REYDW>37@T/5@98 ;):@B'W(Z^I\S/<9(2$&? 0+@9> MBFS1<90+D==8+W@9LD7M[HN0;2\EN7Y0GQ^ADA:HS"M AC:WU8Z/O]T]N8W%_;J0K0F#)#" YPP"7F -! M7,N7@BENJ#$">O54:D48.V*N-T>R'6+DD=HM*WXF.4C7P/@X3,V(.CTMJB0K MSG,]_L05>5K4NRW#T_;@H)*@=OK]L%K,7>K+L0X-1D9;^Y( %4H K*@S.DY! MP3 JAJSV-Z+U?/V+RL+5!_7K9>G;=R"<$$4 MSH&L%'7':!(PF".@A62&E%7!>%C-/&_HL7?+YW864FX>.D_-K(G^[K63.Y19 MSVEY%+X" ^B3#%DM1,:=%%DM1K:78Z2TUG#]4TWR_L#3SO[!A-R$!>$CQ.; MU34#-C8ZH+(L,02F)-:)*%@!H5D.\@)Q!0NCI#(A9_&'@4<^9M3L"NO_*YXOZ[&QU5AQIGQCP M>KYXWFHU4XQRC8T"9<'A+D.68BKL MALM_D0-%+I+VV\;OS;V-E90;<_Y5?])R7]/\S6]R\:RT2''%<8\A*4+OT(&PJ!R%$%BDJ9"E%4%"+H]DYZ$2<\C3@7.3O)G!V$ MWA4=.Q/;O71[M!Z2?#/5Y^RYM'O13R_^#.4%/KCP9>-HW*9:7J87<-IEZ&@$ MWRQ7QT,*K[OS8;U2S[*^ WIH9KNO &4$SGF%73D=+@ F6@&."@*8D06F6.+" MKV1V)\K([GF/6^=1[X$#"V5U<]3M%Y-I'N;:HI0.*EK3J]2 @C3M8T]6;*97 MO?-",OT/AQFEWCQ*&QI^X\>]\J?U:FE_E'4#BLU:N^LGB^]"0:@:V^G1II[238O!'E!5KV=\4!.=F[:#>)\,(9%@6H_ M'#OL)!YZH,X'WSUTF-B+/GRC7ZTVVZO+):I@!:$VSH+,7="51 F20XJQ',A M)*UT'E2:M 5G["/(77*IPQV\BFUCRF\IFD#_,-<:J7K$[9E.Q9+=D&E&F?@6 M3*>JMS==NA^/,]C;EN/OEE^M8UBM7>4X798"YK"R=BH)P)1H0+FJ "D$-SE& M2NMJMM2?766)!W_K[03U^@ZSW7?X!MK[^WP0(?OA(,0?L_DR.Y,CS)R[>?0S MZN&T1)GV "J"S=M+Q41&WHTUJ:E[J7UM\'XOA9F]TO-]NX![I>QW8O/*_OA^ M_;#ZMIQA4PJ!"@$H8AI@P@R@!=0@+Y$HH8 E\BNBT8$Q\OR\0\WVL':V8D M)NFAU,$0?1Y-6B'7V?=F>U$7\[B(9$2+DJ@<6"-5KK@_!4P@ 0PJ45%IP@T/ MBJ##11C9>,]ZP=;G$4=)SHJ]_CE)C=PNFOUFZG')"]WTZ*R9VT3C*/G!\9R, M6T:W2X#?0SE=#X(\R^KZC!1YD6#80<[]H]N"F(F<%D17.<@5J0 N.064E17@ M')6ER3DC/*BB1Q*I1O9JB[[*=M('W&9)\;'XNQ5-%U=Q':HJ4LC]BK=4!VQ_YWP+9G7^X.Y__G,U]9F%M\_ MZJ?5>CN#HF"&%7:I5U8D:1YU'E M4,4##RI/<'?9"7"4^J*W^J0O*GJ&\5*51&_5["@?VO!P[,FD_<[JS?;-;T]Z MN=$S WDE"E,!;4A=NRL' AH$)%:R)%1RJ5746>0%S%2GCSO03.]00\\:+YGQ M/5T,5S3R/'&OW)L>Y2).#QM52'9>>#GZQ">$C:K=G@DV/Q8?\.,?=@[1 M.C+N]%:;@&FO9+4JN#-E:+V)V,K7=3=D#[8=>3WVJ*Y=";=V-6P M)!Q)B1 H)''C" @67D+?^2)*V $4W);)"-\B#@'\[>-?F_>;+;S1PNX MF9E2&(YH#AB4$&!3ED"0' *IJ37/O7-/KN,B4D M)W3?:1@O"9+96W0=+:']&N^%D]I;U.]/;&][,;X9_+[ 3)U_L;E_WGY9K>?_ MH=6L()4A5"H@*F)L,$\K($H* 4&&5-C^8\Z#.[^W8(WL!O;%DC8.^F[76&Z3 M\2-Z>*/W-LK\##\1$6$F?UXPZFZ7H;7)[OLYB&K6WJ-=PL[L;4B3MV'O4;FI MYWK?*[&S_.[FR_>/_-M?;=2PGO/%9D:D*?,\9X"1@@'LZE=3P>M*UK*PBW9> MJJ#R\8THH\_F>\R[S*)F1]B[["_KU2;X%EH33;XS]T#E0V?K.+TC9ND.O9+- MS$T8$\_&'6K>SL!=#T>F4:R6GUV6@=ND>[!#[$O(8"RK0B@*8%42@'%.@2A* M#8S,H5"84L:#;+099F0CO6S$5TJ:QI\9)/<7WUT>-D.,/2&YQD/W=8W5+LPFPM0+.(FYZT& ZYP MG@TV\=W-6S5N+VTV///2A47KC12<4(6 T*@'F1 "A& >T*%51&(B$0B]3 M5'3B]F9IZU*^6!71@-VQE_NHPGS02WQ*+U@R=(2]NL3"_1]:*K1K%W DE(AJ MA)^>GYX6<[U^L)^]WO=@(]Q(B"D&3&(&,#%NGU!#4&&B"D--I;57+X@V@+'= M[!XQJR$#RMLU<='MVU)H&.B=+I0+;+O7JF5 E;Z!VL:5X?/\2,-JZW5HTED\ MK^F]Z:KC=4A]4?ZNZ[FX4/#]]HL;CB\?]./3:LW7W]\]/O'YVGVN MV+W>?-1R]7GI-C[?+0_^ZA7?ZL]U\9[W9G=5OR[$M]\ 8#D1$FH-\D(J&Q7: MT% H:']B'$K"*\944*GYT20=V7/5,+9MJ4?5EL_3#G:KO'_CW'=*SOC?6H_Z;YNNW-E2>D9)72FOI+D/9 M&!4)##C)*>!2<<3+DAH6E%06)<7(T\&#_< T=X"AY55C&/7!?F@ZWMIB"%!*1@[*HD'4%6 *.C !5H759 M( QA6-G*;KBQUZ8=,VS4-;<>\CR7ALDH"5S?#6 C?&7FI62JY54WV+1K)"_% M;Q8Z?F_%9_H\[/,2_LJW^_WZC_II'VZ\-_LB7GSQ;NEBCGK_;0:Y%@A)#(HJ MSP$FG -6Y0I(A3FC5!B%PI8K46*,["+L=ZD*3PB*8-,S.AB=H\"8X2JA:"^3 M]1CU>B31UG8:[1/F'44(,7E>4CQ137E+ T:+KH_X5:^W<['0'^P'IZVC4W4F M\OYX1Q,L*,0Y,$4) =;* ):7!$ NJ,XU+B4.VE_OP1O9S9RA9T?X71Y\X'F8 M+W]^_B8A*V&.91 A,?42?=1,5S*Q$VWJJHD^JC<43O1Z+3:I\=,7O5BX- &^ M_#ZCG)6DRB6 PNV.FKP 7$-I%QW2V/_CM!3>)6QNAY\FL;%&S/:0H:F-%VQT M6^YP'<,,-4B]B 3')BT&I#A>##=QDF.3*K=ICHU/C7L,<8I"1:Y+F1L):*%* M@&%I+8U:]?;>4JT?MCFQLDZV.%LYC>_",\H'ZN%>AY[JS U)2*"4HR!DFKEJW H)9KR]H45 F*#0Y#^N3%B; R'[<->,^R9-= M"A3:'2V06C^O.R9A81ZUDZMI*CW%DI&L)5H@_,0-T>+(N6V'%CE.VMJ1Q^BD M8@89@4J0%[GKVB%S0!7%H."\,H94A*B@])<^P)%=3D<91(^H(HY"/U>3DI@P MUS*,DV35($>*FGKA?A=U'_NB&>_WXMS V_EROK5KX:\N -K:+X?;V[ZWJ^7M MQD9,,TZ,II I( MIUYR8"<"U0D BK2NL2L-D4-V+;KB17< .'-3HV0D^V^'? MN25*F /H(<_/_--1$F;\0]@(-GT_)1,9?@_8I&;OI_BUT7N^%5D(8'^?[)73 M8+E=UQ?X/LXWAS/2RA",><6!T,+=[&<:<&YRD%>5882BJH1!Q>5Z\$8V^N.% MPPOXS.%'GC'W\>=G]@E9";/[082$7V_W4S/5??4>M&DOH/NI?G.CW/.U5(5F MZ]M$IZWQ4P^D&3,%+*M"NTK/!F!158 5>0&(IERY30BARF$E9UNQ1W8*+456 M=W?]S@Z$8CN-A;#LYRY&XB[,=22D+4&9VEX"1BM8VX[\PJ5K>RGI+V+;/T2< MXW%I=.^6=LU2%PWXH-?SE9K+_=G;,9-N)ADLE?T?,%KF-OC(*6 *2J UDKDA ME10TR.?XP8[L;OZZ6FZ_++YG3P>\C"_=*<>^P]@AHS#,QW@2ZN=>TM,4YED< M?G82X"X[B)#M9;"_.4B1SJ>$:9W(G7B"3NI)PHBX=B*!;T=FQO+-%_>_-__^ M//_*%\Y>/EKC6<_E5BOW#_=+=?F+LR=GT 8RG!8(J%()&\H(X[I1,> *:2N6 M<\BEGCW5DG_:\O76S[D,DBG$F*XE\T\HM9AWNV/6,^B[["35[A^=/[K^W<4+ M/^G/\Z6[0>[NRNT^XL#,W$&?'X>2(=?$#XG*QJ/4!J4"%12452F4QJQ4E=I_ M?F^6ZG?YZ1WDFOZSL\@O\ZD9A9$IE?VL.'>%.>W:@4%K?X4LN3!:5 J*D.[# MDWUB$5V*$WU:4WX\?J'!9*2'10R>?-]%$QZ>3I^"J%3)]H-DF385/P5M-XGZ M20:=(/_XVVJFB&257=@ G4,.<)F[0L;(KGMDSCC4N3$BZ')Q(/[XN<=DQ-QC MRY^?&QN1E3#'%9=W_&WU0EG')RI>(N?8HO]^,XY/U S*-SX;)C+;>-]WZ*.6 MVOHPL=!U\XE93DH!2V7=2575Q?@*( 22H!0%MBX'(H154,)P,\[8.;^'SEI-7FG/XRDJC[Q:;;8S94B))"R!U,K9K52 0F8# JVU$A*:"@5E M7MU"C&RR-U.;PQQ24Z2FQ<]>ARD;9JIA>@ZL%G*NRB@50FJ %ZP*E9,@&XP99 X0Y JPP D!KEP7) M"8,R#S' +K#I9\^+DJ79F]^>]-(=Z7W47^WP?/'',$/M)%)!PU6%($"4E,#5 M30.,\@K '),<:B0+6,R6^K/+<'N8D$^VX_,&^?\06OT\8:IO78+P)9*98(_I MHW(BW]D)-:D7]5'ZVI]ZO1-[]]%^U'9DOG#KUW?+5_QION6+62&Q*6G.@3:H M E@J!&A>5D C9+C)"U:5@=<7&W'&]J='U.S)PH+Y,I,[X- +A2Y*ANL> M:-4GM1VBR_IXU:-VQ$6\3J62W:5K1IGX.ERGJK9Z>#%<^ M\%RDH9GP7?:N6_'AG80OU1JKB_ >Y64["%^JVML]^.KQX<4*9U1!KDTE@224 M %P5&#""=Y1Z1F@8<9%Y40QZEYF/K\X7SH%ZM/ MV'IRT/1,Y#T/O;#_^ODO>JG7?'&_5/?J<;Z<;^J4\J]ZOPZ;,8&DT+D$!MEH M'&-" !5VSB=Y#EFI3*Z8"+KNX04[LK']E:__H=U^T5WV>2=(G0? +T0)O/;A M1Z>?=:8G*J MCOS6?M5F$F,.>:4 U95\6R^)&W#-K9L;/ M>:30-\P_G%2=IG)-GX;IKH@UPTQ]'ZQ3V8;+7]W/QYKK5^L)5NOO?U^M__%N M^6&]DGJSF7&<:US8M;J"%048<0IX1230)2T)@04F15!60S/,Z*:Z![W+'*S; M!]\#VU!ZW96($T*5K_4.)2#4=F-UCS#;+M62&6TCR,0FVZ7HK<%V/IWB8N9' MK?3CDSMLV%T7V7?QRB5"Q @#:%FZ'&58 H$Q!I622#!<:DB##N]\0$3'J9^.I>0JS^"04#;R5V:WS*'7ND&M M<@9+04E.0I*8$I';^+\T&EY M]7.2Z=D*P.GU2M;AUH-]=48E MK*C,(4"DH"Y# P%:<0T@ASC7&AI$O5S%]*E2U!KIB;!HYHR70PT63NF)O'/&S$U_GOLGL*N-YI+\5X^ZUD.C8T!& 2$ M0AN@E 4!HM(YD!Q6C!LM11&48W U_N@[!?M&?'NXT-V 2RY*A6694PFT@-8W M$"T YP4'@DK*A%%,$19>BF8 (]'%9=+R@BAC6+("&%UQ@'%E ,7V*X-I51!7 M_:40,+3$RV!6@HNVI.7$=Y,H6LO0_2!/Y2+V?!I52+:]]^*KK0G6;62$5DNXT->?<&F!)(*"BE !*I0IB*J1%4-7O M0=*,G\X16I]B$+=^)CT98V$.H">]X_WRI=I>MU'P$ED>-[+\?K,]VF@;E/71 M.FAD[Z355F\^\.]N??:P^HDO_['9%]H6E.40V] )YJ("N,@%8% 60!68:U1R MA:N@0N6M2".[((>;[7$#FQ^U:FS"6S=LMS@(5Q=<7M6J@H M,:LXSW--BA"[[44JB0R_'V]2!^"M M_K4C\'\Q?%?T3=W<^UXI^SW9[/_X>;[4:%8A5-HU10&$<15Y62X!-9H#2B16 M')48":^,DDZ4D0U_AYOM$>\./V0.NS,8#N"I?S\UB?9AIAVM>-!^:Z]B49NO M[:-.MA/;J]CYMFS_P[%F^5%_KF^-++>_\$<]HSG4I$[+1$0!C(@&G!D#RJ*J M,*4JY]1KD[8-8!IC/&%F#C34!*\X\;6^>$VC#,]7R0AS:]9D@*5=#3BQD36K M;+[&'N.[N&\/DX3OEVGSQDN""Z$M+$X"T3L^.I]D3]]O:@OZM6>Y=$A';9NWH[,E?$4?>W.KET,]; MI&0FS$\,)"4\.]E3TU1YR7UPTV8D>RI_DXOL^UY\%O*'0_;::Q=0:Z,TI9@ MPQEVE[,8$(I20!G62E E*^2]L]>(,+*I'W-Y]W<.74,S!QN>HGS)2__NWF!M MP\PW6-&H_.5&908E,E^..'E&2\:"-A+BQ!A[;A[S5E$<[YXS]^AL!L[G M041FO]9RC;,[.8R:T?K&> GQPFUE0HCJ[SH3-%KLV>"K.@]@\6ZI]&__0W^? M46,X,H(#J%V3.H8EX 6$=BU!4%%P0G+C57BU%6&:T\$]:%:C9A8V]'SPFA?? M \(!VD:=$/HK&G%&V*+,@$/"ZQ$G/B5L4>CVF+#MP=@J"E?Y-J_G&[E8;9[7 M9Q-7*73!8%F"DKG6QSDW-G2 !2@+#"7)$60HJ/2*#^C(QMB0#G82PDYB'M-7 M/)]^@4!JEL*,. %!$?4;_#5.5M/! W+B.@_^)-S6?@AX-])A/&^VJT>];LL) ME8:76-N%?JD% ]@8 2BL0KNO'&=A-[]'19M7W\>?J&=*P$ MNH4AA(0[!#\U4_F"'K1IW8"?ZC<>P/.UR$Z1[LS@T$5VKC>OGM=KBS)CBFF) M& 1,Y"Y L/$YLV$Y$!JZFFU[C(3%28+ UI$M M//D9=P+MPXQZI_@9XEVVQTS82;);J53M)%M0INTIV:WJ36/)GL?C3/5?^7KN MUN,N5^#^M_EFQB"BLC($:'=!#:L2NA[O @BA<&G_B0:>O5T#C&RR?HUSMO)$^V67.T\@37]^\4>GVPN;M(T,*ZG_:6CMTIV+WPF6^ MR^U,:2%H41&0\\+868HJ0*F[$%)BI&4!JPH&5;AKP1G=HNH:\T=8Z\SWP(%F MU4:3GXDE4#[,W&+TCBRHWZI5TGKZMR@O4$Z_5=7F:OKMCZ>HSKT[OY[+#[NZ M"S,!.7,5Y0 TE0TKH9WV*',-,"I:**VQT";H,+D3;>PDC^MBTP?X;(\_I CW M-7%^)IR,CC!#CF=B8*WM%@U'*;)]C?6"U;5;U.XNJ]WVTIB%?O^^GF_U>V,V MLTH6M*2$ VZHZWS#*\ $0?8GI,LJAQ@).5K%WZ,87B8P<>G?NZP6;V7,&,5J M3Y^ GP<9@] )$DD\2!RID.T-%9-6M#VA_PY+V]Y0$U?C]G:8-"T CN&Q*^>I MI!!N+0Y=MFD.>%$40):\A)4T!=4J[,"Z&6CT0^KK9@!_'M8-('#]D$+MP..E MF^X HRPA^A0;J6' RRPB^I3M:R P;?42X>YEO7+H 27: <@5P* M#K!DSD"KRBXB.%*Y-H)([](KUX./;)0U1K8R&J M&&: H=H%I6ZUJ1&5M74SV&0)6VUJG.=JM3X3-]-]X@M7[+"NR_J+WNXW6@L! M69U<41$B 2Z8!*) !" .*T5S(K0.*I+:B#*R.>WALI_T4GYYY.O8O(IFAOSF MN<%ZA]E8A,KAC:Z[5$K5U[H18]HVUEUJWG2M[GPXLGC#?&DCV=VZY2V7[@CW M>WVX2$TE&*PX, :5 %=V92SR7 (HC#$*"R%1T'%0&]#(YOFS7EHR]G?W(@Y= M6_GQL\P46H<99X#"X442>K1)516A#6;:,@@]RM[4/>A[?F AI*9$7(,J@U'! M "%& ,P5!HQ5%&A:D8HP:ZDR*">B"VST(Z<]=)H\YD[:?$^?TI 1>@05RT-\ ML:3QTY0[H5ZF:%) 6K+7.Y$9B8<"!C^[J@97]5(^:G>7^?"/KDX.FN$<(V;R M G#FMJU-J0&3C %E&,$2%K0,N_P8*L#(;N!4B*.&;"@)=)1I]T3FI K,;@SE MW,]?C,EDF ])3&)XKF0D$ZF2*$/AI\VNC"3G)NTR=IP!J=.[*BN';&#!!-(R MUT#K$@'K?(A=OK,*%(1!*$2I8WN7A6^_)']O^K!_[;K& ,(1L+ %T18B,$:E?N!:Z[>W##3*E0&729 M(4*&B?;5'63*OEFALH-4=]E1KNP@6&8E"S/O&/K][']D4N,V]%+R&>Q& M!C"2R,_$2#"I(QI T;6G&C)4HIO:GYZ?GA9SO9ZA"C,"R^>WQRR1F: M\\HH[0S8'>MARMQF!0;*<,RM06.(@W8E0\!'-O&C*%DM2W84YBZ[R1W?"11F M^$$\^_F"L=@+%4&!5V1MD ,O;YY%7Y> <;=U#91)#G(>5 M0,/ M**]JOOMH/*B<^[5*(]1N/T*\6*'V:R6[JK+?/!N>$'=O#5LYXWZ[X)]G4*!" MO5H^/J^6G+]Q^8/?;[7HN MGK>[/J$V1O]JOZLV0'<]?\]GT%DI.*H4*0$5L@2X,+DK/B0 +RDDVA245$%M M/0?*,_J1_U&Z;"=>MI,O.Q?0-;A]?:C'_<88+;9@P*?F M-\M.^%F$N8T7^!CBNB@,)R]E>X4!TDS?=V$X=8T-&1(,&UM=]8'_]LZN-K9S M,Y?U;L7Z-D./K3J:AM?_=%+,A;"W%(T 1'56'N4&U"5M6WDB:NS]BAX6Z6U[X4P ML]6;1WFY-[DRLLZ47,\W_SA=Z](D5Q*Z/N:DBIQA4OD8 MKR?>I."^I$IR;D GHXD;Q\8 MJ/+.$[J7G+/#L"A0[?!\AYG$[07J='!^H:\-S.?^16]GD)$*84,!%])8?U^JZE?NE0*C[3 M^DSZU)G5;NB7R:0^4ZHU<_K\F. YE(#4C&D);7S<5E&E/UIP_/Z_@^N[W-"=\%BC9_M!0A->&RAS<\E M#&(A,G4Q7/.(U,1NM9+E'[; 3)QDV*WL;29AS_,C7(QR][!<31Y7!O>#7KN( M?9:CDA*C.3 (VYD?80T$5@3DQ @MJYQ5)"@9(%2 D>/M_CL]!YGVO=+W8B6\ M&M7$NI]?&)/+,'^1G,:TEZ,ZN)CB./OK3?H64.[CSQ_Q5_ MFF_Y8OX?UEP.#]V=]TZ7V_G7B'83U_3Y;@E$DQ*Z*S >'Q%;"8U:)]M-N!Q] MX@V%1M5N]Q2:'PLSW23-$Z\?_UUDY1&&I%4 M=[-)Y2&.QT-V5?VDJJ[JK@\*>"5*X/ZY0K8F0M9!!W$7J\ZLIC[!]<*8Z[J=GM;E<:Q%E MZ67_J"+]OTR]8F\437@;9MZ(@S@6N"I$!>9N<^-U30&RM )<*@9<^"S=]F:U M0"SNAKV?T#(7[&>T_9QP<;,^-@ZL<97*"4&\4K@TE74Q,(0 24.!\.J*-;:D@MH0':2IHU1F M5M/+!/D)'8'Z(0IS-2<+'J>S+DA]^.,?X MB==BO][__'EGA'Z_.9_F5*VH-$1A)@$UE0*(& Q$R3@H65TIHHPF9,(DBF'" M,ROPU2B&AI.B9:78;HJ+L6%3)E2,8!NFYG,@%J?YF<":.,3BMN2SS+,8(7O' MT1:WP1B?+%V<.@<+EE#3VB- MJ+5\[47KDKM$>NZ[+3OH=0H MM\M>]TGI;0K[^Z?#_B V_H1O)0V"4#(*RHIA@#BQ0%+, /%GN)ASA&3006X8 MN64BWF.-AV?AX5CJ<<9%;.0["F!H_)L+EJ0H.!F1A&@X1- ),?'H\@M'QB&B M7L?'06^E[9@O[H':E/;WMBEK,OKZR\NJDE55B0%3;CM%LG;Q,V8E(,)4&C-D MM3*KC3F$[:B1U.,R1PYQIN#JUK/EQN=07'_]'XJ.Q[A].19M+0RL*+5 ,>$\ M&&H%$(@B8"J()4-((V-7A^U!/-X/[Z/Q/7$1C[CH$-^W.(-"+P%NF%LT(V1Q MACGS]S/:O4H$(I,#%DM]41L0IR(,H:ML.V)$$" M&*6H*G$I#483FZ@O-K:WKW=X\NC>8_N5Q"L/WY?0)'\YAUZ?\52_H3CWU_*67+E.]H?(+'NX?T/8J_/]6\\G ME+4>.^Q]_&W;'4%Q6U&EE+]QLRYL8 ("KA4!I855I2K#8!W4Q:-_^;FS2CIZ MQ>&W;>2!W CU6\L5@PYR M?%'[.?S4I.;=/QFU_66S]I_:JXU^TW7!Z'YYVK5\5BBVB/MCALI%O\0"!H4! M")4&5YQ0'C>'/H;XS";EV%[ZC)>F<.O(37%\(-55C0(ZS#V8"[XX8Y43N=2& MW%$0Y.W$'4;Z'BVXHT 9Z+T=MT:J"3J(]<;H[\7.3P/9OU)N#WEZ]&5FCN!: MK9WAD9H+ZGOEE,99'Z%J(&LI 3<0(\J$D3IJ".=MDC.;FS."A6XIQIJ3FZ!I M5G,-*79?7>;+C+D"0C/E3+86BD/.%>1Q9<9Y84NJ,3ZR4!QY*+XYQ[)CX]OL M8(9:Y)P Q=KA:<@DV-Y08;-9W)L$%[:SH0!<6]?@-U,'&7SZM#XT%8^^BGF[ M\;4>9J/69M]S&@&=*Z'K!_==.SCROK_"9__(2FK)J:$6&,*KBR_B^!^$S*#ZW[2P>"NO(%J*A M.R5+_0RF, N10_@X>W"5A>Z)%J_&19^8 YYS_/I M19UJN_N\;1L<-C-:OO/K[KY^M]5FY4(2PS!!0&'!?1,5#7BE!#",4V6HQ 8% MY4($TIM9?T]%CFM"Q]1UZ.X>)/;++3[LI415/Y]!_7P6R>K21?HUL,KZ:A9!@5", M F:)D=)0"$G4H-5>*G.?.5Y,:__O2#7NA250?:<*&ZFVE^/:9SD&'!4IEY;V MTEA6.\?$O-+*T8>G:.,*5Q;+NM3 <.5VV!(+P)2J08419ZSD%2QU3(%#NVR4 MOL77+7STKW3:EJ)L4=HUMSKE5IU9=.4>RC&N#9.#3K?5N<]FW_BS[W*-Y^,5]KOM%[,[N4962XRQ MY:!$_M;('^ER+B0H)6,8,EQA&71[?;7R[#?3CE;TM?.U_+=5+EFJ.!T+%BA* MI7J93]*ARY464YI> L;)=-&O_[ZM[UQ<=NIW^=SN\_G MK%Y((;&E 9K['0YB#;@0"%B.B"305KR.ZLH1S\+NE+3U@I,>QT'H+N1K;^;-33KEF\;5]L] ].U.^VGSX_M04E[^TQ8>Z# MV37EM^_6&_/V8#[M5T1(5I6E!)109\6GGS)$';=MK7KQ3\]PT7 <>^R76TD7O]Z9U;_RH.'1OG0U4^[%Q(M_XL'M]N M_L>(W0^.WQ6J5%4K!@'4)02HIAI(*2 0A!!#M-15&>57)G$QL_EUWV.6WN(U M',LPVS@[0G&&\+)%[$/1L?3UH?"T"T]\GE:QT;+/T$HVG(>[M9J-AFFL%6W\ M8G&V2+4I!JN__;R2HJ+*U 8H+!E @E$@."Q!:2M"2XH$EB3$L#PO.;.5>+/] M9/RT@,B+_3.1Q_4_39 X9?[;CV\_?O^F^/GCJX_?_SQ=;:]9'CG2Z1YN5;#[ MX5G[SI9:1)6N63_J1<]OTLMW!ML5VM*61BL)A"#([:L" RDH!P81@BI"RA*I MR/&AF1H;IDT-;1L;[MO&AEW'L6ULJ\<@Y B&4%-#05UJ7TN*"6"EK8%A-56\ M+*F)BQ'OV">SKQWD0WR'S"#8PIR/^W3'3,]U2M,5$U]!2/2PIG(LBH!A[P&=4U*2*TM M5:G2<_N'R,[M1;S,>#_-_/*,%"TG15\*LA M[8P%IYK!JHS*.KPF,;-QN)@J[&OD/,W(.ZUK6 +OK"8)&WDG%25G_%73H"BY MKI*N"2Q[530HX-55T/"34YHA7DX]?;<63(K;@DQ=5T"834' M"!$%F/+=7B#2R'*D"!OX](T90&Y&U"&2YZU(64 V3LTJ P'H[]A9<3[B?#OG\UF?Y9>0:5E5$,(JDIK@+CD0*B2 <@H-;R6PN*H'B;CY&;> MS1OBQ3>FI?IML6[XB,Q1N0%8F(W(!T.<96@1: FW9?T=Z5DR3,*DS#7=?)S8 MLK/,@P2_FEP>]E9*HUKUJ]%/CV9KU\>FS* ?09 M'I!KK1'655#QWRU",^OVOJ/L;_U/M*/30&^B-:[>.3&(4^R%Q(]I>)L'AK36 MM\EP1+;#O2WC>&/:;Y-C.PYW9P@NLM[/#%P]#H_40LD^$$]F15?7UFGIDT6A?N. MK1"IK8),@1HVM\"5 E(CYC-?-8+8*A/6LS&,W,S&Y*.#U A/,&+[OXU1@ ^4 M5?+(PX_!]*B&@2Y)RKV=%9,(QR@K-FGNT72,XORD8)%'O:7;JRSG,P5+=.$Y MA;^5F.#BC*7_SW=Y^R(>_0G13\9Y9FMU,-K_PL65E_]P]F1[">3BSYT_:GIC MVO^[GQ^?_!7S][^K7]UWJ)E?_+VUQD<#R*)*"P:D](D?J$9 5JH&W+>3(+!2 MJ(P:V[QK821R2K+?GG"7,P_[EHXB?+OS1UM5^VQ(APCP0D!E?&%O'7E>YN* M"I3(<))3AS4'#BX)@;NCG-5_W29 &X&*S-%XUPD$-P# @;,J,3 M9Z*?@>G2'I\'S_[]!,S/,P 3$3MD!B@M>L@ 5%SX$"'U: 1LLYR(42$5!=! M1,Q[6;L=_+#>B(WJ+\.O-(6&UA@0Y@( !$L)!!4"6,A+RC732-H,W0Y&6)@[ M$^Q8M?_YO&K_Z5BU?V(L>_.#,=3#?.AYL8PSLC>:'_3!N&3S@P!,YFU^,,; M'Z'Y00! @J:9>A4DZZIG=6&(YIRQ,E@M_+/"5R26+'\3N_:ZY!M-_%X]/YA0_ M(-_)MY8,4(Q]EKUB@-FZ!%9C6!I;,RBCYL<&T)S9MET6+WX6N^*+IYY A9%Y (D\.+TKQ''W?7K'EH&A8>.YM,DM1WBV)\]?F#5*\5XG>+0A&*O5N MOIIF%IJN)7ZJH3QT.U-%+"-2&4"P3^,3E2]D%AQP(RHL:FEYV/B.00HSJWQ' MK[F03.S4?PU*F'I/$C5.F>.DC%;;04DR*>GU^HNJY*!X+Q5P^,$T=?/'TX>O MOBG0=N,/JMP.C%R-C.J M8:;PW!0-.[&Q="B\@2'V#*!%1M[9\(J/RB.%SQ6LAY)=-H:/!.,JM(]]/SF@ M:"MQWVWW^U=?Q/JQ;=AQ=K37QBX2LZP(@"754,"EYS0'E= M H2-<[88K8#%7.F:(:Y55!'@G*"G99S\ 4$/#NWF@C(^OLN+8DJ4EX)%OE O MBOK2\5X*-#U!7](R"?DE']_XGDW=_8*EL(::,8!L20%BW-E_;A$H*<$&-"H(BTCE3!TI(X;GU0<8D: M?;R/IF5+WIU%O_T-",#P!Y>(4)="4%0)&(PV0P#7@S I@$&:T9B4W-LJI'Z"S MM J^2QT$-813BC8F23]1)4,$GZB85V+-HIWO[C,,Z8:HXWIZ_7B:LO[#K'_Y M]6#TJR]F)WXQQZ*3JS[D75Q>BEI+COW]AP&H-A@P796@K* 07#,B=%0Q2!3U MF17[R$LA6F:.HQ5 (>-C[SA82V.ME:5#M%+6_8$@$+2J ">8UX*;DBL6-Z%B M-F"31E8T5(HA@)-G5\2!'&969P,NSMB>L.KX.*O$:UDY']F0_5PC"81,ICF. M]J(&.PF6EV8\;9').>;?;3>.X-Z%J'[A_4I!+6EM2V"P\,OR1T MKSSQ 8%'TL.'WHA39#_M_/O-P6?5M5=A/YG/VYW/=O&9YT_[%:/$8,8J0!2O MG!I+"9AU?XA:5H)@!)$.BJEN$9I9B5O2ISO;$_&BI1ZFQ3?!&M?AG!#$:7"J M],$J'"K:R$@YMT2KN^XOSRI[<^%%%#94O*.Z!C^?NNLZ;C>'77,@_--Z_Z^/ M;ITN64HI45+F/'TE*751%"R!K+@&!&M-.>8JL.5( *W9]]TSRH4G77C:BQ-!2-A];XJ7;?L=IK3P_GM3Y.L-^/8KB0V,CPU,GZ\C5\C% M[8P+"F1)7-B.!0&2^6F)#%+"2DB-X#&I(3TT9D[_Z"[.VW$)[9SU;-7\=^31A#OZ8Z+I M^XWI+GA+2X2$N@805AB@VOU-,$F!PM2:LL0,PO >7E?+S[V''K.4'<&4J^YK M.,8U;KJ0D=MC=ODB[O,GR9EVJ1\G;]P5_Z XH_?\UV\M=]D_R/'%C?_P4YF\ M[]=?3XT;FLMN+2S558F D9PXB\$T$$XT "LHM#0453BJGOH6P>7]\+-^( GY M 3U@J1KQ;TV^_?V MO$7WBU(';DQ%(!: 4,4 U!-(_D[%/7'@#!?Y M1*Z3.$*W&ZOI*]>=RR>-%A#4FCJ_CVL.F"8E4!1I!H6@4)BH*;G/:\]\2M,- MPGVF%SD%]PR$,,N0*%JITD5NEJ&")329ZA$@6X.I\[47;B[5(]9U8ZF^AQ*.*'\TA\_NTW/A3=/9 M<&LWYK=FAKE].0XR7]5*FUJ6 @AA%4"25H!7@H":,N<:U\;7EH9L1S%$ M9]ZG?$5>QT;;UM%[<(Z3;H9[RTOD*/

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esmc-20240331_htm.xml IDEA: XBRL DOCUMENT 0000862668 2023-07-01 2024-03-31 0000862668 2024-05-13 0000862668 2024-03-31 0000862668 2023-06-30 0000862668 us-gaap:SecuredDebtMember 2024-03-31 0000862668 us-gaap:SecuredDebtMember 2023-06-30 0000862668 us-gaap:ProductMember 2024-01-01 2024-03-31 0000862668 us-gaap:ProductMember 2023-01-01 2023-03-31 0000862668 us-gaap:ProductMember 2023-07-01 2024-03-31 0000862668 us-gaap:ProductMember 2022-07-01 2023-03-31 0000862668 us-gaap:ServiceMember 2024-01-01 2024-03-31 0000862668 us-gaap:ServiceMember 2023-01-01 2023-03-31 0000862668 us-gaap:ServiceMember 2023-07-01 2024-03-31 0000862668 us-gaap:ServiceMember 2022-07-01 2023-03-31 0000862668 2024-01-01 2024-03-31 0000862668 2023-01-01 2023-03-31 0000862668 2022-07-01 2023-03-31 0000862668 us-gaap:PreferredStockMember 2023-06-30 0000862668 us-gaap:CommonStockMember 2023-06-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000862668 us-gaap:RetainedEarningsMember 2023-06-30 0000862668 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0000862668 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000862668 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000862668 2023-07-01 2023-09-30 0000862668 us-gaap:PreferredStockMember 2023-09-30 0000862668 us-gaap:CommonStockMember 2023-09-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000862668 us-gaap:RetainedEarningsMember 2023-09-30 0000862668 2023-09-30 0000862668 us-gaap:PreferredStockMember 2023-10-01 2023-12-31 0000862668 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0000862668 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0000862668 2023-10-01 2023-12-31 0000862668 us-gaap:PreferredStockMember 2023-12-31 0000862668 us-gaap:CommonStockMember 2023-12-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000862668 us-gaap:RetainedEarningsMember 2023-12-31 0000862668 2023-12-31 0000862668 us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0000862668 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000862668 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000862668 us-gaap:PreferredStockMember 2024-03-31 0000862668 us-gaap:CommonStockMember 2024-03-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000862668 us-gaap:RetainedEarningsMember 2024-03-31 0000862668 us-gaap:PreferredStockMember 2022-06-30 0000862668 us-gaap:CommonStockMember 2022-06-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000862668 us-gaap:RetainedEarningsMember 2022-06-30 0000862668 2022-06-30 0000862668 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0000862668 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000862668 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000862668 2022-07-01 2022-09-30 0000862668 us-gaap:PreferredStockMember 2022-09-30 0000862668 us-gaap:CommonStockMember 2022-09-30 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000862668 us-gaap:RetainedEarningsMember 2022-09-30 0000862668 2022-09-30 0000862668 us-gaap:PreferredStockMember 2022-10-01 2022-12-31 0000862668 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0000862668 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0000862668 2022-10-01 2022-12-31 0000862668 us-gaap:PreferredStockMember 2022-12-31 0000862668 us-gaap:CommonStockMember 2022-12-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000862668 us-gaap:RetainedEarningsMember 2022-12-31 0000862668 2022-12-31 0000862668 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0000862668 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000862668 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000862668 us-gaap:PreferredStockMember 2023-03-31 0000862668 us-gaap:CommonStockMember 2023-03-31 0000862668 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000862668 us-gaap:RetainedEarningsMember 2023-03-31 0000862668 2023-03-31 0000862668 us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-03-31 0000862668 us-gaap:ConvertiblePreferredStockMember 2023-01-01 2023-03-31 0000862668 us-gaap:ConvertiblePreferredStockMember 2023-07-01 2024-03-31 0000862668 us-gaap:ConvertiblePreferredStockMember 2022-07-01 2023-03-31 0000862668 us-gaap:StockOptionMember 2024-01-01 2024-03-31 0000862668 us-gaap:StockOptionMember 2023-01-01 2023-03-31 0000862668 us-gaap:StockOptionMember 2023-07-01 2024-03-31 0000862668 us-gaap:StockOptionMember 2022-07-01 2023-03-31 0000862668 2018-02-14 2018-02-14 0000862668 2018-02-14 0000862668 2022-07-01 2023-06-30 0000862668 us-gaap:NotesPayableToBanksMember 2018-06-29 0000862668 us-gaap:NotesPayableToBanksMember 2023-07-01 2024-03-31 0000862668 esmc:TDBankMember us-gaap:NotesPayableToBanksMember 2023-03-29 0000862668 esmc:TDBankMember us-gaap:NotesPayableToBanksMember 2023-03-29 2023-03-29 0000862668 esmc:TDBankMember us-gaap:NotesPayableToBanksMember 2023-04-29 2023-04-29 0000862668 esmc:TDBankMember us-gaap:NotesPayableToBanksMember 2024-03-31 0000862668 us-gaap:SecuredDebtMember 2024-03-31 0000862668 us-gaap:SecuredDebtMember 2023-03-31 2023-03-31 0000862668 us-gaap:SecuredDebtMember 2023-07-01 2024-03-31 0000862668 esmc:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0000862668 esmc:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-03-31 0000862668 esmc:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2024-03-31 0000862668 esmc:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2024-03-31 0000862668 esmc:CustomerOneMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0000862668 esmc:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0000862668 esmc:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-03-31 0000862668 esmc:AccountsReceivableBenchmarkMember 2023-07-01 2024-03-31 0000862668 esmc:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2024-03-31 0000862668 esmc:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2024-03-31 0000862668 us-gaap:AccountsReceivableMember 2023-07-01 2023-09-30 0000862668 esmc:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0000862668 us-gaap:AccountsReceivableMember 2024-01-01 2024-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2024-01-01 2024-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierTwoMember 2024-01-01 2024-03-31 0000862668 us-gaap:AccountsReceivableMember 2023-07-01 2024-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2023-07-01 2024-03-31 0000862668 us-gaap:AccountsReceivableMember 2023-01-01 2023-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2023-01-01 2023-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierTwoMember 2023-01-01 2023-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2022-07-01 2023-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierTwoMember 2022-07-01 2023-03-31 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember 2023-07-01 2024-03-31 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2023-07-01 2024-03-31 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierTwoMember 2023-07-01 2024-03-31 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierThreeMember 2023-07-01 2024-03-31 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember 2023-07-01 2023-09-30 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember esmc:SupplieroneMember 2023-07-01 2023-12-31 0000862668 esmc:AccountsPayableBenchmarkMember us-gaap:SupplierConcentrationRiskMember esmc:SupplierTwoMember 2023-07-01 2023-12-31 0000862668 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-03-31 0000862668 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-03-31 0000862668 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-07-01 2024-03-31 0000862668 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2023-03-31 0000862668 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-03-31 0000862668 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-03-31 0000862668 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-07-01 2024-03-31 0000862668 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2023-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2024-01-01 2024-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-07-01 2024-03-31 0000862668 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2023-03-31 0000862668 us-gaap:GeographicConcentrationRiskMember 2022-07-01 2023-03-31 shares iso4217:USD iso4217:USD shares esmc:vote pure 0000862668 --06-30 true 2024 Q3 false false 7415329 false 000-20127 0.001 0.001 35000000 35000000 7415329 7415329 7415329 7415329 0.001 0.001 2000000 2000000 2000000 2000000 10-Q 2024-03-31 Escalon Medical Corp. PA 33-0272839 435 Devon Park Drive Wayne PA 19087 (610) 688-6830 Yes Yes Non-accelerated Filer true false common stock, $0.001 par value 564707 889674 256390 256293 1491827 1807599 132624 153878 1359203 1653721 1804929 1587989 166600 249790 4151829 4637467 53971 34064 276089 503647 54355 69986 62787 62787 4599031 5307951 33262 37087 3172 3105 1118057 1205510 589877 651978 112389 112389 282950 329638 403069 426227 86333 87125 2629109 2853059 135483 159511 143289 146435 15974 214103 294746 520049 2923855 3373108 645000 645000 7415 7415 69702043 69702043 -68679282 -68419615 1675176 1934843 4599031 5307951 2567387 3285396 8101834 8582183 128114 148918 407904 462436 2695501 3434314 8509738 9044619 1578727 1720853 4835402 5021470 1117534 938161 3401902 3108177 155848 185750 515213 641316 2852109 2844764 8752517 8770963 -156608 589550 -242779 273656 5541 4315 16888 15188 0 0 0 0 -162149 585235 585235 -259667 258468 12830 13006 38842 38735 -174979 572229 -298509 219733 -0.02 0.08 -0.04 0.03 -0.02 0.04 -0.04 0.02 7415329 7415329 7415329 7415329 7415329 13478936 7415329 13478936 2000000 645000 7415329 7415 69702043 -68419615 1934843 0 0 0 0 0 -21197 -21197 2000000 645000 7415329 7415 69702043 -68440812 1913646 0 0 0 0 0 -76321 -76321 2000000 645000 7415329 7415 69702043 -68517133 1837325 0 0 0 0 0 -162149 -162149 2000000 645000 7415329 7415 69702043 -68679282 1675176 2000000 645000 7415329 7415 69702043 -68876441 1478017 0 0 0 0 0 -320724 -320724 2000000 645000 7415329 7415 69702043 -69197165 1157293 0 0 0 0 0 -6043 -6043 2000000 645000 7415329 7415 69702043 -69203208 1151250 0 0 0 0 0 585235 585235 2000000 645000 7415329 7415 69702043 -68617973 1736485 -259667 258468 20354 -93400 26763 34424 227558 215772 -274164 107573 216940 61238 -83189 -27798 -87453 35375 -62101 -33063 -244817 -226404 -23158 -36985 -792 -42955 -262900 -29781 31038 6687 0 7155 -31038 -13842 27853 3165 3079 2686 -30932 -5851 -324870 -49474 1145967 850034 821097 800560 564707 544320 256390 256240 821097 800560 889674 593869 256293 256165 1145967 850034 16985 15697 Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the “Company” collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (“Sonomed”), Escalon Digital Solutions, Inc. (“EMI”), and Sonomed IP Holdings, Inc. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the “FDA”). The FDA and other government authorities require extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements (“financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and have been consistently applied. Certain information and footnote disclosures normally included in financial statements presented in accordance with GAAP, but which are not required for interim reporting purposes, have been omitted. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to present fairly the financial position as of March 31, 2024, and the results of operations and cash flows for the interim periods ended March 31, 2024 and 2023, have been included. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended June 30, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on October 13, 2023. Operating results for the three months and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nine months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the full year ending June 30, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company’s common stock trades on the OTCQB Market under the symbol “ESMC.”</span></div> 2024-03-31 2024-03-31 2024-03-31 . Going Concern<div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the continuous enhancement of the current products, development of new products; changes in domestic and foreign regulations; ability of manufacture successfully; competition from products manufactured and sold or being developed by other companies, the price of, and demand for, the Company’s products and its ability to raise capital to support its operations.</span></div><div style="margin-top:0.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company’s operations have not generated sufficient revenues to enable consistent profitability. Through March 31, 2024, the Company had incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> historical recurring losses from operations and incurred negative cash flows from operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for the next 12 months following the issuance of these unaudited condensed consolidated financial statements.</span></div><div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These unaudited condensed consolidated financial statements do not include any adjustments relating to the realization of the carrying value of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-top:0.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:6.75pt;padding-right:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's continuance as a going concern is dependent on its future profitability and on the on-going support of its shareholders, affiliates and creditors. In order to mitigate the going concern issues, the Company is actively pursuing business partnerships, managing its continuing operations, and implementing cost-cutting measures. The Company may not be successful in any of these efforts.</span></div> 2024-03-31 <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (“ASC 326”), authoritative guidance amending how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The guidance requires the application of a current expected credit loss model, which is a new impairment model based on expected losses. The new guidance is effective for interim and annual reporting periods beginning after December 15, 2022. The adoption of the new guidance will not have a material impact on the Company's unaudited consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the current expected credit loss model prospectively from fiscal year 2024, and assessed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowance for expected credit losses to reflect the risk of loss, even when that risk is remote. The Company continues to use the aging matrix in conjunction with the historical information, current conditions, and reasonable and supportable forecasts. The Company groups most of the trade receivable by pools after adoption of the new standards while it analyzed the credit loss of the trade receivables one by one before adoption. The major difference is the estimate of the current expected credit loss for the receivable that are current on their payment. For the nine-month period ended March 31, 2024, the adoption of the new guidance did not have a material impact on the Company's unaudited consolidated financial statements. The Company will continue to assess the current expected credit loss. It may need to recognize a credit loss in the income statement earlier than under the legacy guidance at certain times when the expected credit loss is increased.</span></div> 2024-03-31 <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated.</span></div> <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></div> <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accounts receivables are recorded at net realizable value. The Company performs ongoing credit evaluations of customers’ financial condition and does not require collateral for accounts receivable arising in the normal course of business. The Company maintains allowances for potential credit losses based on the Company’s historical trends, specific customer </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">issues and current economic trends. Accounts are written off against the allowance when they are determined to be uncollectible based on management’s assessment of individual accounts. The Company adopted the current expected credit loss model prospectively from fiscal year 2024, and assessed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">allowance for expected credit losses to reflect the risk of loss, even when that risk is remote. The Company continues to use the aging matrix in conjunction with the historical information, current conditions and reasonable and supportable forecasts. The Company groups most of the trade receivable by pools after adoption of the new standards while it analyzed the credit loss of the trade receivables one by one before adoption. The major difference is the estimate of the current expected credit loss for the receivables that are current on their payment. With adoption of the new standards, the small credit loss rate applied to current receivables will be mostly offset by the lower expected credit rate applied to over 120 days past due when less than 100% of expected credit loss is applied. The historical credit loss rate is adjusted for current conditions and management's assessment for factors such as international relations, economic conditions, and special-term contracts etc. For the nine-month period ended March 31, 2024, the adoption of the new guidance did not have a material impact on the Company's unaudited consolidated financial statements. The Company will continue to assess the current expected credit loss. It may need to recognize a credit loss in the income statement earlier than under the legacy guidance at certain time when the expected credit loss is increased. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recorded an allowance for credit losses of approximately $132,624 and $153,878 as of March 31, 2024, and June 30, 2023, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activity for the allowance for credit losses during the three-month and nine-month periods ended March 31, 2024, and the fiscal year ended June 30, 2023, is as follows:</span></div><div style="text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:35.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.181%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31, </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,878 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (Reversal)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,624 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,949 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,624 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,949 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2024-03-31 132624 153878 2024-03-31 2024-03-31 <div style="text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:35.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.181%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31, </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,878 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (Reversal)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,624 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,949 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,624 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,949 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 133524 241349 153878 236349 0 -98400 20354 -93400 900 0 900 0 132624 142949 132624 142949 Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis and include freight-in materials, labor and overhead costs. Inventories are written down if the estimated net realizable value is less than the recorded value. The Company reviews the carrying cost of inventories by product to determine the adequacy of reserves for obsolescence. In accounting for inventories, the Company must make estimates regarding the estimated realizable value of inventory. The estimate is based, in part, on the age of inventory. If actual conditions are less favorable than those the Company has projected, the Company may need to increase its reserves for excess and obsolete inventories. Any increases in the reserves will adversely have impact on the Company’s results of operations. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company is able to sell such inventory any related reserves would be reversed in the period of sale. In accordance with industry practice, service parts inventory is included in current assets, although service parts are carried for established requirements during the serviceable lives of the products and, therefore, not all parts are expected to be sold within one year. 165000 43000 2024-03-31 440000 300000 2024-03-31 <div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:27.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.550%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 316000 259000 426000 332000 284000 185000 560000 425000 197000 149000 583000 462000 403000 295000 403000 295000 The Company utilizes the two-class method to compute net (loss) income per common share. These participating securities included the Company’s convertible preferred stock which accrues dividends payable. The two-class method requires (loss) earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.<div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Diluted net income per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options. The Company analyzed the potential dilutive effect of any outstanding dilutive securities under the “if-converted” method and treasury-stock method when calculating diluted earnings per share, in which it is assumed that the outstanding participating securities convert into common stock at the beginning of the period or date of issuance, if later. The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the average market prices for the years then ended are less than the exercise price of all the outstanding stock options and, therefore, the inclusion of the stock options would be anti-dilutive. </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Numerator for basic loss per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Net (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income applicable to common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,979)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298,509)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for diluted loss per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income applicable to common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,979)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298,509)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic (loss) earning per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic (loss) earning per share - weighted average shares outstanding<br/></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average preferred stock converted to common stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,063,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,063,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Denominator for diluted (loss) income assumed conversion</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,478,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,478,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.08</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.495%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,407,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,407,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive securities not included in loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,564,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,564,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Numerator for basic loss per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Net (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income applicable to common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,979)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298,509)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for diluted loss per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585,235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,468 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undeclared dividends on preferred stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,830 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,006 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,842 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,735 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income applicable to common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,979)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572,229 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(298,509)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic (loss) earning per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator for basic (loss) earning per share - weighted average shares outstanding<br/></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average preferred stock converted to common stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,063,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,063,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Denominator for diluted (loss) income assumed conversion</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,478,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,415,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,478,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net (loss) income per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.08</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.03</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net (loss) income per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -162149 585235 -259667 258468 12830 13006 38842 38735 -174979 572229 -298509 219733 -162149 585235 -259667 258468 12830 13006 38842 38735 -174979 572229 -298509 219733 7415329 7415329 7415329 7415329 0 6063607 0 6063607 7415329 13478936 7415329 13478936 -0.02 0.08 -0.04 0.03 -0.02 0.04 -0.04 0.02 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes convertible preferred stock and securities that, if exercised would have an anti-dilutive effect on earnings per share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.495%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,407,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,407,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive securities not included in loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,564,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,564,820</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 157000 157000 157000 157000 157000 157000 6407820 0 6407820 6407820 0 0 6564820 157000 6564820 6564820 157000 157000 <div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of March 31, 2024 and June 30, 2023, the Company has recorded a full valuation allowance against its deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of operations. As of March 31, 2024, and June 30, 2023, no accrued interest or penalties were required to be included on the related tax liability line in the consolidated balance sheets.</span></div> 2024-03-31 2024-03-31 Inventories <div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.156%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Raw Material</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Work-In-Process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Finished Goods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for obsolete inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.156%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Raw Material</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Work-In-Process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">        Finished Goods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for obsolete inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1027000 882000 388000 86000 650000 881000 2065000 1849000 260000 260000 1805000 1588000 Related Party Transactions and Preferred Stock<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of March 31, 2024, and 2023, the related party interest accrual of $112,389 related to the debt prior to the exchange, remained as an on demanded payable. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2018, the Company entered into a Debt Exchange Agreement (the “Exchange Agreement”) with Richard DePiano, Sr., (Mr. DePiano Sr.), the Company's former Chairman and DP Associates Inc. Profit-Sharing Plan of which Mr. DePiano Sr. is the sole owner and sole trustee (the “Holders”).  Pursuant to the terms of the Exchange Agreement, effective February 15, 2018, the Holders exchanged a total of $645,000 principal amount of debt related to the accounts receivable factoring program the Company owes the Holders for 2,000,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Each share of Preferred Stock entitles the Holder thereof to 13 votes per share and will vote together with all other classes and series of stock of the Company as a single class on all actions to be taken by the Company’s stockholders.  As a result of this voting power, the Holders as of March 31, 2024 beneficially own approximately 77.81% of the voting power on all actions to be taken by the Company’s shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Subject to the terms and conditions of Preferred Stock, the holder of any share or shares of the Preferred Stock has the right, at its option at any time, to convert each such share of Preferred Stock (except that, upon any liquidation of the Company, the right of conversion will terminate at the close of business on the business day fixed for payment of the amounts distributable on the Preferred Stock) into 2.15 shares of Common Stock (the “Conversion Ratio”).  The Conversion Ratio is subject to standard provisions for adjustment in the event of a subdivision or combination of the Company’s Common Stock and upon any reorganization or reclassification of the capital stock of the Company. If the Holders were to convert their shares of Preferred Stock into Common Stock at the Conversion Ratio the Holders would receive a total of 4,300,000 shares of Common Stock, or approximately 36.70% of the then outstanding shares of Common Stock assuming such conversion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Each outstanding share of the Preferred Stock accrues dividends calculated cumulatively at the annual rate of $.0258 per share (such amount subject to equitable adjustment in the event of any stock dividend, stock split, combination, reclassification other similar event), payable upon the earlier of (i) a liquidation, dissolution or winding up of the Company or (ii) conversion of the Preferred Stock into Common Stock. Upon either of such events, all such accrued and unpaid dividends, whether or not earned or declared, to and until the date of such event, will become immediately due and payable and will be paid in full. The dividends payable to the holders of the Preferred Stock is payable in cash or, at the election of any such holder, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a number of additional shares of Common Stock equal to the amount of the dividend expressed in dollars divided by the then applicable Conversion Ratio, described above. As of March 31, 2024, and June 30, 2023, the cumulative dividends payable are $316,173 ($0.1581 per share) and $277,331 ($0.1387 per share), respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Mr. DePiano Sr. passed away on October 3, 2019, and left a will by which he appointed Richard J. DePiano, Jr., the Chief Executive Officer of the Company, as executor. Richard DePiano Jr. was elected to serve as Chairman of the Company's board. Mr. DePiano, Jr. qualified as executor and has control over the listed shares in his capacity as executor of Mr. DePiano Sr.'s estate.</span></div> 645000 2000000 13 2024-03-31 77.81 2.15 4,300,000 0.3670 0.0258 2024-03-31 316173 0.1581 277331 0.1387 On June 29, 2018, the Company entered a business loan agreement with TD bank receiving a line of credit evidenced by a promissory note of $250,000. The interest is subject to change based on changes in an independent index which the Wall Street Journal Prime. The index rate at the date of the agreement is 5.0% per annum. Interest on the unpaid principal balance of the note is calculated using a rate of 0.74 percentage points over the index, adjusted if necessary for any minimum and maximum rate limitations, resulting in an initial rate of 5.74% per annum based on a year of 360 days. The Company was required to put $250,000 in the TD bank savings account as collateral. The Loan is guaranteed by Mr. DePiano Jr. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TD bank elected to exercise the term note conversion option to convert the loan balance of $201,575 to a five-year term note effective March 29, 2023 the "Conversion Date"). The scheduled monthly principal and interest payments in the amount of $4,247 began on April 29, 2023. Commencing on the Conversion Date, the aggregate principal balance outstanding bears interest at a fixed per annum rate of 9.49% pursuant to the loan's terms and conditions. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future note payable payments as of March 31, 2024 are as follows: </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:34.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.400%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Year ending June 30,</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TD Note Payment</span></div></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:34.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.400%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2024 (remainder of FY 2024)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8,530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">37,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">41,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">36,412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">168,745 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div> 250000 0.050 0.74 0.0574 250000 201575 P5Y 4247 0.0949 2024-03-31 <div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:34.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.400%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Year ending June 30,</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TD Note Payment</span></div></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:34.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.400%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2024 (remainder of FY 2024)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8,530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">37,434 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">41,145 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">36,412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">168,745 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"></td><td style="width:38.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.181%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending June 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EIDL Payment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remainder of FY 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,461 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div> 8530 37434 41145 45224 36412 168745 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic Injury Disaster Loan ("EIDL")</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    EIDL is designed to provide economic relief to businesses that are currently experiencing a temporary loss of revenue due to the Coronavirus (COVID-19) pandemic. EIDL proceeds can be used to cover a wide array of working capital and normal operating expenses, such as continuation to health care benefits, rent, utilities, and fixed debt payments. The Company received a $150,000 EIDL loan. The annual interest rate is 3.75%. The payment term is 30 years and the monthly payment of $731 started on July 1st, 2021. The EIDL loan is secured by the tangible and intangible personal property of the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The future annual principal amounts to be paid as of March 31, 2024 are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"></td><td style="width:38.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.181%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending June 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EIDL Payment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remainder of FY 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,461 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div> 150000 150000 0.0375 P30Y 731 The future annual principal amounts to be paid as of March 31, 2024 are as follows:<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"></td><td style="width:38.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.181%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending June 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EIDL Payment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (remainder of FY 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,461 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div> 2024-03-31 782 3202 3324 3451 3582 132120 146461 <div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to the concentration of credit risk, consist principally of cash and cash equivalents, restricted cash and trade receivables. Concentration of credit risk with respect to trade receivables is generally diversified due to the large number of entities comprising the Company's customer base and their dispersion across geographic areas principally within the United States and international. The Company routinely addresses the financial strength of its customer and, as a consequence, believes that its receivable credit risk exposure is limited. The Company does not require customers to post collateral. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Major Customer</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    One customers accounted for 13% of net revenue during the three-month period ended March 31, 2024. One customer accounted for 11% of net revenue during the nine-month period ended March 31, 2024. No customer accounted for more than 10% during the three-month and nine-month periods ended March 31, 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of March 31, 2024, the Company had two customers that represented 16% and 11% of the total accounts receivable balance. As of June 30, 2023, the Company had one customer that represented 24% of the total accounts receivable balance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Major Supplier</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's two largest suppliers accounted for 36% and 11% of total purchases for the three-month period ended March 31, 2024. The Company's one largest supplier accounted for 40% of total purchases for the nine-month period ended March 31, 2024. The Company's two largest suppliers accounted for 44% and 11% of total purchases for the three-month period ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> largest suppliers accounted for 44% and 10% of total purchases for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-month period ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of March 31, 2024, the Company had three suppliers that represented 29%, 12%, and 11% of the total accounts payable balance. As of June 30, 2023, the Company had two suppliers that represented approximately 36% and 11% of the total accounts payable balance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregated Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Domestic and international sales from operations are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:13.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.418%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,510 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,045 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> One 0.13 2024-03-31 One 0.11 2024-03-31 No 0.10 2024-03-31 two 0.16 0.11 one 0.24 two 0.36 0.11 2024-03-31 one 0.40 2024-03-31 two 0.44 0.11 two 0.44 0.10 2024-03-31 three 0.29 0.12 0.11 two 0.36 0.11 Domestic and international sales from operations are as follows:<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:13.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.418%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,510 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,045 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1339000 0.50 1903000 1903000 0.55 0.55 4394000 0.52 5258000 0.58 1357000 0.50 1531000 1531000 0.45 0.45 4116000 0.48 3787000 0.42 2696000 1 3434000 1 8510000 1 9045000 9045000 1 Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company leases certain facilities and equipment under operating leases. Total lease expense, under ASC 842, was included in cost of goods sold and marketing, general and administrative costs in our unaudited condensed consolidated statements of operations for the three and nine months ended March 31, 2024, and 2023 as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:23.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31, </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease costs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total:</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,970 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,324 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,992 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,084 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Supplemental cash flow information was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:28.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.497%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31, </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,224 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,387 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,883 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheets as of March 31, 2024:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:68.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (reminder of FY 2024)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,857 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less interest </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,924 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Average lease terms and discount rates were as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:39.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 2024-03-31 <div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:23.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31, </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease costs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,084 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total:</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,970 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,324 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,992 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,084 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:28.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.497%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended March 31, </span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,224 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,350 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,387 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,883 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:39.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> 84970 85324 254992 256084 84970 85324 254992 256084 88224 86350 262387 256883 88224 86350 262387 256883 2024-03-31 <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:68.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024 (reminder of FY 2024)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,514 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,857 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less interest </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,924 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 88514 212415 3928 1200 1200 600 307857 8933 298924 P0Y11M19D P1Y8M1D 0.0572 0.0569 Contingencies <div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, from time to time is involved in various legal proceedings and disputes that arise in the normal course of business. These matters have included intellectual property disputes, contract disputes, employment disputes and other matters. The Company does not believe that the resolution of any of these matters has had or is likely to have a material adverse impact on the Company’s business, financial condition or results of operations.</span></div> 2024-03-31 2024-03-31 2024-03-31 2024-03-31 2024-03-31 2024-03-31 2024-03-31 2024-03-31 2024-03-31 2024-03-31 2024-03-31 2024-03-31 2024-03-31